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Background: In recent years, considerable attention has been directed towards the
use of cellular therapies in the management of acute and chronic liver failure. The
majority of clinical studies have utilised hepatocyte infusions, although there is
limited understanding of the factors which limit the engraftment of cells in the face
of liver injury. The use of stem cells as sources of hepatocytes which can contribute
to liver repair has been examined in rodent models, but the extrapolation of these
findings to human stem cells is unclear.
Aim: In this thesis the factors which regulate the adhesion and survival of
hepatocytes in the face of acute liver injury environment are examined. In addition,
factors which regulate the differentiation of human stem cells towards hepatocytes
are examined in vitro and in vivo.
Materials and Methods: Human hepatoblastoma (HepG2) cells were used as a
model of human hepatocytes to study the effect of serum from patients with acute
liver failure. Various laboratory assays were used to determine effects on adhesion,
cell necrosis/apoptosis, integrin expression (flow cytometry) and integrin activation.
Human cord blood was used as a source of human stem cells for both in vitro
experiments and the in vivo work with the NOD-SCID mice.
Results: Paracetamol-induced liver injury results in the marked up regulation of
collagen on hepatic sinusoids. Adhesion ofHepG2 cells to Collagen after exposure to
fulminant serum was reduced within only a few hours. Apoptosis occurred
approximately 24-48 hours after incubation and is associated with caspase3
activation. Furthermore, fulminant serum reduces the adhesive capabilities ofHepG2
cells by a rapid down-regulation of their Pi-integrin activity. Loss of cellular
adhesion and subsequent apoptosis can be reversed by treatment ofHepG2 cells with
the stimulatory mAb TS2/16. Human cord blood could not be directed in vitro down
the hepatocytic lineage under any of the different combinations of cytokines/matrix.
In vivo however infused human cord blood cells are capable of engrafting into
NOD-SCID mouse liver and differentiating down the hepatocytic lineage without
fusion to host hepatocytes.
Conclusion: In this thesis, mechanisms regulating the engraftment and survival of
HepG2 cells during exposure to fulminant serum were identified. Human stem cells
were also demonstrated in vivo (but not in vitro) to differentiate into hepatocytes
within the NOD-SCID mouse liver with no evidence of cellular fusion.
AIMS AND STRUCTURE OF THE THESIS
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This thesis deals with acute liver injury and the role of cellular therapies in the
treatment of it. At the time ofmy studies, hepatocyte transplantation had been
studied in experimental animal models and was being muted as an adjunctive
treatment for patients with acute and chronic liver injury. Furthermore, pioneering
work demonstrated that stem cells, both rodent and human, had the capacity to
differentiate into hepatocytes and deliver biological benefit.
The first part of this thesis (Chapter 1; Introduction) provides a general
background of liver disease in terms of the aetiologies and clinical management. The
literature pertaining to the use of hepatocyte transplantation is then reviewed, to
highlight both the benefits and the drawbacks of this technique. One of the major
issues of hepatocyte transplantation remains the relatively low level of cellular
engraftment and survival in the face of acute liver injury, which has limited its
applicability and effectiveness. This observation forms the cornerstone of the first
halfofmy experimental work. The remainder of the introduction summarises the
literature relating to another possible cellular therapy, using marrow and cord blood
derived stem cells. Stem cells have recently been shown to have far greater
pluripotentiality than previously thought being able to differentiate towards multiple
non-haematopoietic lineages including hepatocytes. Thus, their potential role as an
alternative source ofcellular therapy is discussed, whilst noting the lack of data
generated with human stem cells.
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The second part ofmy thesis (experimental work) uses the information above to
generate questions which constitute my experimental work. My experimental work
breaks down into two major components; the first part examines the mechanisms
which regulate the engraftment and survival of transplanted hepatocytes as would
occur in liver injury (Chapters 2-3). This chapter details the in vitro model I
established to test hepatocyte transplantation/survival and the subsequent work
undertaken to identify the mechanisms which affected these processes in liver injury.
The second half ofmy thesis studies the pluripotentiality of human stem cells both in
vitro and in vivo (Chapter 4 & 5) as a prelude to their possible usage as a cellular
therapy in liver injury.
The discussion section (chapter 6) includes a critical discussion of the results, the







1.3 STEM CELL TRANSDIFFERENTIATION AND TRANSPLANTATION
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1.1 GENERAL INTRODUCTION
Context of Acute Liver Failure: Aetiology and incidence
Acute liver failure (ALF) is a dramatic clinical condition that even with advances in
modern management carries a high level of morbidity and mortality (Newsome et al
2001; Ritt et al 1969; Schiodt et al 1999). ALF is, however, a relatively infrequent
condition and thus appropriate studies aiming to establish the incidence of ALF are
difficult to conduct, often requiring multiple centres or long study times. A large
retrospective study from the United States (US) of 295 patients with ALF admitted to
13 transplant centres over a two-year period confirmed that paracetamol overdosage
was the commonest cause of ALF in the US (Schiodt et al 1999). It was however,
unable to provide accurate data on incidence as data in some cases were obtained
solely from transplant databases and thus only patients considered for transplant were
included (Riordan et al 1999). Patients who did not satisfy transplant criteria were
thus excluded, an important factor considering that many studies have demonstrated
that a large proportion of patients with paracetamol-induced ALF either do not meet
transplant criteria or have medical/psycho-social contra-indications to transplant
(Mutimer et al 1994; O'Grady et al 1989). Furthermore, the population from which
ALF patients are drawn is not always well defined thus preventing appropriate
calculations of prevalence and incidence (Makin et al 1995). The Scottish Liver
Transplantation Unit (SLTU) is the national liver transplantation unit for Scotland,
and is the referral unit for management of all patients with acute liver failure,
irrespective of suitability for transplantation. 379 patients with paracetamol-induced
acute liver injury were admitted to SLTU between December, 1992, and March,
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2001. Of these patients, 190 developed encephalopathy, thus fulfilling the definition
of acute liver failure (Newsome et al 2001). In 2001, 21 such patients were admitted
from a population of 4-99 million (1991 UK Census figure), but it is known that
around 50% of paracetamol-overdose patients die at home or are not referred to
SLTU (Blair et al 1998). Therefore, the incidence of paracetamol-induced acute liver
failure for Scotland in 2001 is 0-84 per 100 000. The incidence for all cause ALF was
1.24 per 100,000 for that year. Legislative changes were introduced in the UK in
August, 1998, to try to restrict the purchase of paracetamol, and hence reduce the
incidence of ALF. Preliminary data from two liver transplantation units in England
suggest that this measure has reduced the number of referrals of patients with acute
liver failure (Hawton et al 2001; Prince et al 2000) however, both these units lack a
geographically well-defined referral population. Our study compared data from
patients admitted to SLTU in 1992-98 with those admitted in 1998-2001 to see
whether incidence and outcome had changed in Scotland since the introduction of
legislation (Newsome et al 2001). The incidence of paracetamol-induced liver
failure, severity of patients' illness, and outcome did not differ between the groups.




Paracetamol is often taken in overdose, and although N-acetyl-cysteine is a highly
effective antidote it must be given within 15 h to be most effective (Prescott et al
1979). Unfortunately, late presentation (>15 h) of overdose patients frequently leads
to the development of acute liver failure, which has a high mortality rate. Activation
of a relatively small percentage of paracetamol to A-acetyl-para-benzoquinone imine
(NAPQI) by cytochrome P450, predominantly CYP 2E1, has been found to be
involved in the mechanism of hepatic and, perhaps, renal toxicity (Bessems et al
2001). Most paracetamol is metabolized by glucuronidation, sulphation and
conjugation with glutathione, which protects the liver at therapeutic doses. Doses of
300 mg/kg per day paracetamol and higher saturate conjugation reactions, deplete
glutathione and result in binding of the benzoquinone imine to cellular proteins,
including enzymes and transport proteins therefore impairing their function and
leading to cell death (Blazka et al 1996; Laskin et al 1986; Moore et al 1985;
Vermeulen et al 1992). The predominantly centrilobular localisation of paracetamol-
induced liver injury is caused by the perivenular localisation of the cytochrome P-
450 (CYP) 2E1, the most important enzyme for the formation ofNAPQI. Oxidative
processes are also considered important in the pathogenesis of paracetamol-induced
liver cell damage. NAPQI is an oxidant, leading to the oxidation of thiol groups of
hepatocellular proteins. The formation of free radical metabolites or reactive oxygen
species may initiate the chain reaction of lipid peroxidation, which is an important
phenomenon in many types of liver injury. Severe paracetamol toxicity can be
prevented by the use of /V-acetylcysteine (NAC), which prevents the hepatic
glutathione stores from being depleted (Prescott et al 1979; Prescott 1979; Prescott et
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al 1980) and prevents progression to severe liver failure and death (if administered
early).
Severity and prognosis ofALF
In the event that severe liver injury results from the paracetamol overdose then
prognostic criteria are utilised to predict clinical outcome. The most widely used
criteria are the King's College Poor Prognosis Criteria (O'Grady et al 1989). If a
patient meets these criteria, they have only a 5% chance of spontaneous survival and
hence they are considered for Orthotopic Liver Transplantation (OLT). The criteria
can be summarised as follows:
Paracetamol overdosage- Concurrent finding of a serum creatinine >300|Jmol/l,
prothrombin time of >100 seconds, and grade III or IV encephalopathy in patients
with normal pH, or the single finding of a pH <7.3 at 24 hours or more following the
overdose after adequate fluid replacement.
Non-paracetamol cause- prothrombin time >100 seconds or presence of any three of
the following: serum bilirubin >300|Jmol/l, jaundice to encephalopathy >1 week, age
<10 or >40 years, aetiology non-A, non-B hepatitis or drug-induced hepatitis,
prothrombin time >50 seconds.
Therapeutic options
If patients with paracetamol overdose are identified early they can receive NAC in
the first instance, but as described earlier those patients who present late are unlikely
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to respond to this and can go on to develop ALF. For those patients who meet the
King's College Poor Prognosis Criteria there is only one clinically effective
treatment, OLT.
OLT is generally a safe procedure, although in the context ofALF the morbidity and
mortality do rise and one year survivals of 70% at 1 year (Bismuth et al 1995;
O'Grady et al 1991) are typical in contrast to 90+% survival for chronic liver disease
patients. Whilst OLT is the only effective treatment at present, it would be
inappropriate in many patients and is limited by a shortage of donor organs.
Furthermore, such patients have to take life-long immunosuppression with
consequent toxicities and side effects. For this reason, alternative therapies have been
explored to help both patients who are unsuitable for OLT and to help patients in the
setting ofOLT when critically ill.
The major two modalities investigated have been Bio-Artificial Livers and
hepatocyte transplantation. Several biological and non-biological liver support
systems have being developed over the years and are briefly reviewed below.
Non-biological systems include haemodialysis, haemofiltration, haemodiafiltration,
use of adsorbents such as charcoal and resin haemoperfiision, haemodiabsorption
plasmapheresis and plasma exchange. Despite prolonged and persistent testing, these
systems have not been proven to alter the course of illness (Bihari et al 1983;
Gazzard et al 1974; O'Grady et al 1988).
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A bio-artificial liver (BAL) or extra-corporeal liver assist device (ELAD) consists of
a mass of liver cells placed in a hollow fibre bioreactor perfused by the patient's own
blood or plasma. There are three critical components of a bio-artificial liver support
system (BAL): a) the biological component (functional hepatocytes), b) the
bioreactor which can accommodate these cells, c) the development of an efficient
circuit between the patient and the BAL in order to provide optimal exchange of
nutrients, oxygen and permit detoxification of the fulminant plasma.
Several systems have been or are in the process of being tested in human clinical
trials, although as yet there are no convincing studies demonstrating clinical efficacy.
There remain many questions as to the ideal cellular substrate (Tsiaoussis et al 2001)
and design of the BAL system. Consequently, more attention has been directed
towards the role of cellular transplantation in liver injury. As will be described in the
subsequent sections such cellular infusions can consist of hepatocytes (primary or
immortalised) or primitive stem cells.
1.2 HEPATOCYTE TRANSPLANTATION
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Orthotopic liver transplantation (OLT) has reduced the mortality of patients with
fulminant hepatic failure, end-stage liver disease, and metabolic liver diseases, but is
limited by donor organ availability and the requirement for lifelong
immunosuppression. It is reasonable to hypothesize that hepatocyte transplantation
may assist the management of these cases in several ways (Gupta et al 1999b;
Holzman et al 1993). In cases of acute liver failure, hepatocyte transplantation may
function as an adjunct treatment to provide temporary liver function to sustain
patients awaiting OLT. As the liver has a high regenerative ability, in some patients,
hepatocyte transplantation may allow enough time for the failing liver to regenerate.
However, at this time it is difficult to predict, even with best available prognostic
criteria (O'Grady et al 1989), which patients with acute liver failure will not need
OLT. On the other hand, for the treatment ofmetabolic diseases, the goal of
hepatocyte transplantation is to replace the metabolic function on a long-term basis
to an extent that should be sufficient for amelioration or, preferably, cure of the
disease. Furthermore, hepatocyte transplantation has several potential advantages
over OLT. Cell transplantation is a nonsurgical procedure with much less morbidity.
Where enzyme or protein replacement is the goal, several patients could receive cells
from a single donor, alleviating the donor organ shortage. Although the cost of long-
term immunosuppression may be similar to that of hepatocyte transplantation and
OLT, the initial expenses of hepatocyte transplantation are estimated to be about
10% that ofOLT. Indeed, for the treatment of metabolic diseases, cell transplantation
can be performed on an outpatient basis, avoiding the cost of hospitalization. If
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hepatocyte transplantation were to achieve its full potential, many cases ofwhole-
organ transplantation could be prevented, providing more livers for cases where cell
transplantation would not suffice. However, discarded livers are the usual source of
hepatocytes for cell transplants, and steatosis greater than 30% is the commonest
reason why a liver is discarded (Strom et al 2003). Thus, the challenge is to salvage
sufficient hepatocytes from such livers to provide an adequate supply of
transplantable hepatocytes. There is an increasing acceptance that hepatocyte
transplantation may not be sufficient alone to result in the survival ofpatients with
ALF, but that it may bridge them to OLT (Strom et al 1997b).
Hepatocytes can be genetically manipulated ex vivo with gene therapy protocols if
needed. In certain cases, hepatocyte transplantation may have several advantages
over current gene therapy methods. If the evidence obtained in experimental animals
can be reproduced in humans, hepatocytes engrafted in the host liver parenchyma
should survive for the lifetime of the recipient and express normal liver functions in a
stable manner. This would avoid immunologic and other complications associated
with the /« vivo use of recombinant viruses or other gene transfer vehicles and would
obviate the problems of promoter "silencing." Hepatocyte transplants have been
tolerated well immunologically, requiring relatively small doses of
immunosuppressive agents. During liver graft rejection, the immune response is
directed predominantly toward bile duct epithelium or endothelial cells. This is
predominantly due to the minimal expression of class I HLA antigens on hepatocytes
(Daar et al 1984), which result in a decrease in their antigenicity. Notably there is
increased expression of class I HLA antigens on the hepatocytes of patients who had
developed acute cellular rejection (So et al 1987). Approximately 20 years of
27
preclinical experience with laboratory animals has established the feasibility of
hepatocyte transplantation in treating liver-based diseases, leading to a movement of
hepatocyte transplantation from the bench to the bedside.
Preliminary demonstration of function after hepatocyte transplantation
Transplantation of isolated hepatocytes has been studied in the laboratory since the
early 1970s. Work in experimental animals demonstrated that following
transplantation into the liver, spleen, or other ectopic sites, hepatocytes displayed
normal architecture at the light and electron microscopic level (Kusano et al 1982;
Mito et al 1979). In addition, hepatocytes that integrated and survived at the
transplantation site display differentiated hepatocyte functions, including albumin
secretion (Demetriou et al 1986; Mito et al 1979; Moscioni et al 1989), glycogen
storage and glycolysis (Kusano et al 1982; Mito et al 1979), bilirubin conjugation
(Demetriou et al 1986; Hamaguchi et al 1994; Moscioni et al 1989; Vroemen et al
1986), ammonia metabolism (Habibullah et al 1994; Schumacher et al 1996;
Takeshita et al 1993), and cytochrome P450 gene expression (Maganto et al 1990).
Animal Models of Inherited Metabolic Diseases of the Liver
Hepatocyte transplantation has been used to correct defects of metabolic function of
the liver and to provide immediate liver function during acute liver insufficiency. In
Gunn rats with genetic deficiency of the enzyme that mediates bilirubin
glucuronidation (bilirubin-UGT), hyperbilirubinemia was ameliorated by hepatocyte
transplantation into the spleen, liver, or peritoneal cavity (Demetriou et al 1986;
Matas et al 1976), and bilirubin conjugates were identified in the bile of the recipient
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animals, indicating function of the transplanted cells (Vroemen et al 1986).
Significant increases in plasma albumin levels occurred following transplantation of
hepatocytes into analbuminemic rats (Holzman et al 1993; Moscioni et al 1996).
Transplantation of normal hepatocytes resulted in reduction of cholesterol levels up
to 50% in hyperlipidemic rabbits with inherited low-density lipoprotein (LDL)
receptor deficiency (Eguchi et al 1996; Gunsalus et al 1997) and, more importantly,
prevented the formation of atherosclerotic plaques in the aorta (Gunsalus et al 1997).
Animal Models of Liver Failure
Hepatocyte transplantation also provides support in experimental models of
fulminant hepatic failure. Enhanced survival or complete recovery of animals with
hepatic failure induced by a variety of mechanisms has been reported (Newsome et al
2000). Transplantation of hepatocytes significantly improves the survival of animals
in liver failure due to D-galactosamine-induced hepatic failure (Makowka et al 1981;
Sommer et al 1979), hepatic insufficiency following 90% hepatectomy (Demetriou et
al 1988), or ischemic liver injury. Hepatocyte transplantation can reverse hepatic
encephalopathy (Ribeiro et al 1992; Schumacher et al 1996) and prevent intracranial
hypertension in animals with ischemic liver failure (Arkadopoulos et al 1998). A
major limitation of hepatocyte transplantation is the inability to isolate an adequate
number of transplantable hepatocytes. A highly differentiated cell line, NKNT-3, was
generated by retroviral transfer in normal primary adult human hepatocytes of an
immortalizing gene that could be subsequently completely excised by Cre/Lox site-
specific recombination. When transplanted into the spleen of rats under transient
immunosuppression, reversibly immortalized NKNT-3 cells provided life-saving
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metabolic support during acute liver failure induced by 90% hepatectomy
(Kobayashi et al 2000).
Animal Models of Liver depopulation
Studies with transgenic mice overexpressing urokinase (uPA) (Rhim et al 1994;
Rhim et al 1995) and in mice deficient in the tyrosine metabolizing enzyme
fumarylacetoacetate hydrolase (Overturf et al 1996; Overturf et al 1997) show that in
situations where the host liver cells have reduced life-span, a small number of
transplanted differentiated adult hepatocytes can correct hepatic failure and almost
completely repopulate the donor liver. Small animal models will be important in the
refinement and identification of relevant mechanisms in relation to hepatocyte
transplantation, whereas large animal models (pig) will be more relevant for
successful translation into clinical practice.
Hepatocyte Transplantation for Liver Failure in humans
Hepatocyte transplantation for the treatment of human disease was first reported by
Mito and Kusano, who transplanted hepatocytes by injecting into the spleen in 10
patients in Japan (Mito et al 1992). In an intra-operative procedure, a lateral semi-
segmentectomy (S3) was performed on 10 patients with liver cirrhosis or chronic
hepatitis. Freshly isolated hepatocytes were infused immediately into the patients. In
two patients, 10 to 600 million hepatocytes were injected directly into the inferior
region of the spleen. The splenic hilum was clamped for several minutes to prevent
hepatocytes from migrating out of the spleen through the splenic vein into the portal
vein and liver. Epidermal growth factor was injected into the splenic artery to
30
stimulate hepatocyte proliferation. Hepatocytes could be detected in the spleen by the
radionucleotide uptake in 8 of 9 patients examined at times ranging from 1 to 11
months. Although the presence of the cells was established, the researchers did not
feel that the transplantation of hepatocytes was responsible for the clinical
improvement noted in the patients, but rather reported the feasibility and safety of the
procedure for future studies.
Habibullah et al. reported that the transplantation of fetal human hepatocytes into the
peritoneal cavity improved the survival of patients with fulminant hepatic failure
(FHF) (Habibullah et al 1994). In a study conducted in India, patients with FHF of
different aetiologies of less than 2 weeks' duration and having portosystemic
encephalopathy with grades III and IV encephalopathy and without other
complicating factors were admitted. Patients who did not give consent for the
hepatocyte transplantation served as controls. Hepatocytes were isolated from
aborted foetuses of either sex with gestational ages ranging from 26 to 34 weeks and
were pooled. The hepatocytes, 60 million/kg body weight, were transplanted
intraperitoneally. Survival in the hepatocyte-transplanted group was 48% and was
statistically different from the 33% survival rate observed in the matched controls in
patients with grade III and IVa encephalopathy. Survival was 100% in the transplant
group in patients with grade III encephalopathy. Hepatocyte transplantation did not
improve the survival of patients with grade IVb encephalopathy, suggesting that
hepatocyte transplantation is most effective when used earlier in the clinical course.
In survivors, recovery from portosystemic encephalopathy was observed after an
average of48 hours of cell transplantation and was accompanied by decreases in
blood ammonia and bilirubin levels. No patients with prothrombin times twofold of
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normal or higher survived. The authors suggested that the data demonstrated the
beneficial effect of fetal hepatocyte transplantation in FHF, with the most
pronounced effects observed in patients with grade III hepatic encephalopathy.
Work in the United States, set out to determine if hepatocyte transplantation could be
used to support hepatic function in end-stage liver failure in patients awaiting OLT.
Eleven patients, seven with fulminant hepatic failure and four additional patients
with chronic liver failure with acute decompensation, received hepatocyte transplants
into the splenic artery (Strom et al 1997a). Relatively few cells (not exceeding 1.2 x
109) could be transplanted owing to the impairment of blood flow caused by
hepatocytes lodging in the splenic capillaries. Two patients died awaiting OLT, six
of the nine patients with FHF survived long enough to receive whole-organ
transplants. Four patients with chronic liver disease with acute decompensation of
liver function received hepatocyte transplantation. One received a successful OLT,
one patient died of complications with an intracranial monitor, life support was
terminated on one patient on day 7 following hepatocyte transplantation because of
intracranial haemorrhage and a fourth patient with FHF resulting from a
trisegmentectomy died 48 hours following hepatocyte transplantation.
The average survival time in the patients who received successful OLT was 3.8 ± 3.3
days (mean ± standard deviation) with a range of 1 to 10 days. In the patients who
died awaiting OLT, survival was 4.6 days ± 2.5 days, with a range of 2 to 7 days.
Survival in control patients who elected to not receive hepatocyte transplantation was
2.8 days ± 2.5 days, with a range of 1 to 7 days. Because of the lack of statistical
significance of the difference in the duration of patient survival in the transplanted
control groups, it is difficult to prove that hepatocyte transplantation improved
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survival. However, some changes in clinical parameters suggest that the
transplantation of hepatocytes, even in small numbers, may be beneficial. In many
cases, blood ammonia levels decreased, cerebral blood flow improved, intracranial
pressure was reduced, and there was an improvement in encephalopathy after
hepatocyte transplantation (Strom et al 1997b; Strom et al 1997a). Increased
cardiopulmonary stability also was documented following hepatocyte
transplantation, by the decreased need or withdrawal of vasopressor drug support. In
the first few days following hepatocyte transplantation, the effects on synthetic
functions, such as circulating clotting factors and metabolic functions, such as
bilirubin conjugation, were variable or absent.
Hepatocytes as a Vehicle for Ex Vivo Gene Therapy
Prevention of rejection of allografted hepatocytes requires the administration of
immunosuppressive agents, which can be avoided by using autologous hepatocytes
harvested from the patient and transplanted back into the donor after phenotypic
correction by introduction of the therapeutic gene (Patel et al 1989). The first long-
term preclinical study of liver-directed ex vivo gene therapy was performed in LDL
receptor-deficient Watanabe heritable hyperlipidemic (WHHL) rabbits (Chowdhury
et al 1991). Primary hepatocytes harvested from WHHL rabbits were transduced
with a recombinant retrovirus expressing the human LDL receptor gene. The
phenotypically corrected hepatocytes were then transplanted into the donor rabbit,
resulting in long-term reduction of serum LDL levels. This was followed by a
clinical trial in patients with familial hypercholesterolemia, who also have
abnormalities of the LDL receptor (Grossman et al 1994; Grossman et al 1995).
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Results of the study in four patients showed a modest reduction of plasma cholesterol
levels and persistence of the transplanted cells and transgene function. Although it is
generally felt that the effect was not adequate for a therapeutic benefit, the
experiments established the feasibility of hepatocyte transplantation and the
longevity of the transplanted cells.
The precise number of hepatocytes needed to sustain the needs of a human recipient
has not been clearly established. Results from animal studies have suggested that
only 0.5 to 3% is required (Lake 1998) but this is at odds with clinical studies which
have demonstrated that the minimum amount of hepatic tissue required to sustain the
human body after partial hepatectomy is approximately 20% (300g) of the normal
liver mass (Lo et al 1997). Human studies of hepatocyte transplantation have not
answered the slightly different question of how much transplanted liver cell mass is
needed to maintain the body's basic metabolic needs in a disease (ALF)
characterised by the almost complete loss of functional hepatocytes. Studies in
patients with ALF have shown that smaller amounts of transplanted liver cell mass (5
to 80g) prolong life without leading to survival (Bilir et al 2000) so further studies
are required to identify the minimum amount of transplanted liver cell mass needed
to result in survival ofpatients with liver failure. The issue ofminimum cell number
is especially pertinent given that the availability of hepatocytes is limited. Of concern
are studies suggesting that hepatocyte transplantation in the context ofALF is
associated with very low levels of engraftment in the recipient liver (Allen et al
2001; Gupta et al 1999b).
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The optimum site of hepatocyte transplantation has also been the subject of much
research, with initial studies looking at ectopic sites because transplanted cells could
not otherwise be distinguished from host hepatocytes. Early studies established that
syngeneic hepatocytes could survive, proliferate and express genes normally in
several ectopic sites, such as the spleen (Gupta et al 1999b). Notably, hepatocytes did
not survive when transplanted into the splenic arterial bed (Mito et al 1978), whereas
cells trapped in vascular spaces, sinusoids and venous radicles were able to engraft
(Darby et al 1986). This dependence on vascular channels is nicely demonstrated by
the mouse spleen, which lacks sinusoids, and hence transplanted hepatocytes rarely
survive (Gupta et al 1999a). It is likely that spleen (with the exception ofmice)
confers appropriate vascular channels with extracellular matrix expression, without
the high velocity flow found in other organs such as the lung (Gupta et al 1999a).
Whilst hepatocytes appear to function well in the spleen, other sites such as the
dorsal fat pad and the peritoneal cavity were less effective in supporting hepatocytes.
This most likely reflected a combination of decreased cell survival and gene
expression and also greater immune responses against soluble gene products released
by the transplanted cell (Gupta et al 1994; Vemuru et al 1992). To this end studies
tried with only partial success to determine whether encapsulating transplanted
hepatocytes in biomaterials would diminish their immunogenicity thus preventing
rejection (Dixit et al 1990). These failed in part because encapsulation prevented the
necessary anchorage of hepatocytes to ECM (thus leading to cell death and/or de-
differentiation) and also because the biomaterials were degraded by the body in due
course leading to delayed immunogenicity. Other studies demonstrate that co-
transplantation of hepatocytes and biliary/endothelial cells into the peritoneal cavity
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led to prolonged survival in syngeneic recipients (Selden et al 1995). However, given
that endothelial cells play a central role in generating allograft rejection it is unlikely
that this will have widespread applicability. In contrast to ectopic sites, the liver
microenvironment offers many unique advantages for transplanted hepatocytes such
as the correct ECM, growth factors, nutrients as well as allowing the interaction with
other liver cells. Some of the most successful examples of hepatocyte transplantation
have been in animal models where the hepatocytes were infused intra-portally into
the liver. These include the amelioration ofjaundice in Gunn rats, which are a model
ofCrigler-Najjar syndrome (Groth et al 1977; Matas et al 1976; Rugstad et al 1970),
and also improved survival of animals with acute liver injury (Sommer et al 1979;
Sutherland et al 1977). Concerns also arose about the efficacy of cell transplantation
as studies demonstrated that intact cells were not necessary for improving outcomes
in animals with acute liver injury (Miyazaki et al 1983). Experiments with
subcellular fractions of hepatocytes demonstrated that an intact cell was not required
and that a heat stable "factor" (or factors) present in the cytosol fraction, which is not
insulin or glucagon, is responsible for the increase in survival observed. This factor
appears to increase the rate of endogenous regeneration of the injured recipient liver
(Makowka et al 1980).
Within the sinusoidal bed can be found the optimum microenvironment for an
engrafting hepatocyte, in terms of extracellular matrix components, growth factors,
nutrients and interactions with other cells. Several hours after cell transplantation the
sinusoidal endothelium is disrupted thus facilitating the entry of hepatocytes into the
space ofDisse. This effect is in part induced by the release of vascular endothelial
growth factor (VEGF) from both transplanted and host hepatocytes, which acts as a
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vascular permeability factor (Gupta et al 1999c). Engraftment of transplanted cells in
the liver requires their deposition in the hepatic sinusoids. Whilst most transplanted
cells (70%-80%) are destroyed in the liver within 24-48 hours, the remaining
transplanted cell fraction is observed to enter the liver plate after several hours, with
such cells eventually integrating within liver parenchyma (Gupta et al 1999c).
However, deposition of cells in hepatic sinusoids activates ischemia-reperfusion
events because sinusoidal blood flow is occluded transiently because of cells serving
as emboli. This leads to microcirculatory perturbations in the liver, activation of
glutamyl transpeptidase expression, and disruption ofgap junctions in native
hepatocytes (Gupta et al 2000b). Cell transplantation activates macrophages, as
demonstrated by their appearance in cellular infiltrates surrounding transplanted
hepatocytes (Gupta et al 1999c). Most transplanted cells that fail to engraft are
entrapped in portal vein radicles and these cells appear to be primarily cleared by
macrophage-mediated processes. Within normal liver architecture, hepatocytes bind
to basement membrane components such as laminin and collagen through cell
surface glycoproteins termed adhesion molecules. The adhesion to extracellular
matrix (ECM) is essential for the growth and survival of hepatocytes, such that their
displacement from ECM leads to dedifferentiation and apoptosis, a phenomenon
known as anoikis (Bretland et al 2001; Frisch et al 2001).
Extracellular matrix disruption in liver disease
The extracellular matrix of both diseased and normal liver has been examined more
closely in the light of suggestions that not only does ECM provide passive structural
support but that it also plays a major role in the maintenance of differentiated
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hepatocyte phenotype and function of liver parenchyma. The pattern ofECM
expression may also be important in cellular engraftment representing a scaffold to
which engrafting cells bind. Whilst there are documented variations in major ECM
expression across different types of chronic liver injury (see table 1.1) compared with
normal liver (Van Eyken et al 1990), there are no published data on their expression
in acute liver injury.
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Table 1.1 Extracellular matrix expression in normal and injured liver
Collagen IV Fibronectin Laminin Tenascin
Normal liver Positive staining of Positive staining of Weakly positive Faint staining of
Sinusoids & Basal Sinusoids & Portal /negative sinusoidal sinusoids
membranes ofblood tracts staining







Alcoholic Positive sinusoidal Positive sinusoidal Positive sinusoidal Positive
liver disease staining staining staining, most marked sinusoidal
Granular near fibrous septae staining
cytoplasmic staining Portal tracts
of hepatocytes negative
Cholestatic Positive sinusoidal Positive sinusoidal Positive sinusoidal Weak positive
liver disease and septal staining and septal staining and septal staining sinusoidal
staining
Acute As per normal liver As per normal liver As per normal liver Strongly positive
hepatitis sinusoidal
staining
Chronic Positive sinusoidal Positive sinusoidal Positive sinusoidal Positive
hepatitis staining staining staining sinusoidal
staining
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Adhesion to matrix; molecular mediators
Integrins appear to be the major receptors by which cells attach to extracellular
matrix, and are also important in mediating cell-cell adhesion events (Hynes 1992).
Integrin mediated adhesion is fundamental to cell transplantation as only after this
has been successfully negotiated can cells respond to appropriate migratory signals
and migrate across the endothelium and into the liver plate. Integrins are
heterodimeric transmembrane proteins consisting of non-covalently linked alpha and
beta chains each with a large extracellular, single transmembrane and short
cytoplasmic domain (Hynes 2002). Integrins are activated by contact with ECM
proteins (Wu et al 1995) which leads to inhibition of interleukin-lbeta converting
enzyme expression preventing apoptosis and thus providing them with a major role
in determining cell survival (Giancotti et al 1999). Once activated, integrins lead to
protein tyrosine phosphorylation which has been shown to play a protective role in
the regulation of apoptosis (Evans et al 1993; McGahon et al 1995; Simizu et al
1996; Tallett et al 1996). In the setting of small cell lung cancer cells, ECM-mediated
protection from etoposide-induced caspase-3 activation can be blocked by either pi-
integrin function-blocking antibody or by a tyrosine kinase inhibitor (Sethi et al
1999; Tallett et al 1996) Other groups have demonstrated that ECM regulates
apoptosis (mammary epithelial cells) through an integrin-dependent negative
regulation of Interleukin-ip-converting enzyme (ICE) expression, whereby
expression of ICE was correlated with the loss ofECM and inhibitors of ICE activity
prevented apoptosis (Boudreau et al 1995). Thus, integrin activation prevents the
ICE-mediated induction of caspase-3 activity. Therefore factors which modulate the
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interaction and hence activity of integrins play an important role in determining cell
adhesion and survival (Diamond et al 1994; Kim et al 1997). Our understanding of
the factors controlling integrin affinity are incomplete but work suggests that control
is exerted in an energy dependent fashion on their cytoplasmic domain (Kim et al
1997). CD98 has been suggested as a potential controller ofPi-integrin affinity; its
crosslinking leading to activation of the Pi-integrin and hence maintenance of
integrin survival signaling (Cho et al 2001).
A clear understanding however does not exist as to what factors in liver injury
modulate the engraftment and survival of transplanted cells, with most work
concentrating on the toxicity of the host environment to donor cells.
Integrin expression on hepatocytes and hepatocellular carcinoma cells
Integrin a5 pi and o2 pi are the major integrin receptors in human hepatocytes.
However, in human hepatocellular carcinoma (HCC) cells it was found that the
expression of integrin a5 pi was decreased and another integrin a6 pi increased
(Masumoto et al 1999). Several studies have described altered expression of P 1
integrins in hepatocellular carcinoma (HCC). Reduced expression of a 2, a 3, and a 5
subunits (Jaskiewicz et al 1995; Yao et al 1997) and overexpression of a 6 subunits
of P 1 integrins (Begum et al 1995) have been shown in HCC with aggressive
phenotypes.
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In vitro models of hepatocyte transplantation
With a view to establishing in vitro models of hepatocyte transplantation groups have
studied the effect of incubating hepatocytes in culture with either toxins or sera from
liver injured patients. Serum from patients with fulminant hepatic failure has been
shown to induce a dose-dependent inhibition of proliferation (Anilkumar et al 1997;
Demetriou et al 1974; Gohda et al 1986; Gove et al 1982; Tada et al 1986; Williams
et al 1977; Yamada et al 1994) and protein synthesis (Shi et al 1998), and in some
studies induces cell death (Fujioka et al 1997; Hughes et al 1976; Williams et al
1977) of cultured hepatocytes.
Cell death: Apoptosis and Necrosis
Apoptosis and necrosis are two major processes by which cells die. Apoptosis is the
ordered disassembly of the cell from within resulting in changes in the phospholipid
content of the plasma membrane outer leaflet (Thornberry et al 1998).
Phosphatidylserine (PS) is exposed on the outer leaflet and phagocytic cells
recognizing this change engulf the apoptotic cell (Fadok et al 1992). Necrosis
however, normally results from a severe cellular insult, and is characterised by the
presence of an inflammatory response. Both internal organelle and plasma membrane
integrity are lost, resulting in spilling of cytosolic and organellar contents into the
surrounding environment. Immune cells are attracted to the area and begin producing
cytokines that generate an inflammatory response. Other techniques that have been
used to distinguish apoptosis from necrosis in cultured cells and in tissue sections
include detecting PS at the cell surface with annexin V binding (Ferlini et al 1997),
DNA laddering (Facchinetti et al 1991), and staining cleaved DNA fragments that
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contain characteristic ends. At the extremes, apoptosis and necrosis clearly involve
different molecular mechanisms, but it is not clear if there is cellular death involving
both the molecular mechanisms of apoptosis and those of necrosis. Many
pathological features can be used to differentiate between apoptosis and necrosis,
although they are not all well suited for rapid quantitation of the phenomena as they
occur (see table 1.2 below).
Table 1.2 Features distinguishing apoptosis and necrosis
Apoptosis Necrosis
Cell size Decreases with evidence Swelling of cells
of fragmentation
Plasma membrane Blebbing of membrane. Lysis occurs early on
Phosphatidyl serine
expressed on surface
Mitochondria Morphology and structure Swollen and architecture
preserved disrupted
Nuclei Clumping and Disruption ofmembrane
fragmentation of
chromatin
Cell degradation No inflammation, just Inflammatory response
phagocytosis visible
Cell death induced by free radicals, however, may have characteristics of apoptosis
and necrosis (Kane et al 1993).
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Cytosolic Aspartate-Specific Proteases, called caspases, are responsible for the
deliberate disassembly of a cell into apoptotic bodies. Caspases are present as
inactive pro-enzymes, most ofwhich are activated by proteolytic cleavage. Caspase-
8, caspase-9, and caspase-3 are situated at pivotal junctions in apoptotic pathways.
Caspase-8 initiates disassembly in response to extracellular apoptosis-inducing
ligands and is activated in a complex associated with the receptors' cytoplasmic death
domains (Ashkenazi et al 1998). Caspase-9 activates disassembly in response to
agents or insults that trigger release of cytochrome c from the mitochondria (Liu et al
1996) and is activated when complexed with dATP, APAF-1, and extramitochondrial
cytochrome c (Li et al 1997). Caspase-3 appears to amplify caspase-8 and caspase-9
signals into full-fledged commitment to disassembly (Thornberry et al 1998). Both
caspase-8 and caspase-9 can activate caspase-3 by proteolytic cleavage and caspase-
3 may then cleave vital cellular proteins or activate additional caspases by proteolytic
cleavage.
There are two main pathways that lead to apoptosis: i) positive induction by ligand
binding to a plasma membrane receptor and ii) negative induction by loss of a
suppressor activity. Each leads to activation of cysteine proteases with homology to
IL-1|3 converting enzyme (ICE) (i.e., caspases) (Thornberry et al 1998). Positive-
induction involves ligands related to TNF. Ligands are typically trimeric and bind to
cell surface receptors causing aggregation (trimerization) of cell surface receptors
(Ashkenazi et al 1998). The intracellular portion of these receptors contains an 80
amino acid death domain (DD) that through homophilic interactions recruits adaptor
proteins to form a signaling complex on the cytosolic surface of the receptor
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(Ashkenazi et al 1999). The bringing together of three receptors, thereby orienting
the intracellular DDs, appears to be the critical feature for signaling by these
receptors. The adaptor complex then recruits caspase-8, caspase-8 is activated, and
the cascade of caspase-mediated disassembly proceeds. Negative induction of
apoptosis by loss of a suppressor activity involves the mitochondria (Green et al
1998). Release of cytochrome c from the mitochondria into the cytosol serves as a
trigger to activate caspases (Liu et al 1996). Permeability of the mitochondrial outer
membrane is essential to initiation of apoptosis through this pathway. Proteins
belonging to the Bcl-2 family appear to regulate the membrane permeability to ions
and possibly to cytochrome c as well (Reed 1997). Although these proteins can
themselves form channels in membranes, the actual molecular mechanisms by which
they regulate mitochondrial permeability and the solutes that are released are less
clear. The Bcl-2 family is composed of a large group of anti-apoptosis members that
when overexpressed prevent apoptosis and a large group of pro-apoptosis members
that when overexpressed induce apoptosis. The balance between the anti-apoptotic
and pro-apoptotic Bcl-2 family members may be critical to determining if a cell
undergoes apoptosis. Thus, the suppressor activity of the anti-apoptotic Bcl-2 family
appears to be negated by the pro-apoptotic members.
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1.3 STEM CELL DIFFERENTIATION AND TRANSPLANTATION
It is widely accepted that peripheral blood cells originate from a small population of
pluripotent stem cells which are found in the bone marrow. These cells are
characterised by their ability for extensive proliferation (without loss of pluripotency
in the in vivo setting) and their ability to differentiate into any of the haematopoietic
lineages. Haematopoietic stem cells have been characterised in vitro by their ability
to generate different haematopoietic lineages in assays such as the Colony Forming
Unit assay (CFU). In vivo assays have included infusion of sorted human stem cells
into sub-lethally irradiated NOD-SCID mice. NOD-SCID mice are class I deficient,
B and T cell deficient, C-5 deficient, and have low NK cells, and are an ideal model
for xenograft transplantation studies (Shultz et al 2000). Notably, they are both
insulitis- and diabetes-free throughout life. In this setting, they can be shown to
reconstitute all of the human haematopoietic lineages within the mouse. Attempts to
identify and purify these haemopoietic stem cells have centred on antigens expressed
on their cell surface. The most commonly used marker for the isolation and
manipulation of stem cells is the CD34 antigen (Sutherland et al 1992). Recently a
novel antigen, AC133, expressed on human haemopoietic stem cells was reported.
This antigen is a unique five-transmembrane (5-TM) molecule and the monoclonal
antibody raised against the protein recognises a subset of CD34 cells in bone
marrow (Miraglia et al 1997; Yin et al 1997). AC133 has been shown to select cells
which engraft successfully in a fetal sheep transplantation model in both primary and
secondary recipients, indicating the presence of long-term repopulating cells.
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Recent studies have demonstrated that haematopoietic stem cells have greater
plasticity than previously thought and can differentiate down multiple non-
haematopoietic cell lineages in rodents (Graf 2002; Krause et al 2001; Petersen et al
1999; Theise et al 2000a). Petersen et al demonstrated that when mis-matched bone
marrow was infused into liver-damaged syngeneic mice these donor cells were able
to differentiate into hepatic oval cells and hepatocytes (Petersen et al 1999). The
method of liver injury used included Acetylaminofluorene (AAF) followed by 2/3
partial hepatectomy, which is designed to prevent a reparative response from
differentiated hepatocytes. Instead regeneration occurs due to the proliferation and
subsequent differentiation of hepatic oval cells (HOCs) which are bipotent primitive
hepatocytes residing in the canals ofHering (Theise et al 1999). AAF is metabolised
by mature hepatocytes to atoxic metabolite which prevents cell division. As HOCs
do not possess the enzymes required to metabolise AAF they are immune to its
effects and thus have a proliferative advantage compared with differentiated
hepatocytes. Several types ofmis-matching were performed including gender (male
to female), Dipeptidyl peptidase IV+ (DPPIV+) to DPPIV - mice and liver
transplantation (liver transplanted from Brown Norway rats into Lewis rats). DPPIV
+ and - mice are transgenic mice which either express the enzyme DPPIV or not.
Similar work by Theise et al demonstrated that such differentiation could occur in
the absence of any intentional liver injury (Theise et al 2000a). There is debate as to
the effect of irradiation on the liver, but at the levels used for marrow transplantation
it causes only a mild effect on hepatocyte proliferation. Whilst much of this work has
used bone marrow derived stem cells there are several reports suggesting that stem
cells obtained from muscle (Asakura et al 2001; Wada et al 2002) and brain also
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share these pluripotent properties (Shih et al 2002). Lagasse et al were able to
demonstrate that this phenomenon had functional significance when they showed
that infusion of syngeneic murine adult bone marrow cells into the
fumarylacetoacetate hydrolase (-/-) FAH mouse, an animal model of tyrosinemia
type I, rescued the mouse and restored the biochemical function of its liver (Lagasse
et al 2000). Histological analysis of the livers of these animals demonstrated almost
total reconstitution with donor-derived hepatocytes and is the most convincing
evidence to date that stem cells may have a therapeutic role in liver injury. Notably,
this is the only model in which infused stem cells had a survival advantage over host
cells, in this case hepatocytes. That adult human stem cells also share some of these
pluripotent properties has been demonstrated in studies utilising archival biopsy
samples (Alison et al 2000) in which donor-derived hepatocytes and cholangiocytes
have been observed in the recipient. In both of these studies, the presumed origin of
stem cells was the bone marrow, and both studies used cross-sex transplants to
differentiate host from recipient hepatocytes. A study by Korbling et al (Korbling et
al 2002) demonstrated that human stem cells mobilised by Granulocyte-Macrophage
Colony stimulating factor (GM-CSF) (as used in the management of haematological
conditions) also retained the ability to differentiate down hepatocytic and other non-
haematopoietic lineages. As yet, the biological relevance of human stem cell
transdifferentiation remains to be clarified, as therapeutic efficacy has not yet been
demonstrated with human stem cells.
After the initial optimism regarding stem cell plasticity there have been reports
which suggest that the actual level of differentiation (into hepatocytes) may be lower
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than previously thought. Wagers et al infused a single Green fluorescent protein+
(GFP) c-kit+ Thyl.l'0 Lin" Sca-1+ cell from murine bone marrow into a lethally
irradiated GFP" syngeneic recipient and only observed 7 GFP+ hepatocytes in the
recipient liver, in the face of 17.6-20.2% peripheral blood reconstitution (Wagers et
al 2002). c-kit+ Thyl. l'° Lin" Sca-1+ are widely regarded as the most pluripotent
murine haematopoietic stem cell in transplantation models (Morrison et al 1994;
Morrison et al 1997; Spangrude et al 1988). The conclusion drawn from these studies
was either that haematopoietic stem cells only exceedingly rarely contributed to non-
haematopoietic lineages, or that there are lineage-committed stem cells in the
marrow which differentiate down the non-haematopoietic lineages (ie they are not
haematopoietic stem cells). To test whether such lineage-committed cells existed
they utilised parabiotic animals. These animals are surgically joined so that they
rapidly develop a common anastomosed circulatory system and develop
haematopoietic chimerism. This model permits analysis of haematopoietic cell
function in the absence of any injury, as irradiation is not required. GFP transgenic
and non-transgenic littermate were surgically joined together but they were unable to
identify any evidence of hepatocyte or other non-haematopoietic GFP' cells in the
GFP" partner, suggesting that if such cells exist they do not contribute to non-
haematopoietic tissues in the absence of injury.
Furthermore, somatic stem cell plasticity has recently been questioned, and it has
been suggested that this presumed differentiation may be the product of cell fusion
between stem cells and pre-existing differentiated cells (Terada et al 2002; Vogel
2002; Ying et al 2002). These observations have important implications for stem cell
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usage and if confirmed in in vivo studies may limit the benefits of stem cell
transplantation.
However, the lack of suitable in vivo or in vitro model systems has hindered detailed
study of stem cell plasticity. With respect to murine in vitro studies several groups
have demonstrated that embryonic stem cells can be directed down non-
haematopoietic lineages including hepatocytes, neuronal cells and myocytes
(Ishizaka et al 2002; Jones et al 2002). Extensive work with murine multipotent adult
progenitor cells (MAPCs) which are a type of mesenchymal stem cell found in bone
marrow has demonstrated the ability of such cells to differentiate into
haematopoietic, hepatocytic, pneumocytic and enterocytic lineages (Jiang et al
2002).
It would be important to develop systems whereby human stem cells could be
directed towards non-haematopoietic lineage in the in vitro setting to facilitate both a
greater understanding of the mechanisms controlling this process and to expand the
clinical utility of human stem cells. In addition, the development of an in vivo model
of human stem cell differentiation down non-haematopoietic lineages is an essential
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2.1 BACKGROUND AND AIMS
Cell transplantation of hepatocytes, has been studied extensively in vivo both in
animal models and humans (Lee 2001) and has been shown to contribute to hepatic
function, although proven benefit has been largely limited to metabolic liver diseases
(Muraca et al 2002). However, when hepatocyte transplantation has been used in
models ofacute liver injury and patients with fulminant hepatic failure there is a
significant reduction in both engraftment and subsequent efficacy (Birraux et al
1998; Gupta et al 2000a). A clear understanding however does not exist as to what
factors in liver injury modulate the engraftment and survival of transplanted cells,
with most work concentrating on the toxicity of the host environment to donor cells.
Serum from patients with fulminant hepatic failure has been shown to induce a dose-
dependent inhibition of proliferation (Anilkumar et al 1997; Demetriou et al 1974;
Gohda et al 1986; Gove et al 1982; Tada et al 1986; Williams et al 1977; Yamada et
al 1994) and protein synthesis (Shi et al 1998), and in some studies induces cell death
(Fujioka et al 1997; Hughes et al 1976; Williams et al 1977).
The present study was undertaken to answer the following questions:
1) Is there a change in the extra-cellular matrix protein expression in acute liver
injury?
2) Do hepatocytes exposed to acute liver injury serum hcn'e altered adhesive
properties?
2) Ifso, does apoptosis contribute to the obser\>ed changes in cellular adhesion?
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2.2 MATERIALS
FHF serum was pooled from patients with acute liver failure due to paracetamol
overdose. All patients were in the intensive therapy unit (ITU) at time of sampling
and fulfilled the poor prognosis criteria for liver transplantation (O'Grady et al 1989).
Samples were taken within 48-96 h of paracetamol overdose and none of the patients
had detectable paracetamol in their serum at the time of sampling. Normal serum was
obtained from healthy individuals. Tissue from liver biopsy specimens was obtained
from the Department ofPathology: the biopsies were from patients who had acute
liver failure fulfilling the poor prognosis criteria for liver transplantation (O'Grady et
al 1989). This study had local ethics committee approval.
2.3 METHODS
Cell culture
HepG2 is a human hepatoma derived line and it was routinely grown in
mono/multiplayer cultures in Dulbecco's' Modified Eagle Medium (DMEM)
containing 10% (vol/vol) fetal calf serum (FCS) in an atmosphere of 5% CO2 in air.
This concentration of serum is standard in the literature (Shi et al 1998). Cells were
subcultured every 7 days at a split ratio of 1:3 using 0.05% (wt/vol) trypsin and
EDTA to detach the cells. Cells used were within 10 and 20 passages of purchase.
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Cell necrosis and apoptosis experiments
Cell necrosis (Propidium Iodide)
1.25 x 106 HepG2 cells were grown on 25cm2 flasks and exposed to media
containing 20% (vol/vol) FHF serum, 20% normal serum (vol/vol), or 10% FCS
(vol/vol) for 1,4, 12, 24, 48 and 72 hours. All cells (adherent and non-adherent) were
collected and resuspended in phosphate-buffered saline (PBS) (pH 7.2) before
determining the cell number and viability with Propidium iodide exclusion on a
Coulter XL flow cytometer (Coulter Electronics, Luton, UK). Briefly, to 1ml of cell
suspension lOOpl of 0.025% Propidium iodide solution was added 10 minutes before
analysis and samples were analysed where non-viable were read as those cells
positive for propidium iodide (Hart et al 2000). The cell count was assessed with a
Neubauer cytometer.
Feu/gen Nuclear morphology (adherent cells)
1 x 10"HepG2 cells were grown on collagen coated glass slide-flasks (NUNC,
Loughborough, UK) and exposed to media containing 20% (vol/vol) FHF serum,
20% normal serum (vol/vol), or 10% FCS (vol/vol) for 1, 4, 12, 24, 48 and 72 hours.
Slides were incubated in Bourn's reagent (Sigma, UK) for 2 hours and then placed in
1M hydrochloric acid for lh. Slides were then washed in water prior to 45min
incubation in SchifFs reagent (see Appendix page 207). They were washed again
prior to counterstaining in light green dye for 10 sec. Slides were then washed,
dehydrated through alcohols, immersed in xylene and then coverslipped. The number
of apoptotic nuclei was counted per 100 cells. This was performed 6 times per slide
54
and each experiment repeated 9 times. Values were expressed as percentage of
apoptotic cells. Two blinded experienced observers counted slides.
Caspase assay
The Enzchek1M Caspase-3 Assay Kit (Molecular Probes lnc, Eugene, Oregon, USA)
was used. This kit allows for the detection ofapoptosis by assaying for increases in
caspase-3 and other DEVD-specific (amino acid sequence Asp-Glu-Val-Asp)
protease activities such as caspase-7. The basis for the assay is the 7-amino-4-
methylcoumarin-derived substrate 7-Amino-4-methylcoumarin, N-CBZ-L-aspartyl-
L-glutamyl-L-valyl-l-aspartic acid amide (Z-DEVD-AMC, where Z represents a
benzyloxycarbonyl group), which is weakly fluorescent in the UV range
(excitation/emission ~330/390nm), but which yields a bright blue-fluorescent
product (excitation/emission ~ 342/44lnm) upon proteolytic cleavage.
The method was as follows:
1) 5 x 106 HepG2 cells were grown on 75cm2 flasks and exposed to media containing
20% (vol/vol) FHF serum or 20% normal serum (vol/vol) for 24 hours. Cells were
then removed with Trypsin/EDTA, PBS washed and then pelleted.
2) lx Cell lysis buffer was then prepared by adding 950pJ of dH20 to 50pl of the 20x
Cell lysis buffer. 20x Cell lysis buffer consists of 1.5ml of 200nM TRIS, ph 7.5, 2M
NaCl, 20mM EDTA and 0.2% Triton X-100. Samples were incubated on ice with lx
lysis buffer for 30 minutes.
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3) The lysed cells were then centrifuged at 5000rpm for 5 minutes in a
microcentrifuge. 50pl of the supernatant from each sample was then transferred to
individual microplate wells. 50pi of the lx lysis buffer was used as a no enzyme
control to determine the background fluorescence of the substrate. As an additional
control, 1 pi of the 1 mM Ac-DEVD-CHO inhibitor stock solution was added to
selected samples. The plate was then covered and incubated at room temperature for
10 minutes.
4) 50pl of the 2x substrate working solution was added to each well. This consisted
of 20pl of lOmM Z-DEVD-AMC substrate and 980pl of the Reaction buffer (20ml
of 50mM PIPES, pH 7.4, lOmM EDTA, 0.5% CHAPS).
5) Plate was then covered and incubated at room temperature for 30 minutes.
Fluorescence was measured in a fluorescent microplate reader using excitation at
485±12.5nm after 60 minutes. Values are expressed as the difference between
samples incubated with and without the Ac-DEVD-CHO inhibitor to ensure that the
values reflect activity of caspase-3-like proteases.
Annexin Vstaining
Annexin V is expressed on the cell surface as an early marker of apoptosis.
Expression of Annexin V is measured flow cytometrically and expressed as
increasing fluorescence. PFOA, a known apoptotic agent to HepG2 cells, is used as a
56
positive control. Cells were grown on 25cm2 flasks and exposed to media as
described previously. Cover the cells with Dispase solution for 5 minutes at 37°C.
Decant the solution and incubate for an additional 10 minutes at 37°C. Monitor
detachment using a microscope. If necessary, incubate for an additional 15 minutes
or until detachment is complete. Suspend the cells in culture medium and pellet cells
by centrifugation, before washing the cells with culture medium.
Dispase was used as trypsin detachment can result in internalisation of Annexin V.
Cells were then washed twice with cold PBS and resuspended cells IX Binding
Buffer (see Appendix page 236) at a concentration of 1 x 106 cells/ml. A 100 pi of
the solution (~1 x 105 cells) was then transferred to a 5 ml culture tube and incubated
with 2 pi FITC-labelled Annexin V (Sigma, Dorset, UK) for 10 minutes on ice
before washing (with 1 X Binding Buffer) and centrifugation. Pellets were re-
suspended in 400pl Binding Buffer prior to analysis on a FACS machine (Hart et al
2000).
Confocal actin microscopy
Cells were cultured on collagen-coated coverslips, fixed with 4% formaldehyde for
20 minutes, rinsed with PBS, permeabilized with 0.5% Triton X, before addition of
fluorescent phalloidin for a further 20 minutes. Coverslips were then washed again
with PBS prior to mounting and analysis on a confocal microscope.
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Scanning Electron Microscopy (SEM)
HepG2 cells were grown on Collagen coated Perspex coverslips (NUNC, UK)
according to the same treatment schedule described in the cell culture section. After
24 h culture samples were fixed using 2.5% glutaraldehyde, and then dehydrated and
coated with gold for scanning electron microscopy (SEM).
Transmission Electron Microscopy (TEM)
HepG2 cells were grown under standard conditions as described in the cell culture
section. Cells were removed from flasks by trypsinisation/FCS and then pelleted into
appropriate tubes. Processing for TEM was then performed as described below.
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1. Fixation
3%Glutaraldehyde in 0.1M Sodium Cacodylate Buffer 2-24hours
2. Wash
0.1M Sodium Cacodylate Buffer 3x20min
3. Post-Fixation
1% Osmium Tetroxide in 0.1M Sodium Cacodylate Buffer 45-60min
4. Wash





100% Acetone (Analar) lxlOmin
6. Mixing
Araldite Mix: Acetone (Analar) 50:50 lx30min
7. Infiltration




Araldite Mix with Accelerator
10. Embedding






Archival sections from explanted livers from patients with FHF and from healthy
livers were obtained. Slides were dewaxed in xylene and progressively dehydrated
through graded alcohols and water. Antigen retrieval was performed using 0.1%
trypsin (15 min at 37°C) or Vector Target Retrieval solution (microwaved for 15
min). Slides were then processed with the Envision Kit (DAKO Laboratories, Ely,
UK) for Collagen IV, Laminin, Fibronectin and Tenascin (DAKO Laboratories, Ely,
UK). ENVISION staining steps are summarised as follows on the next page.
This is a two-step IHC staining technique. This system is based on an HRP labelled
polymer which is conjugated with secondary antibodies. The labelled polymer does
not contain avidin or biotin. Consequently, nonspecific staining resulting from
endogenous avidin-biotin activity in liver, kidney, lymphoid tissues and cryostat
sections is eliminated or significantly reduced. This protocol offers an enhanced
signal generating system for the detection of antigens. Primary antibodies produced
in mouse react well with the labelled polymer.
Principles of procedure
Any endogenous peroxidase activity is quenched by incubating the specimen for five
minutes with Peroxidase Block. The specimen is then incubated with an
appropriately characterized and diluted mouse primary antibody, followed by
incubation with the labelled polymer, using two sequential 30-minute incubations.
Staining is completed by a 5-10 minute incubation with 3,3'-diaminobenzidine




1. Dewax in xylene for 5minutes
2. Rehydrate through alcohol into water
3. Antigen retrieval as above
4. Wash in water
5. Apply peroxidase block (10ml H202 in 290ml tap water) for 10 minutes
6. Load in sequenzas
7. Wash with PBS
8. Apply primary antibody in DAKO diluent for 30 minutes
9. Wash with PBS
10. Apply labelled polymer for 30 minutes.
11. Wash with PBS
12. Apply DAB Chromagen for 5 minutes
13. Wash with double-distilled water
14. Wash in water
15. Counterstain in Haematoxylin for 30 seconds
16. Wash in tap water
17 Wash in Acid-Alcohol
18. Wash in tap water
19. Wash in Scott's water for 15 seconds. Scott's tap water is used to "blue" nuclear
structures subsequent to staining with haematoxylin. This mild, buffered bluing agent
will not loosen or float away your tissue or smear preparation. It blues quickly and
any excess is easily removed with a tap or distilled water rinse.
20. Wash in tap water
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21. Dehydrate through alcohols
22. Place in clearing xylene, then 2nd Xylene and then mounting Xylene
23. Mount
Adhesion assay
HepG2 cells were grown on 25cm2 flasks and exposed to media containing 20%
(vol/vol) FHF serum, 20% normal serum (vol/vol), or 10% FCS (vol/vol) for 1, 4, 12,
24. 48 and 72 hours. All cells were then removed from the flasks (Trypsin/EDTA),
washed with PBS and placed onto Collagen IV (1 pg/cm2) coated wells (BD
Biosciences) of a 96 well plate at a concentration of2x 10" cells /lOOpl for a period
of lh. Collagen IV coating involved placing lOOpl of a 1 pg/cm2 Collagen IV
solution into wells, leaving for 2 hours before aspirating any remaining solution.
Wells were then PBS-washed, fixed with methanol, stained with methylene blue and
then lysed with 1M hydrochloric acid. Plates were then read on a spectrophotometer
to quantify cellular adhesion. Results were expressed as a percentage of the adhesion
results obtained with cells cultured with DMEM and 5% FCS (vol/vol) (Sethi et al
1999).
Cell count assay
After PBS washing HepG2 cells were re-suspended in PBS. lOOpl of cell suspension
were then mixed with lOOpl of Trypan Blue solution. 30pl of the cell suspension
was then placed under the coverslip on the haemocytometer (Neubauer) and counted




For the immunohistochemical analysis, 6 separate acute liver failure liver explants
were examined for their expression ofECM markers. An initial dose-ranging study
of fulminant and normal serum was performed to identify the optimal concentration
to use in subsequent experiments. In the cell adhesion work experiments were done
in multiples of eight on at least three separate occasions. Apoptosis work was done
on in triplicate on at least three separate occasions.
2.5 STATISTICAL ANALYSIS OF DATA
T test assuming unequal variances was used to compare groups. Where multiple
analyses were required ANOVA with post-hoc analysis was performed. A p value of
<0.05 was used to define significance.
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2.6 RESULTS
Liver injury leads to up-regulation of Collagen IV in the hepatic sinusoids and
portal tracts.
We determined the ECM composition of unselected liver specimens from patients
with paracetamol-induced fulminant hepatic failure by immunohistochemical
staining for collagen IV, fibronectin, laminin and tenascin. There is a marked
increase of collagen IV in the hepatic sinusoids of patients with paracetamol-induced
FHF (Figure 2.1, B/C) compared with healthy controls (A). This contrasts with the
immunostaining of laminin (J-L) and fibronectin (D-F), which is only seen to occur
in areas of hepatocyte necrosis, and probably reflects non-specific uptake of
antibody/chromagen by dead cells. Tenascin is expressed in the same distribution as
Collagen IV although at much lower levels (G-I).
20% is the optimal concentration of Fulminant Serum
My initial work aimed to identify the optimal concentration of serum to use in my
subsequent experiments. Using Normal serum at concentrations of 10-30% there was
evidence of increased cell death (Figure 2.2) at the highest concentration (30%),
whilst the lower concentrations (10 & 20%) were not associated with any toxicity.
The levels of cell death were compared with cultures grown with 10% Fetal Calf
Serum (FCS). Study ofFulminant serum at the lowest concentrations (10%)
demonstrated no significant toxicity, and for this reason all subsequent experiments
were done with sera at a concentration of 20%. The difference in cell death between
cultures with 20% Normal and Fulminant serum was only significant at 48 hours
(p<0.0001); 4.32 ± 0.67 vs 18.2 ± 1.84% respectively.
Figure 2.1
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Legend for figure 2.1
The left hand column details the expression ofCollagen IV (A), Fibronectin (D),
Tenascin (G) and Laminin (J) in normal healthy liver. Expression ofCollagen IV can
be seen to be strikingly up regulated in B/C, with most of its expression localised to
sinusoidal endothelium and portal tracts (see arrows). In contrast, Fibronectin (E/F)
and Laminin (K/L) display only evidence of non-specific uptake by necrotic
hepatocytes. Tenascin is expressed in the same distribution as Collagen IV although
at much lower levels (G-I). Scale bar 20pm.
66
Figure 2.2
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Legend for figure 2.2
These figures demonstrate cell death as measured by the inability of dead cells to
exclude propidium iodide. Error bars indicate the Standard Errors. In the upper
figure, the amount of cell death is similar for cells cultured with 10% fetal calf serum
(FCS), or 10 & 20% normal human serum. However, 30% normal human serum does
lead to increased cell death. In the lower figure, differing concentrations of fulminant
serum are used. Only 20 and 30% can be seen to cause increased cell death. The
difference in cell death between cultures with 20% Normal and Fulminant serum was
only significant at 48 hours (p<0.0001); 4.32 ± 0.67 vs 18.2 ± 1.84% respectively.
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Adhesion ofHepG2 cells is impaired by exposure to fulminant serum
In view of the marked up-regulation ofCollagen IV expression in liver, I studied the
binding ofHepG2 cells to collagen-coated plates after previous culture with
fulminant serum. Exposure to fulminant serum for only 4 hours caused a marked loss
of adhesion on to Collagen coated plates (figure 2.3), which contrasted with normal
serum, which did not alter adhesive properties (54.9 +/- 6.3 % vs. 92.7 +/- 10.1 %;
p<0.01). This effect of fulminant serum was assessed morphologically by scanning
electron microscopy (SEM) images which revealed striking differences in
morphology after 4 hours culture as demonstrated by rounding up of cells cultured
with fulminant serum (figure 2.4), in marked contrast to the well-spread cells
cultured with normal serum. Panels A & B from Figure 4 depict adhesion ofHepG2
cells after 4 hours exposure to Normal serum, whilst Panels C & D depict HepG2
cells 4 hours after exposure to Fulminant serum. Further analysis revealed changes to
cytoskeletal structure as demonstrated by disruption of actin cytoskeleton (figure
2.5). Panels A & B in Figure 2.5 depict intact actin cytoskeleton ofHepG2 cells after
24 hours exposure to Normal serum. The fine microfilaments can be seen clearly
stretching across the cell maintain the cell's structure. In Panels C & D the effect of
Fulminant serum can be seen on cells. Specifically there is no longer evidence of the
delicate microfilament structure and cells appear more rounded in morphology. This
key observation that serum from patients with FHF markedly down-regulates the




Effect of 20% serum on cellular adhesion to collagen coated plates
1 4 24 48
Hours
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Legend for figure 2.3
This chart demonstrates the early loss ofcellular adhesion in cells cultured with
fulminant serum (black bars) compared with those cultured in normal serum (white
bars). This difference becomes significant after 4 hours culture and persists at 24 and
48 hours culture. Error bars are +/- SE. * * p < 0.01
Figure 2.4
Scanning electron microscopy of HepG2 cells exposed to 20%
serum
Charts A and B demonstrate the characteristic flattening and
attachment of HepG2 cells to collagen coated plates. These cells
have been cultured with standard media containing 20% normal
human serum. In contrast charts C and D demonstrate cells
grown with 20% fulminant serum. There is evidence of rounding-
up and a suggestion of imminent detaching of the hepatocytes
(see arrows). Scale bar 20|^m.
11
Figure 2.5
Actin Confocal Microscopy of HepG2 cells
exposed to 20%serum
Charts A and B demonstrate the intact actin cytoskeleton of
HepG2 cells grown on collagen coated plates (fluorescent
phalloidin viewed with confocal microscope). These cells
have been cultured with standard media containing 20%
normal human serum. The actin microfilaments can be clearly
seen to extend throughout the cell (see arrows). Charts C and
D demonstrate cells grown with 20% fulminant serum. In con¬
trast the microfilaments can no longer be clearly seen and
there is a granular texture to the cytoplasm. Scale bar 10jnm.
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The loss of cellular adhesion precedes cell death and is due to caspase-3
mediated apoptosis.
The next step was to determine whether loss of adhesion was the result of impaired
cell viability, or whether it led to cell death. Cell death studies on collagen coated
plates (Propidium iodide exclusion) demonstrated that whilst fulminant serum causes
cell death this occurs over 44 hours after the loss of cellular adhesion becomes
apparent (Figure 2.6). At 24 hours, no significant difference exists between cells
exposed to fulminant and normal serum. However after 48 hours culture the
percentage ofPi-permeable cells was 18.2 ± 1.84 and 4.32 ± 0.67 for fulminant and
normal serum-exposed cells respectively (p<0.001). Studies of early markers of
apoptosis, Annexin V staining, showed that significant apoptosis does not occur in
cells incubated in fulminant serum until 24 to 48 hours exposure (Figure 2.7). Values
are expressed as mean Annexin V fluorescence, with increasing apoptosis leading to
a shift to the right of the curve and an increase in the mean fluorescent intensity.
PerFluoroOctanoic Acid (PFOA) at a concentration of 450pmolar is a known pro-
apoptotic agent, which can be shown in the figure to clearly produce a peak of cells
positive for Annexin V after only 24 hours exposure. At 48 hours cells exposed to
fulminant and normal serum have respective values of42.3 ±2.17 and 18.1 ± 1.35
(geometric means of fluorescence, p< 0.001). The curves for fulminant serum at 24
and 48 hours can be seen to be shifted to the right when compared to the curves for
normal serum. That apoptosis is delayed (after loss of adhesion) after exposure to
fulminant serum was confirmed by Feulgen staining ofadherent cells (figure 2.8).
The amount of apoptosis rises such that it is 6.36 +/- 1.34 % by 48 hours (vs. 0.87 +/-
1.3% for normal serum; p<0.001). HepG2 cells activate caspase 3, congruent with
74
this being the process by which apoptosis occurs. (Figure 2.9). Values are expressed
in fluorescent units, as the assay is read on a plate fluorometer. Whilst the difference
is non-significant at 24 hours, after 48 hours exposure the results from fulminant and
normal serum exposed cells is 28700 ±1410 and 15800 ±1100 respectively
(p<0.001). Figure 2.10 provides evidence for fulminant serum causing apoptosis, as
depicted in Panels B-C, where there is morphological evidence of apoptosis (48
hours incubation) in HepG2 cells exposed to fulminant serum. In addition, there is
evidence ofcytoplasmic and nuclear vacuolation, confirming the ongoing injury to
cells at this late stage. Panel A depicts HepG2 cells grown with 20% Normal serum.
The effect of apoptosis can also be seen to result in a decrease in viable cell count in
cells exposed to fulminant serum as detailed in Figure 2.11. Whilst 1.25 x 106 cells
incubated with Normal human serum reach a viable count of 3 .15 ± 0.17 x 106 cells
after 48 hours culture, those exposed to fulminant serum for a similar duration are
unchanged at a lower comparative number, 1.25 ± 0.16 x 106 cells (p<0.001). We
have therefore demonstrated that the down-regulation of adhesion occurs much
earlier than the first evidence of apoptosis. This suggests that loss of adhesive status
is one of the causes of apoptosis rather than the result of it.
75
Figure 2.6




Legend for figure 2.6
This chart depicts the effect of serum on cell death, as judged by their inability to
exclude Propidium Iodide. Here fulminant serum is seen to cause a significant
increase in cell death, compared with normal serum, but only after 48 hours culture
which is 44 hours after the loss of cellular adhesion.
Error bars are +/- SE. * * * p < 0.001
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Figure 2.7
Assessment of effect of 20% serum on apoptosis (Annexin V) by flow cytometry
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Legend for figure 2.7
This chart depicts fluorescent Annexin V staining ofHepG2 cells exposed to PFOA,
Fulminant serum and Normal serum after increasing incubation times. Annexin V
binding is an early marker of apoptosis. PFOA, a known apoptotic agent to HepG2
cells, is used as a positive control. Expression ofAnnexin V is measured flow
cytometrically and expressed as increasing fluorescence. Differences in Annexin V
staining between cells exposed to normal and fulminant serum are minimal at 4 and
24 hours incubation with differences becoming more marked by 48 hours.
Figure 2.8







Legend for figure 2.8
This chart uses Feulgen nuclear morphology to quantify the amount of cellular
apoptosis. Fulminant serum causes increased cellular apoptosis, peaking at levels of
6% after 48 hours exposure, compared to normal serum which does not lead to any
increase at all. Whilst this effect becomes statistically significant after 24 hours
culture, it becomes much more profound after 48 hours culture. These levels of
apoptosis can be compared to the much higher levels of apoptosis seen with exposure
to the known apoptotic agent perfluoroctanoic acid (PFOA). Of note, the apoptosis
seen with fulminant serum does not become appreciable until after 24 hours, which is
over 20 hours after the impairment of cellular adhesion was seen.
* p < 0.05, 0.001 (apoptosis in cells cultured with fulminant serum versus cells
cultured with normal serum).
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Figure 2.9























Legend for figure 2.9
This chart illustrates levels of caspase 3 activity after 24 and 48 hours exposure to
different sera. Only after 48 hours does fulminant serum lead to a significant increase




Transmission Electron Microscopy of HepG2 cells
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Legend for figure 2.10
This chart depicts Transmission Electron Microscopy pictures ofHepG2 cells after
exposure to fulminant serum. Picture A represents culture with serum from normal
controls. Pictures B and C represent cytoplasmic vacuolation and production of
apoptotic pyknotic nucleii in cells exposed to serum from patients with fulminant
hepatic failure. Scale bar 5p.m.
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Figure 2.11
Effect of 20% serum on viable cell count
86
Legend for figure 2.11
This graph compares viable cell count in cultures exposed to fulminant and normal
serum. There is a significant decrease in cell count which becomes significant at 24
hours and most marked at 48 hours. * p < 0.05^ *** p < 0.001 (apoptosis in cells
cultured with fulminant serum versus cells cultured with normal serum).
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2.7 CONCLUSIONS
In this study I have demonstrated that paracetamol-induced liver injury results in the
marked up regulation of collagen IV on hepatic sinusoids which are known to be an
important portal of adhesion and subsequent entry of potentially engrafting cells into
the liver plate (Gupta et al 1999a). Whilst previous studies have examined the
expression of different ECM markers in chronically damaged liver injury (Van
Eyken et al 1990) such data are lacking however in acute liver injury, and therefore
this study provides novel information on ECM distribution in this setting. With this
knowledge, I tested adhesion of hepatocytes to Collagen after their exposure to
fulminant serum and was able to show that serum from patients with FHF reduces
their adhesive capability within only a few hours. My studies have indicated that loss
of adhesive ability precedes apoptosis and is not a consequence of it. Apoptosis does
occur approximately 24-48 hours after incubation with fulminant serum. Further
confirmation of this comes from the caspase 3 data, which is the final part of the
caspase activation process.
Several different factors have been identified as being elevated in FHF serum,
including TNF, IL-6, IL-18, Fas &TGFJ3i, but it is difficult to discern what their
relative contributions are (Gove et al 1982; Harrison et al 1994; Sullivan et al 1981;
Yamada et al 1994). Although some have demonstrated that some of these properties
lie within the sub-lOkDa ultrafiltrate there is every likelihood that these properties
are the additive effects ofmany biological compounds (Yamada et al 1994), and thus
it is rather simplistic to assume that one compound underlies all the observed effects.
Furthermore, the removal of compounds found in high concentrations, or indeed the
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supplementation of others that liver failure serum may be deficient of, is not a
practical strategy to improve outcomes of hepatocyte transplantation. A more
realistic treatment is to identify the deranged cellular mechanisms, which are the
downstream consequence of liver injury and attempt to pre-emptively treat cells to
improve engraftment and hepatocyte survival.
In this work I have demonstrated that 10-20% normal human serum is not harmful to
HepG2 cells as there are levels ofnecrosis similar to HepG2 cultures grown with
10% Fetal Calf Serum. Whilst I have shown that Fulminant serum is toxic at
concentrations of20% or higher I have not shown this is specific to liver injured
patients as I did not examine serum from patients with other illnesses. Having
established the model and observation, I proceeded in my next chapter to identify the
mechanism which underlies this.
CHAPTER 3
STUDY OF MECHANISMS IMPAIRING HEPATOCYTE ADHESION AND
SURVIVAL IN ACUTE LIVER INJURY




3 5 STATISTICAL ANALYSIS OF DATA
3.6 RESULTS
3.7 CONCLUSIONS
3.1 BACKGROUND AND AIMS
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In the light ofmy findings in the previous chapter regarding the impairment in
cellular engraftment that results from exposure to liver injury serum, my aim was to
identify the mechanisms which may underpin this phenomenon. To this end, it is
important to review the location within the liver where engraftment occurs. In the
sinusoidal bed can be found the optimum microenvironment for an engrafting
hepatocyte, in terms of extra-cellular matrix (ECM) components, growth factors,
nutrients and interactions with other cells. The adhesion to ECM is essential for the
growth and survival of hepatocytes, such that their displacement from ECM leads to
dedifferentiation and apoptosis, a phenomenon known as anoikis (Bretland et al
2001; Frisch et al 2001). Integrins appear to be the major receptors by which cells
attach to ECM, and are also important in mediating cell-cell adhesion events (Hynes
1992). Integrins are heterodimeric transmembrane proteins consisting of non-
covalently linked alpha and beta chains each with a large extracellular, single
transmembrane and short cytoplasmic domain (Hynes 2002). Integrins are activated
by contact with ECM proteins (Wu et al 1995) which leads to inhibition of
interleukin-lbeta converting enzyme expression preventing apoptosis and thus
providing them with a major role in determining cell survival (Giancotti et al 1999).
Therefore factors which modulate the interaction and hence activity of integrins play
an important role in determining cell adhesion and survival (Diamond et al 1994;
Kim et al 1997). Our understanding of the factors controlling integrin affinity are
incomplete but work suggests that control is exerted in an energy dependent fashion
on their cytoplasmic domain (Kim et al 1997). To identify the mechanisms which
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control adhesive capacity ofHepG2 cells I studied the expression of those integrin
receptors which regulate adhesion to collagen IV, and also which are found on
HepG2 cells (Torimura et al 1997). (3i, 0C2, & o^are the major integrins that control
the binding to collagen IV and these were subsequently studied. CD98 has been
suggested as a potential controller ofPi-integrin affinity; its crosslinking leading to
activation of the Pi-integrin and hence maintenance of integrin survival signaling
(Cho et al 2001). Activity of the Pi-integrin receptor can be modulated by
administration of activating antibodies such as TS2/16, which acts by directly
inducing a conformational change of Pi-integrins (Weber et al 1996).
The present study was undertaken to answer the following questions:
1) Is there a change in the expression of integrin receptors in hepatocytes exposed to
acute liver injury?
2) Is there a change in thefunction ofthe integrin receptors?




FHF serum was pooled from patients with acute liver failure due to paracetamol
overdose. All patients were in the intensive therapy unit (ITU) at time of sampling
and fulfilled the poor prognosis criteria for liver transplantation (O'Grady et al 1989).
Samples were taken within 48-96 h of paracetamol overdose and none of the patients
had detectable paracetamol in their serums at the time of sampling. Normal serum
was obtained from healthy individuals. Liver biopsy specimens were obtained from
the Department ofPathology and were from patients who had acute liver failure
fulfilling the poor prognosis criteria for liver transplantation (O'Grady et al 1989).




HepG2 is a human hepatoma derived line and it was routinely grown in
mono/multiplayer cultures in DMEM containing 10% (vol/vol) FCS in an
atmosphere of 5% CO2 in air. Cells were subcultured every 7 days at a split ratio of
1:3 using 0.05% (wt/vol) trypsin and EDTA to detach the cells. Cells were used
between passages 10 and 20.
Integrin analysis
HepG2 cells were grown on 25cm2 flasks and exposed to media containing 20%
(vol/vol) FHF serum, 20% normal serum (vol/vol), or 10% FCS (vol/vol) for 24 and
48 hours.
Cells were removed from these flasks with trypsin/EDTA, PBS washed and then
incubated with Fluorescein conjugated mouse monoclonal antibodies directed against
Pi, ot2 and a.(, integrin molecules (Serotec Ltd, Oxford, UK). Isotype controls were
used for these antibodies (Serotec Ltd, Oxford, UK). Expression of these markers
was then assessed using a Coulter FACS machine (Sethi et al 1999).
pi-integrin activation analysis
Cells were grown on 25cm2 flasks and exposed to media containing 20% (vol/vol)
FHF serum, 20% normal serum (vol/vol), or 10% FCS (vol/vol) for 1, 4 and 24
hours. Cells were removed from these flasks, washed and incubated with HEPES
buffer. The cell pellet obtained was split into 3 aliquots. All aliquots were incubated
with HEPES buffer containing the 12gl0 antibody (Sigma, UK) for 30 minutes (this
antibody recognizes the active configuration of the Pi-integrin). Aliquot 1 (termed
native) had no additions, aliquot 2 (termed inhibited) contained EDTA (to inhibit pi-
integrin activity) and aliquot 3 (termed activated) contained Manganese (to activate
Pi-integrin activity). After this samples were washed, pelleted and incubated with a
secondary FITC antibody (anti-mouse) directed against the 12gl0 antibody. These
samples were then processed flow cytometrically to quantify the amount of 12gl0
binding (which assesses the activity of the Pi-integrins). In the forward vs side
scatter box a gate (Rl) was placed to catch viable whole cells, thus excluding sub¬
cellular debris. The amount of FITC staining in the gated population was then
expressed in the histograms shown in Figure 3.1. Using the following equation an
estimate of the relative activity of the pi-integrin in a given culture condition could
be calculated using the geometric means (Sethi et al 1999):
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Legend for figure 3.1
This figure depicts the binding of the 12gl0 antibody to HepG2 cells. 12gl0 only
binds to Pi-integrin receptors which are in the active conformational state. The
amount of 12gl0 binding is measured by the amount of fluorescence detected with
the flow cytometer. Increased fluorescence, and hence 12gl0 binding, is denoted by
a shift to the right on the histogram. No antibody chart represents the inherent
autofluorescence ofHepG2 cells. No primary antibody chart represents HepG2 cells
incubated only secondary antibody without the 12gl0 antibody. Isotype antibody
represents HepG2 cells incubated an isotype antibody (instead of 12gl0) followed by
the secondary antibody. Native state refers to HepG2 cells incubated with 12gl0
followed by the secondary antibody. Inhibited state and Activated states are as




This assay is described on page 61 in chapter 2.
Apoptosis assays
These assays are described on pages 53-56 in chapter 2.
TS2/16 antibody
This antibody is derived from a hybridoma and was used at a concentration of
25pg/ml in tissue culture (on the basis of maximal flow cytometric binding data)
(Weber et al 1996). It was a gift from Dr Tariq Sethi (CIR, University ofEdinburgh).
Differing concentrations of the TS2/16 antibody were added to 200,00 HepG2 cells
for 30 minutes. Cells were then washed with PBS and pelleted. Pellets were
resuspended with a 1/10 dilution of an anti-mouse secondary antibody conjugated
with FITC. Again cells were incubated for 30 minutes prior to PBS-washing and
further pelleting. Samples were then analysed flow cytometrically, measuring
fluorescent intensity (as a proxy for tS2/16 binding). For assessment of adhesion,
cells were incubated with sera for varying time-points, then washed and then
incubated with the TS2/16 antibody. For assessment of apoptosis, the antibody was
added at the beginning of the experiments with the different serum.
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3.4 EXPERIMENTS
Flow cytometry work for integrin expression and activation was performed in
triplicate on three separate occasions. In the cell adhesion work experiments were
done in multiples of eight on at least three separate occasions. Apoptosis work was
done on in triplicate on at least three separate occasions.
3.5 STATISTICAL ANALYSIS OF DATA
T test assuming unequal variances was used to compare groups. Where multiple
analyses were required, ANOVA with post-hoc analysis was performed. A p value of
<0.05 was used to define significance.
3.6 RESULTS
Down-regulation ofPi-integrin receptor activities rather than loss of total Pi-
integrin receptor expression is associated with decreased cellular adhesion
After 24 hours culture with fulminant serum, when adhesion was significantly
impaired, there was increased expression of the Pi- and a6-integrins (Figure 3.2). To
assess the activity of the Pi integrin an antibody that recognises only its active
conformational state, 12gl0, was used. Importantly however, as shown in Figure 3.3
the proportion of Pi-integrin receptors in their active conformational state was much
lower after culture for 24 hours with fulminant serum (33.2 +/- 6.2% vs. 68.6 +/- 2.4
%; p<0.01) compared with cells cultured with normal serum. Furthermore, Figure 3.4
demonstrates that this down-regulation occurs early, between one and four hours
after exposure to fulminant serum, at the same time as loss of adhesion of these cells
is demonstrated. I have therefore demonstrated that whilst the levels of the integrins
that mediate binding to collagen are increased after exposure to serum from patients
with FHF, the activity of the integrin, pi, is rapidly and significantly down regulated.
I conclude therefore that a possible mechanism behind the loss of cellular adhesion
and hence apoptosis is down-regulation of the Pi integrin activity on HepG2 cells.
Figure 3.2
Integrin expression on HepG2 cells after 24 hours culture with 20% serum
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Legend for figure 3.2
This chart represents the mean fluorescence of Pi (CD29), 0C2 (CD49b) & 014
(CD49f) integrins on HepG2 cells, after 24 hours exposure to different sera. In the
cultures exposed to fulminant serum there are higher levels ofpi-integrin (CD29)
and 012-integrin (CD49b) compared to cultures with normal serum.
** p < 0.01, ***p< 0.001
Figure 3.3




Legend for figure 3.3
This chart assesses the percentage of Pi-integrin receptors which are in their active
conformational state. After culture with fulminant serum for 24 hours, the proportion
in the active conformational state is much lower than those cultured with normal
serum or FCS. No difference was seen between Pi-integrin receptor activity in cells
cultured with FCS and normal serum. * * p < 0.01
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Figure 3.4
Early down-regulation of Pi-integrin after exposure to 20% fulminant serum
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Legend for figure 3.4
This chart demonstrates a time course analysis for p,-integrin activity after exposure
to fulminant serum. As can be seen there is a rapid down-regulation of the activity
between one and four hours after exposure to fulminant serum.
* p < 0.05
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Activation ofPi-integrin receptor activities prevents the loss of cellular adhesion
and onset of cellular adhesion seen with fulminant serum
To see whether modulation of Pi-integrin activity would influence adhesion and
apoptosis I added TS2/16 antibody (Pi-integrin receptor activating antibody) to cells
after incubation with fulminant serum. I decided upon the optimal concentration
(25pg/ml) by a binding assay to identify the concentration at which TS2/16 saturated
Pi-integrin binding (Figure 3 .5). The adhesion of cells incubated with TS2/16 and
fulminant serum was greater than cells incubated with fulminant serum alone at all
time points. The adhesion of cells incubated with TS2/16 and fulminant serum is
greater than cells incubated with normal serum at all time points until 48 hours. At
the 48 hour time-point there was no significant difference between the two groups






Legend for figure 3.5
This chart demonstrates the optimal binding concentration ofTS2/16 antibody to
HepG2 cells. Amount ofTS2/16 binding was measured flow cytometrically and
expressed as a geometric mean on the vertical axis.
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Figure 3.6
Effect of TS2/16 incubation on adhesive properties of HepG2 cells exposed to
20% serum




g fulminant serum +
TS2/16
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Legend for figure 3.6
This chart illustrates the effect of adding of Pi-integrin antibody (TS2-16) to HepG2
cells after defined periods of exposure to differing sera. As can be seen addition of
the TS2-16 antibody can reverse the loss of cellular adhesion in cells which have
been cultured in fulminant serum for up to 24 hours. At longer exposures (48 hours)
the effect of the antibody on adhesion is only partial. At the 48 hour time-point there
was no significant difference between the two groups (Fulminant + TS2/16 86.4 ±
6.1 vs Normal 106.9 ± 8.9, p= 0.19) (Figure 3 .6).
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Given that I had shown that TS2/16 antibody can reverse loss of adhesion seen with
fulminant serum I then went on to look at its effect on cellular apoptosis. Using
Feulgen nuclear morphology I was able to show that adding TS2/16 reduced the
levels of apoptosis with fulminant serum at both 24 ( 1.74 ± 0.17% vs 2.43 ± .35%,
p=0.049) and 48 hours (2.68 ± 0.34% vs 5.19 ± .053%, p =0.002). Although the
levels ofapoptosis were still higher than cells incubated with normal serum, the
absolute levels seen (2.68%) with addition of the antibody constituted a 48.6%
decrease on fulminant serum only cells (Figure 3.7). This anti-apoptotic effect is also
supported by measurement of caspase activity after 48 hours incubation (Figure 3.7).
Caspase activity with fulminant serum only was 20380 ± 1045 versus 17340 ± 940 in
TS2/16 supplemented cells (p=0.02). Furthermore no significant difference in
caspase activity existed between cells cultured with normal serum (14541 ± 1029)
and cells supplemented with fulminant serum and TS2/16 (p=0.06). This further
strengthens the causative relationship between decreased integrin activity, loss of
cellular adhesion and induction of apoptosis ofHepG2 cells on collagen coated
plates.
Figure 3.7


































Legend for figure 3.7
These charts detail the effects on cellular apoptosis of administering activating pi-
integrin antibody (TS2-16) to cells cultured with fulminant serum (the antibody was
added at the beginning of the incubation period). In chart A, the addition ofTS2-16
antibody to fulminant serum is seen to significantly decrease cellular apoptosis after
24 and 48 hours incubation compared with cultures of fulminant serum alone. Chart
B depicts caspase activity in similar groups and demonstrates a similar reduction
after administration ofTS2-16 antibody to cultures with fulminant serum after 48
hours incubation compared with cultures just exposed to fulminant serum.
* p < 0.05, ** p < 0.01
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3.7 CONCLUSIONS
In this chapter, I have shown that serum from patients with FHF reduces the adhesive
capabilities ofHepG2 cells by a rapid down-regulation of their Pi-integrin activity.
This loss ofPi-integrin activity and cellular adhesion results in the later activation of
caspase-3 and concomitant apoptosis. Importantly, I have demonstrated that the
effect of liver injury serum is a specific effect and not just a non-specific toxic effect.
This is evidenced firstly by the absence of any apoptosis at any of the early time-
points, when integrin affinity and adhesion are compromised. Secondly, we
demonstrate that loss of cellular adhesion and subsequent apoptosis can be reversed
by treatment of the hepatocytes with the stimulatory mAb TS2/16, again reinforces
the point this is not a non-specific toxic phenomenon. That TS2/I6 antibody can
reverse loss of adhesion in cells that have already been exposed to fulminant serum
for 24 hours, indicates that such cells are not committed to apoptosis at this stage.
The increase in Pi and as integrin expression seen after 24 hours culture with serum
from patients with FFIF is occurring at a time of impaired cellular adhesion and
suggests a possible compensatory response by the cells to increase their attachment.
This is confirmed by assessment of the activity of their Pi-integrin, which is seen to
be lowered after 4 hours incubation. Manipulation of integrin activity has been
suggested to occur by modification of its cytoplasmic component (inside-out
signalling), and several mechanisms have been identified including covalent
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modification, the attachment of activator proteins or the removal of repressor
proteins. Examples of down-regulation of integrin activity include the oncogenic
transformation by Rous sarcoma virus leads to phosphorylation of a tyrosine residue
in the cytoplasmic subunit leading to reduced binding of Pi-integrins to both talin
and fibronectin (Tapley et al 1989). Serine phosphorylation has been demonstrated in
mitotic cells to lead to the rounding and detachment of cells as a consequence of
integrin down-regulation. A further possibility is external modulation of integrin
affinity (outside-in signalling), although this tends to result in up rather than down-
regulation and in the context ofour study may be the result of a loss of such a
stimulating signal in serum from patients with FHF. Other important regulatory
factors include temperature (Luque et al 1996), extracellular divalent cations
(Masumoto et al 1993), and interaction with intracellular signal transduction
molecules such as calreticulin (Coppolino et al 1997) and members of the small
GTPase family such as R-Ras (Zhang et al 1996) and Rho A (Hotchin et al 1995).
Once activated, integrins lead to protein tyrosine phosphorylation which has been
shown to inhibit apoptosis(Evans et al 1993; McGahon et al 1995; Simizu et al 1996;
Tallett et al 1996). In small cell lung cancer cells, ECM-mediated protection from
etoposide-induced caspase-3 activation can be blocked by either Pi-integrin function-
blocking antibody or by a tyrosine kinase inhibitor(Sethi et al 1999; Tallett et al
1996). Other groups have demonstrated that ECM regulates apoptosis (mammary
epithelial cells) through an integrin-dependent negative regulation of Interleukin-ly?-
converting enzyme (ICE) expression, whereby expression of ICE was correlated with
the loss ofECM and inhibitors of ICE activity prevented apoptosis(Boudreau et al
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1995). Thus, integrin activation prevents the ICE-mediated induction of caspase-3
activity. The stimulatory mAb TS2/16 acts by directly inducing a conformational
change ofPi-integrins. Evidence for this comes from work which shows that TS2/16
stimulates the ligand-binding function of solubilised Pi-integrin in column binding
studies(Chan et al 1993). Furthermore whilst deletion of the cytoplasmic domain of
an a-subunit ofPi-integrins abolishes phorbol ester stimulation it has no effect on
TS2/16 stimulation(Kassner et al 1993; Kawaguchi et al 1993). This indicates that
the effect of TS2/16 does not depend on intracellular processes. Finally Fab
fragments of the TS2/16 antibody have similar stimulatory properties excluding the
possibility of a receptor cross-linking mechanism(Arroyo et al 1993).
The differential control and order of adhesion and anti-apoptotic signals by integrin
activation is not fully understood, and in our model, it is not clear if apoptosis is
resultant on decreased cellular adhesion or occurs independently. Our data suggests
that cytoskeletal re-organisation (as determined by adhesion and actin cytoskeleton)
precedes the onset of apoptosis and suggest it may play a role in inducing apoptosis.
Pi-integrin is important not only in mediating adhesion and hence survival but also
plays an important role in cellular migration. Studies with Pi-integrin knockout
haematopoietic stem cells demonstrated their failure to engraft, although their
subsequent haematopoietic differentiation was not impaired. Of note stimulation of
CD34 cells with TS2-16 antibody (activates Pi-integrin) abrogates almost all marrow
directed migration and leads to engraftment in fetal liver (Ramirez et al 2001). This
observation is of particular relevance with respect to my findings and raises the
possibility that Pi-integrin activity may be important in liver homing. Furthermore, 1
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have shown in Chapter 2 that there is up-regulation ofCollagen IV expression on
paracetamol-damaged liver which is a potent ligand for fh-integrin and a possible
entry point for engrafting hepatocytes during cellular transplantation. Thus the down-
regulation ofPi-integrin I have observed suggests that this not only decreases
hepatocyte homing but also prevents some of the collagen mediated binding on the
damaged liver.
In this study the HepG2 cell line was used, which is a differentiated human hepatoma
cell line. This line has many characteristics in keeping with primary hepatocytes
including a moderately differentiated phenotype and similar integrin expression
repertoire, which allow it to act as a suitable model for primary hepatocytes (48).
Furthermore, modifications of this line are used in Bio-artificial liver support
systems (49) and in hepatocyte transplantation (50). Extrapolation of this data to
primary hepatocytes does however require recognition of potentially important
differences. Primary human hepatocytes may for example be more susceptible to
apoptosis if they are unable to bind to extracellular matrix, as immortalised/tumour
cell lines have down-regulated some of their apoptotic pathways (Wiesenauer et al
2004). However, this model system is not studying anoikis; it models the early phase
of hepatocyte transplantation, demonstrating that the ability of cells to adhere to
matrix is reduced after only 1-4 hours exposure to fulminant serum. In this regard,
differences in anchorage-independent growth between HepG2 cells and primary
hepatocytes are less important in the interpretation and extrapolation of this data.
Different susceptibility to serum-induced apoptosis between the two cell types may
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explain the relatively modest levels of apoptosis seen with HepG2 cells, although it
would suggest that this mechanism will be of greater importance with primary
hepatocytes.
In conclusion, therefore I have made the important observation that serum from
patients with FHF rapidly decreases their adhesive capacity as a prelude to apoptosis.
I have also identified an underlying mechanism, namely a rapid down-regulation of
Pi-integrin activity. Furthermore, I have shown that addition of a Pi-integrin
stimulating antibody partially reverses this phenomenon and leads to prolonged
hepatocyte adhesion and survival. Pre-activation of pi-integrin could therefore offer
a means of enhancing the efficacy of cell transplantation.
CHAPTER 4
STUDY OF HUMAN HAEMATOPOIETIC STEM CELL TRANS-
DIFFERENTIATION IN VITRO




4.5 STATISTICAL ANALYSIS OF DATA
4.6 RESULTS
4.7 CONCLUSIONS
4.1 BACKGROUND AND AIMS
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Recent studies have demonstrated that stem cells have greater plasticity than
previously thought and can differentiate down multiple non-haematopoietic cell
lineages in rodents (Graf2002; Krause et al 2001; Petersen et al 1999; Theise et al
2000a). Human studies have also confirmed that human marrow contains cells which
can differentiate into hepatocytes and biliary cells (Alison et al 2000; Korbling et al
2002; Theise et al 2000b).
In vitro studies have demonstrated that stem cells of both rodent and human origin
could differentiate down epithelial lineages. At the time of this research, no studies
had reported hepatocytic differentiation in vitro. Furthermore it is unclear if during
liver injury chemicals are released which promote the attraction and differentiation of
human stem cells.
Many different markers can be used to define a cell as a hepatocyte. Albumin and
aFP are two commonly used markers of hepatocytic differentiation. In addition,
albumin expression would demonstrate a synthetic function of the hepatocyte.
Pan-cytokeratin expression is used to define epithelial differentiation, rather than
hepatocytes per se. cEBPp and HNF4a have been demonstrated to be important in the
transdifferentiation ofpancreatic cells into hepatocytes after administration of
dexamethasone. It has been proposed that dexamethasone increases transcription of
cEBPp, which leads to increased fatty acid synthesis (including Acyl CoA). Acyl
CoA leads to nuclear translocation ofHNF4a which is responsible for the
transdifferentiation ofpancreatic cells (Shen et al 2000).
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This work was undertaken to answer the following questions:
1) Could human cord-blood stem cells differentiate into hepatocytes in vitro?
2) Does acute liver injury alter the differentiationprofile?
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4.2 MATERIAL
Human cord blood was obtained with patient consent and full approval from the
Lothian Regional Ethics Committee (LREC/1993/4/76).
4.3 METHODS
Freshly collected heparinised whole cord blood samples were received from the
Scottish National Blood Transfusion Service (Edinburgh, UK) following informed
donor consent. Mononuclear cells were isolated using Histopaque 1077 (Sigma, UK)
density centrifugation following the initial description by Boeyum (Boeyum A
1968). Briefly, heparin-treated (103IU/mL) whole blood was carefully layered over
an equal volume ofFicoll-Hypaque1M and spun at 540g for 20 minutes. The interface
('buffy coat') containing the mononuclear cells was collected and washed twice in
Hank's Balanced Salts Solution (HBSS; Gibco, UK). A trypan blue exclusion assay
was used to assess the viability of the harvested cells prior to their usage.
FACS Analysis
Cord blood mononuclear cell surface phenotype was characterised using standard
FACS analysis. Briefly, 100,000 cells per test were pelleted by centrifugation for 5
minutes at lOOOrpm and cell pellets resuspended in individual monoclonal antibody
(mAb) solutions using the manufacturer's (Dako, UK; BD Pharmingen, UK; Sigma,
UK) recommended test concentrations (confirmed in our laboratory to give optimum
results in our hands). Test samples were immunostained for 20 minutes on ice with a
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panel of directly FITC- and/or PE-conjugated mAb against human cell surface
markers. The panel included mAb against the following markers: MHC1 (pan-
nucleated cell) (200 pg/mL; Sigma, UK), gly-A (erythrocyte) (100 pg /mL; Dako,
UK), CD3 (T Cell) (12.5 pg g/mL; BD), CD1 lb (granulocyte) (100 pg /mL; Dako),
CD 14 (monocyte) (60 pg /mL; Dako), CD19 (B cell) (25 pg /mL; BD), CD33
(myeloid progenitor) (6 pg /mL; BD), CD34 (stem cell) (25 pg /mL; BD), AC 133
(stem cell) (25pg /mL; Dako), CD45 (pan-leukocyte) (50 pg /mL; BD) and CD56
(NK cell) (50 pg /mL; Dako). Cell subsets were double-immunostained using a
subset-specific mAb as well as an antibody against CD45. Following
immunostaining, cells were pelleted, washed in FACS handling buffer (lxPBS/1%
BSA/0.1% Sodium Azide/0.5M EDTA) and resuspended in FACS fix (1%
formaldehyde) prior to analysis using CellQuest software on a Becton Dickinson
FACSCalibur machine.
Cell isolation and purification by positive selection for AC133
Cord blood was processed as described above and then re-suspended in Magnetic
Cell Sorting (MACS) Buffer in a total volume of 300pl per 108 total cells. Cell
suspension was then filtered through a 30pm mesh to remove clumps. This was
followed by a further wash in buffer and resuspension in 300pl buffer. lOOpl ofFcR
Blocking re-agent was added per 108 total cells and mixed well. Then lOOpl of
AC133-coated microbeads were added per 108 cells, mixed well and incubated for 30
minutes at 6-12°C. The final labelling volume was 500pl. After this cells were
washed with 5-10 ml ofMACS buffer, then centrifuged before removal of the
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supernatant and re-suspension in MACS buffer to a volume of 500jj.1. The suspension
was then applied to the column in the VarioMACS magnet. The column was washed
four times with MACS buffer after this. At this time the column was removed from
the magnet, 1ml ofbuffer was placed onto the column and the contents eluted into a
fresh tube. This tube was washed and centrifuged again with MACS buffer. It was
resuspended with 500pl ofMACS buffer and applied to a fresh column within the
VarioMACS magnet. The procedure was repeated as per the first run through the
magnet.
Confirming AC133 purity
Using the FACS VANTAGE ® flow cytometry sorting machine, AC 133 positive
cells were quantified as a percentage of low side scatter mononuclear cells using the
ISHAGE flow cytometry guidelines which uses forward/side scatter gating followed
by gating on the marker CD45 and AC 133.Initially events are plotted on a forward
scatter vs. side scatter dotplot and a gate is placed around the low side scatter
population ofmononuclear cells which predominantely comprise of lymphocytes and
which excludes debris, platelets, macrophages, monocytes and unlysed erythrocytes.
In the next stage, the selected mononuclear cell population is then displayed on a
CD45 vs. AC 133 dotplot and the cluster ofAC133+/CD45 intermediate events
detected are gated. Finally the AC133+/CD45 intermediate population selected is
then quantified as a percentage of the total events gated in the first stage of analysis
i.e. low side scatter mononuclear cells.(Keeney et al 1998)
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Cell culture
AC133+ cells were divided up into aliquots of 30,000 cells/well and cultured with
Stem Cell Medium (Gibco Life Technologies) in the presence or absence or different
cytokines. These cytokines were Flt-3 ligand (50ng/ml), Thrombopoietin (lOng/ml),
Hepatocyte Growth Factor (FIGF; 20ng/ml), Neurotrophin Growth Factor (NGF;
lOOng/ml) and Fibroblast Growth Factor ot/p (FGF; both 20ng/ml). Cytokines were
supplemented on days 3, 7, 10, whilst half-media change, occurred on day 7. At the
end of 14 days, cells were either labelled for flow cytometry or stored in RNA later
for subsequent rtPCR analysis. Cultures were performed on uncoated, gelatin coated
and Collagen coated plates. Gelatin was purchased from Sigma (Type A porcine
skin, approx 300 Bloom), and made into a 1% solution in sterile distilled water, and
then diluted further to 0.1% in PBS. 100p.l were added to each well and allowed to
dry, prior to addition of stem cells.
For experiments studying the role of acute liver injury on differentiation Stem cell
Medium with TPO/Flt-3 and varying concentrations of acute liver failure serum were
used.
mRNA isolation
Cells were remove from the 24-well-plates with cell scrapers and washed twice with
PBS. An aliquot of40,000 cells was centrifuged at 3000g for 5minutes. The pellet
was re-constituted with 20pl PBS, to which 180 pi RNAlater was added. Cells were
then stored at minus 80°C until further analysis.
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Samples were thawed and washed twice in PBS prior to pelleting and reconstitution
with 100 pi Cell Lysis Buffer. It was incubated with this at 75°C for 5 minutes. 2 pi
DNAase was added and the sample incubated at 37°C for 30 minutes and then 75°C
for 5 minutes. Two 10 pi aliquots (4000 cells worth) were removed for usage in the
reverse transcription reaction. To this was added either 2 pi ofRandom decamers,
OligoDt or Random Decamers. OligoDts would theoretically be better for mRNA
which consisted of long poly-A tails. In addition, 4 pi of dNTP mix and 16 pi of
nuclease free water were added. This mixture was vortexed and then centrifuged at
500g for 30 seconds. The sample was then heated at 75°C for 3 minutes, placed on
ice for 1 minute afterwards, re-centrifuged at 500g for 30 seconds and then returned
to ice for a further minute. At this stage 2 pi of lOx RT buffer, 1 pi ofMMLV-RT
and 1 pi ofRNAase inhibitor were added. Importantly the MMLV-RT enzyme was
missing from the control, termed the RT Negative sample. This mixture was
vortexed, centrifuged at 500g for 30 seconds and then placed at 42°C for 1 hour. It
was then stored at minus 20°C prior to PCR analysis.
PCR analysis
PCR is an in vitro method of nucleic acid synthesis by which a particular segment of
DNA can be specifically replicated. It involves two oligonucleotide primers that
flank the DNA fragment to be amplified and repeated cycles of heat denaturation of
the DNA, annealing of the primers to their complementary sequences, and extension
of the annealed primers with DNA polymerase. These primers hybridise to opposite
strands of the target sequence and are oriented so that DNA synthesis by the
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polymerase proceeds across the region between the primers. Since the extension
products themselves are also complementary to and capable of binding primers,
successive cycles ofamplification essentially double the amount of the target DNA
synthesised in the previous cycle. The result is an exponential accumulation of the
specific target fragment.
The polymerase chain reaction was performed by incubating 1-2 pi cDNA samples
with 0.5 units of AGS GOLD DNA polymerase in 5 pi of 10 x Complete Reaction
Buffer, 5 pi ofAGS GOLD enhancer solution, 2 pi Primer mix, 1.6 pi dNTP mix
making up to 50 pi with double-distilled water. All reagents were kept on ice and the
DNA polymerase was added last. PCR cycling was carried out on a MJ Research
PTC-100 thermal cycler for 35 cycles. The annealing temperature varied depending
on the product and primers used. Two control tubes were run in parallel, one in
which water replaced the RNA and a second omitting reverse transcriptase to ensure
there was no genomic DNA contamination. Specific primers were used and these and
the resulting product size are shown in Table 4.1. Primers were designed to span an
intron to ensure genomic DNA was not amplified. Primers for the constitutively
expressed gene GAPDH were used to confirm the integrity of the RNA and efficacy
of the PCR reaction. After the PCR, the size of product was ascertained using
electrophoresis. A 5 pi sample ofPCR product was mixed with 3 pi of loading buffer
to visualise loading and dye front on running gel. Products were loaded on a 2%
agarose gel which contained ethidium bromide and placed in a tank containing TBE
and run at 120 V over 45 minutes and products were visualised using ultraviolet
light. A lOObp ladder (Promega, USA) was included to ensure that products seen
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were of the expected size. The 500bp band is of triple intensity to the other bands.
Products were purified and the identity of all PCR products was confirmed by direct
sequencing as described below.
Table 4.1
PCR Primers
Gene Primer Sequence (5'-3') Product size (bp)
Albumin Forward TGCTTGAATGTGCTGATGACAGGG 165
Albumin Reverse AAGGCAAGTCAGCAGGCATCTCAT 165
aFP Forward GTGGTTAAAGGAAACGCTCG 212
aFP Reverse CATACATTTCAGCAGGTGCG 212
GAPDH Forward GAACGGGAAGCTCACTGGCAT 310




1) 2 minutes at 94°C
2) 30 seconds at 94°C
3) 30 seconds at 48°C
4) 30 seconds at 72°C
5) 10 minutes at 72°C
Steps 2-4 were repeated 34 times
Albumin
1)2 minutes at 94°C
2) 30 seconds at 94°C
3) 30 seconds at 58°C
4) 30 seconds at 72°C
5) 10 minutes at 72°C
Steps 2-4 were repeated 34 times
Sequencing ofDNA
The first step in sequencing is to denature the double stranded DNA into single
strands. The overall approach of sequencing DNA involves creating sub-fragments of
all possible lengths from the DNA we want to sequence, grouping them according to
which base they end in. To create these fragments a chain termination method is
employed called the dideoxy method. Dideoxy analogues of normal DNA precursors
cause premature termination of a growing chain of nucleotides being made by DNA
polymerase. This allows generation of fragments of the stretch ofDNA we want to
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sequence and by using four different dideoxy analogs, one for each of the four bases,
we can generate four sets of fragments. To identify these, the same DNA primer is
used for each reaction but four different fluorescent dyes are used, one for each of
the bases. When a sequencing gel is run, a separate colour is obtained for each base.
A laser beam scans the bands and the four different dyes fluoresce in different
colours. A computer which then prints the sequence records the colour ofeach band.
Purification of products for sequencing
This was done for all products prior to sequencing using a Hi-Pure purification kit in
order to remove any primer dimers which may affect the sequencing signal. First, the
amount ofproduct present was measured and made up to 50pl with H20. Binding
buffer (250p.l) was then added to each sample and the sample then added to a column
sitting in a collection tube. Next, the samples were centrifuged at 13000g for 1
minute. The elute was discarded and 500j_il ofwashing buffer was added to the
column and this was centrifuged for 1 minute at 13000g. These two steps were
repeated using 200pl ofwashing buffer and then 40j_il of elution buffer was added to
a column sitting in a clean tube and centrifuged for 1 minute elute was put through
the column again and products run on an agarose gel and tested in a
spectrophotometer to ascertain purity and quantification.
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Method for sequencing DNA
For the sequencing reaction, 30-90ng of purified PCR product was added to 4pl of
sequencing mix, 4pl of% term and lpl of primer at a concentration of 5pmol/pl
This was then made up to 20pl with H2O and the mixture placed in the PCR machine
at 96°C for 15 seconds, 50 °C for 25 seconds and 60 °C for 4 minutes for 25 cycles.
Once finished the tubes were spun briefly and then 50pil of 96% ethanol and 2|il of
3M sodium acetate were added to each tube. The samples were vortexed thoroughly
and left at room temperature for 30 minutes before spinning for 30 minutes. The
supernatant was removed and pellet washed with 100p.l of 70% ethanol. This was
spun again for 10 minutes and supernatant removed and pellet allowed to dry. This
was then resuspended in 4pl formamide: EDTA buffer (5:1 ratio of deionised
formamide: 50mM EDTA) and was ready for loading on the sequencing gel.
The sequencing gel was made by mixing 50g urea and 15 ml 40% acrylamide and
making up to 80 ml with water. One teaspoon of amberlite was added to this and the
mixture was heated gently until the urea dissolved. This was filtered to remove the
amberlite and then 10 ml ofTBE added. The mixture was made up to 100 ml with
water and just prior to pouring 500pl 10% APS and 45pi TEMED were added. The
gel was then poured between the glass plates with spacers in situ and allowed to set
prior to placing in the sequencer along with running buffer and loading with samples.




Cells were removed from the 24-well plates with cell scrapers and washed twice with
PBS. They were reconstituted with PBS and placed on cytospins at 150g for 5
minutes. Cells were permeabilized with 0.1% Triton X for 30 minutes at 4°C. Slides
were then blocked with 20% animal serum in PBS with 0.05% Tween (species is
determined by the species of the secondary fluorescent antibody) for 10 minutes at
room temperature. Then a 1/150 dilution of the primary antibody (in blocking
solution) was added to each slide for incubation at room temperature for 1 hour.
Slides were placed on a moist tissue in a sandwhich box. After the incubation, slides
were washed three times with PBS containing 0.05% Tween. The secondary
antibody was then added (dilution 1/300) and again incubated for 1 hour at room
temperature. Finally, slides were washed three times with PBS prior to fixation and
coverslipping with antifade.
Primary antibodies were HNF-4 (goat), c-EBP(i (mouse) and pan-cytokeratin, with
respective secondaries were rabbit anti-goat conjugated with 488-Alexafluor and
goat anti-mouse conjugated with 568-Alexafluor. These antibodies were chosen to
check for evidence of early hepatocyte commitment.
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4.4 EXPERIMENTS
The haematopoietic profile of human cord blood samples was characterised by FACS
and CFU analysis to demonstrate that they were rich sources of human stem cells
(n=10). This data is presented in chapter 5.
The next set of experiments was designed to see what the quantity and purity of
AC133 cells by VarioMACS isolation was. This was performed by ISHAGE flow
cytometric analysis (Keeney et al 1998), and was done on 9 separate occasions.
The remainder of the work set out to study the role of different culture conditions on
differentiation of AC133+ cells. Cells were cultured in triplicate wells on three
separate occasions in the following culture conditions:
1) Thrombopoietin (TPO; lOng/ml) & Flt-3 ligand (50ng/ml)
2) TPO/Flt-3 & HGF (20ng/ml)
3) TPO/Flt-3 & NGF (lOOng/ml)
4) TPO/Flt-3 & FGFa (20 ng/ml)
5) TPO/Flt-3 & FGFp (20ng/ml)
6) TPO/Flt-3 & NGF & HGF
7) TPO/Flt-3 & NGF & HGF & FGFa/p
Analysis then took place as described above in the methods section: flow cytometry,
immunofluorescence, rtPCR, morphology.
4.5 STATISTICAL ANALYSIS OF DATA
Data is expressed as Mean +/- standard error of the mean (SEM).
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4.6 RESULTS
Yield and purity of sorted AC133 stem cells
Table 4.2 displays the mean number ofmononuclear cells obtained after
mononuclear cell prep and the number of AC 1331 cells obtained after one and two
runs through the VarioMACS column. The mean purity of AC 133r cells obtained
after column isolation is also shown in the table. After one run through the column,
only 12.4% of the cells were AC133+, and for this reason, cells were eluted through
two columns to ensure satisfactory purity (91.3%).
Table 4.2





a % of original
cell count
Purity of final




Pre 86.0 x 106±
38.4 x 106
Post 5.11 x 105±
2.49 x 105




Pre 91.2 x 106±
2.93 x 106
Post 1.34 x 105±
3.82 x 104
0.39 91.3 ± 17.9
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Figure 4.1
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AC133-PE expression
The top two panels depict the forward versus side scatter for the
mononuclear cell preparation before and after VarioMACS column pro¬
cessing. The post-column panel can be seen to have excluded large
numbers of cells with a similar forward scatter to the gated popula¬
tion, the remaining cells representing lymphocytes and sub-cellular
debris. The lower panels look at the double staining pattern of the
gated population for CD45 and AC133. After column isolation there is
a clearly defined AC133+ population which is CD45dim.
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Legend for figure 4.1
This figure gives a graphical illustration of the flow cytometric confirmation of the
isolation and purity ofAC133+ cells after use ofVarioMACS. The true AC133+ stem
cell population can be seen to be AC133bnght and CD45dim. There are some CD45bnght
contaminating lymphocytes seen in the post-column isolate but this is much fewer
than in the starting preparation.
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Cell culture
Total cell number was measured by Neubauer cytometer after 2 weeks culture, as
shown in table 3. From this table it can be seen that the use ofmatrix and multiple
cytokines leads to maximal cellular expansion.
Table 4.3
Cell quantification after culture
Final cell number after 2 weeks culture (x 10 )
Uncoated Collagen-coated Gelatin-coated
TPO/Flt-3 1.93 ±0.62 4.96 ± 1.23 4.56 ± 1.22
TPO/Flt3 + HGF 1.35 ±0.64 4.32 ±0.97 5.12 ± 1.56
TPO/Flt3 + NGF 1.70 ±0.37 4.42 ± 1.72 3.90 ± 1.21
TPO/Flt3 + FGFa 4.00 ± 1.59 6.67 ±2.11 6.80 ±2.76
TPO/FIt3 + FGFp 4.23 ± 1.87 7.55 ±2.65 7.20 ±2.31
TPO/Flt3 + NGF
+ HGF
3.90 ±0.75 6.78 ±2.33 5.99 ±3.02
TPO/Flt3 + NGF
+ HGF + FGFa/p
2.30 ±0.84 7.77 ±2.52 8.09 ±3.62
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Morphology
Pictures ofAC133+ cells were taken under different culture conditions, and depicted
in figure 4.2. Panels A and B represent cells cultured with TPO/flt-3 whilst panel C
demonstrates that without these 2 anti-apoptotic cytokines there are few cells
remaining, most ofwhich look spindle-shaped and necrotic. Panels D-J represent the
morphology of cultures as grown under different cytokine combinations (see
methods; D-J correspond to 1-7 with respect to cytokine combinations). There was





Legend for figure 4.2
Light microscopy pictures taken of cultured AC133+ cells. Panels A and B represent
culture with TPO/Flt-3. Panel C is medium alone without the aforementioned growth




Analysis of freshly isolated samples obtained after AC 133 isolation revealed them to
be 91% AC133+, with 2.5% CD3, 2% CD14 and 1% Glycophorin positive. There
was no evidence ofpositivity for CD 19. After 2 weeks culture cells were removed
from plated and analysed flow cytometrically. The results are summarised in Tables
4.4 and 4.5, and depict the percentage of cells in each culture condition which had
differentiated down haematopoietic lineages. For collagen-coated plates, there was
no marked variation in cellular differentiation across the different cytokine
combinations. The majority of cells appear to differentiate down T cell or
mononuclear cell lineages, with only minimal red cell (Glycophorin) or B cell
differentiation. On gelatin-cultured plates there appears to be a shift towards
mononuclear lineages as compared with collagen-coated plates which have greater
numbers ofT cells (CD3).
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Table 4.4




marker Range (%) Mean (± SE)
Median
TPO/Flt-3
GlyA 1-10 5(1) 5
CD3 41-57 46 (8) 42
CD14 30-41 35 (6) 32
CD19 0-8 4(1) 3
TPO/Flt3 +
HGF
GlyA 0-12 5(1) 4
CD3 46-73 61 (10) 58
CD14 28-41 36(5) 40
CD 19 0-7 3(1) 2
TPO/Flt3 +
NGF
GlyA 1-8 6(1) 7
CD3 36-61 45 (8)
CD14 42-58 43 (7) 41
CD19 0-4 2(1) 2
TPO/Flt3 +
FGFa
GlyA 1-8 4(1) 4
CD3 43-60 53 (7) 52
CD14 25-47 35 (8) 35
CD19 0-5 2(1) 2
TPO/Flt3 +
FGFp
GlyA 1-12 5(2) 5
CD3 38-56 48(12) 49
CD 14 22-47 30 (9) 31
CD19 0-5 3(2) 3
TPO/Flt3 +
NGF + HGF
GlyA 0-6 3(2) 3
CD3 27-52 40(8) 38
CD14 22-46 30(13) 30




GlyA 0-7 4(2) 5
CD3 37-63 50(9) 49
CD14 18-34 25 (5) 26
CD19 1-8 4(1) 5
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Table 4.5




marker Range (%) Mean (± SE)
Median
GlyA 1-12 6(1) 5
TPO/Flt-3
CD3 27-52 36(5) 36
CD 14 38-73 60 (9) 58
CD19 1-5 3(1) 4
GlyA 0-10 4(1) 5
TPO/Flt3 + CD3 21-53 30(7) 32
HGF CD14 32-66 51(9) 50
CD19 1-15 9(1) 10
GlyA 1-9 5(1) 5
TPO/Flt3 + CD3 32-65 38 (7) 39
NGF CD14 42-75 63 (12) 66
CD19 2-12 8(1) 7
GlyA 1-9 5(1) 4
TPO/Flt3 + CD3 23-49 33 (6) 33
FGFa CD14 45-64 57(7) 58
CD19 1-9 6(1) 5
GlyA 1-9 4(2) 4
TPO/Flt3 + CD3 28-52 34 (6) 35
FGFP CD14 30-66 52 (5) 51
CD19 1-9 5(2) 4
GlyA 0-7 4(1) 4
TPO/Flt3 + CD3 21-62 37(11) 36
NGF + HGF CD14 31-49 38 (6) 37




GlyA 0-9 5(1) 4
CD3 32-59 47(7) 46
CD14 12-43 27 (6) 28
CD19 1-6 3(1) 4
Across all the culture groups, there are cells which did not stain with the above
markers. Further analysis of non-haematopoietic differentiation was undertaken
further on in this chapter using immunofluorescent analysis.
Figure 4.3
Optimisation of rtPCR on HepG2 cells
GAPDH
1 2 3 4 5 6 7
ALBUMIN
1 2 3 4 5 6 7 8
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1 2 3 4 5 6 7 8
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Legend for figure 4.3
This figure demonstrates the sensitivity of the rtPCR system for detecting GAPDH,
albumin and alpha-feto-protein transcripts in HepG2 cells. Picture a depicts presence
ofGAPDH transcripts as produced with either Random Decamers (lanes 1-2) or
OligodT primers (lanes 3-4). Lane 6 is the RT negative control and lane 7 is the
water blank PCR control. Lane 5 is the ladder, with the thick band representing 500
base pairs. Lanes 1 and 3 represent 100 cells worth of cDNA whilst lanes 2 and 4
represent 10 cells worth. Pictures b and c depict sensitivity for albumin transcripts.
Lanes 6 and 7 are the controls as per picture a, and lane 5 represents the GAPDH
control band. Lanes 1-4 in picture b represent 200, 100, 50 and 25 cells worth of
cDNA, whereas Lanes 1-4 in picture c represent 25, 10, 5 and 1 cells worth of
cDNA. Picture d depicts sensitivity for alpha-feto-protein transcripts. Lanes 5 and 6
are the controls as per picture a, with lane 7 representing the GAPDH control. Lanes
1-4 in picture d represent 100, 50, 25 and 10 cells worth of cDNA.
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rtPCR data
HepG2 cells were cultured in the standard manner (described in chapters 2 &3).
Samples ofHepG2 cells were processed for cDNA synthesis and rtPCR as described
in the methods section. In the first stage, the presence of the ubiquitous housekeeping
gene GAPDH was tested for. Two different primers were used for cDNA synthesis;
oligodT and Random Decamers. 10 and 100 cells worth of cDNA produced with
these respective primers were placed in the PCR reaction, and the products produced
were as shown in figure 4.3 picture 1A. These suggested that the GAPDH product
was of higher quality with the OligodT primers, and consequently this was used
subsequently in cDNA synthesis.
To ascertain the sensitivity of the system for detecting albumin and alpha-feto¬
protein transcripts diminishing amounts of cDNA were placed in the PCR reaction.
As shown in figure 4.3 picture 3B and 3C as little as 10 cells worth of albumin
cDNA produced by HepG2 cells could be identified. This was slightly higher than
alpha-feto-protein transcripts, which required at least 25 cells worth of cDNA to be
present (figure 4.3 picture ID).
Having established the limits of the detection system samples of cultured AC133+
cord blood cells were processed in similar fashion to determine whether there was
any evidence of differentiation down the hepatocytic lineage. Figure 4.4A
demonstrates that freshly isolated human AC133+ cells do not produce albumin or
alpha-feto-protein transcripts, and that GAPDH transcripts can be easily detected.
Furthermore, only 25 cells worth ofGAPDH is required for the system to detect it.
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Figure 4.4B confirms that AC 133" cells cultured in a variety of different cytokine
combinations produce relatively similar amounts ofGAPDH. However, as figures
4C and 4.4D demonstrate there was no evidence of albumin or alpha-feto-protein
transcript production in any of these. In these experiments 100 cells worth of cDNA
was used in the PCR reaction. This work was performed on uncoated, collagen
coated and gelatin coated wells, with similar (ie negative) results in each case.
w
Figure 4.4
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Legend for Figure 4.4
This figure demonstrates the detection ofGAPDH, albumin and alpha-feto-protein
transcripts in AC133+cells. Picture a looks at the presence ofGAPDH in 100 and 10
cells worth of cDNA (lanes 4 and 5 respectively). Lanes 1 and 2 are the RT negative
control and the PCR water blank control. Lanes 6 and 7 represent the absence of
albumin and alpha-feto-protein transcripts in freshly isolated AC133+ cells.
Picture b represents the controls in lanes 1 and 2. Lanes 3-9 are the GAPDH controls
from different cytokine combinations, and match up with the lanes 1-7 in pictures c
and d. Lanes 1-7 correspond to the cytokine combinations detailed in the methods
section. Lane 8 in pictures c and d represent the result obtained from HepG2 cells
and acts as a positive control. Pictures c and d demonstrate that there is no evidence




Figure 4.5 depicts the staining ofHepG2 cells for a pan-cytokeratin antibody
detected with a FITC secondary antibody. Panel A represents contrast light
microscopy, panel B is DAPI nuclear staining and panel C the cytokeratin staining.
There was no evidence of positive staining of AC 133" cells at either isolation or after
any combination of cytokine cultures (Olympus microscope xlOO).
Figure 4.6 depicts the staining of cEBPP on HepG2 cells with a Texas Red
secondary. Panel A represents contrast light microscopy, panel B is DAPI nuclear
staining and panel C the cEBP(3 staining. There was no evidence of positive staining
ofAC1334 cells at either isolation or after any combination of cytokine cultures
(Olympus microscope xlOO).
Figure 4.7 depicts the staining ofHNF4a on HepG2 cells with a FITC secondary.
Panel A represents contrast light microscopy, panel B is DAPI nuclear staining and
panel C the HNF4a staining. There was no evidence of positive staining ofAC133+















cEBP-beta staining in HepG2 cells
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Figure 4.7





Acute liver injury serum- effect on stem cell survival and differentiation
Cells were cultured in standard media as described in the methods section, with
varying concentrations ofnormal human or fulminant human serum. After 2 weeks
culture the number of cells was counted by Neubauer cytometer as shown in table 4.6
(n-7).
Table 4.6
Cell quantification after culture with sera
Culture condition




TPO/FLT 3 ligand alone 2.09 ±0.91 9.54 ± 1.46
1% Normal serum 4.60 ±0.82 10.2 ±2.14
10% Normal Serum 4.24 ±0.61 12.5+2.62
1% Fulminant serum 4.61 ±0.53 11.2 ±2.14
2% Fulminant serum 4.22 ± 0.74 10.3 ±2.33
5% Fulminant serum 5.25 ±0.54 14.9 + 3.36
10% Fulminant serum 4.90 ±0.85 19.6 + 2.21
Analysis of cell death was carried out using Propidium Iodide exclusion (method
described in chapter 2). The results of this are shown in table 4.6. They indicate that
fulminant serum at a concentration of 10% does induce increased cell death as
compared with equal percentage normal serum (p <0.05).
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Table 4.7




marker Range (%) Mean (± SE) Median
GlyA 3-8 6(1) 7
CD3 29-48 38(5) 36
TPO/Flt-3
CD14 27-49 39(4) 41




GlyA 3-6 5(2) 6
CD3 15-36 22 (4) 21
CD14 15-37 26 (7) 26




GlyA 1-6 4(2) 5
CD3 12-29 18(2) 17
CD14 23-38 32(5) 31
CD19 3-6 5(1) 4
TPO/Flt3 + GlyA 2-7 5(2) 4
1% CD3 9-28 19(4) 18
Fulminant CD14 28-53 41(11) 40
serum CD19 1-6 4(2) 5
TPO/FIt3 + GlyA 2-7 5(2) 6
2% CD3 9-24 17(3) 16
Fulminant CD14 29-49 38 (7) 37
serum CD19 1-5 3(1) 3
TPO/Flt3 + GlyA 0-6 3(1) 4
5% CD3 7-14 10(1) 11
Fulminant CD14 28-43 35(7) 34
serum CD19 0-8 4(1) 4
TPO/FH3 + GlyA 1-8 5(2) 6
10% CD3 5-11 8(2) 7
Fulminant CD14 22-38 29 (5) 30
serum CD19 3-7 5 (1) 6
Table 4.7 shows the respective haematopoietic lineages down which the stem cells
differentiated. When compared to control cultures there were lower levels of T-cell
differentiation (CD3) seen in all cultures supplemented with serum (p< 0.05,
ANOVA). There was a significant trend towards lower levels of CD3 differentiation
as percentage concentration of fulminant serum increased.
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Further rtPCR analysis and immunofluorescent analysis was carried out as described
previously in this chapter. There was no evidence of albumin or alpha-feto-protein
transcripts in any of the culture combinations, nor was there any evidence of staining
for cEBPP, HNF4a and pan-cytokeratin.
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4.7 CONCLUSIONS
Building on recent studies, this chapter set out to establish whether human cord
blood stem cells could be differentiated down the hepatocytic lineage in vitro.
In this work, mononuclear cells were further sorted for the expression of a stem cell
marker, AC 133, to ensure that a more pluripotent population of cells was used. By
using this more pluripotent population it was hypothesised that it would increase the
chances ofculturing cells which had the capacity to differentiate towards
hepatocytes.
As described in the results although good purity for AC 133 was achieved there was
no evidence of hepatocytic differentiation in any cytokine culture combination. There
are several possible reasons for this:
1) This may reflect the choice of cell type Potentially more primitive, AC133negat,ve;
cells have been discarded, and it may be these cells which have the capacity for such
lineage differentiation.
2) The choice of cytokines may have been inadequate.
3) The choice of extra-cellular matrix may have been inadequate. Although uncoated,
collagen and gelatin were used, perhaps these were not sufficient to sustain and
stimulate hepatocytic differentiation. Other possible matrices which may have been
important to examine include Matrigel, and also co-culture with
hepatocytes/fibroblasts. In view of the negative outcome of these studies, I proceeded
to examine whether such cells would have a greater chance of differentiating in an in
vivo model system (chapter 5).
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Since this work was undertaken other groups have reported successful
differentiation of cord blood derived stem cells into hepatocytes in in vitro studies
(Kakinuma et al 2003). Their most successful cytokine combinations utilised FGFa
(20ng/ml), FGFp (lOng/ml), LIF (lOng/ml), SCF (lOng/ml) and HGF (lOng/ml) in
DMEM supplemented with 15% FBS, 2mM L-Glutamine, 25mM HEPES, lOOU/ml
penicillin, 100p.g/ml streptomycin, 0.25pg/ml amphotericin B and 300pM
monothioglycerol. Other groups have demonstrated that human and murine bone
marrow also contains stem cells which have the ability to differentiate into
hepatocytes. Notably these groups used Matrigel cultures with FGF-4 and FIGF
(Jiang et al 2002; Schwartz et al 2002).
In keeping with cytokine combinations acute liver injury serum did not lead to
hepatocytic differentiation of cultured stem cells. Again, this may reflect the lack of
adequate matrix to facilitate hepatocytic differentiation. As with HepG2 cells
fulminant serum does appear to cause cellular necrosis, although in the case of stem
cells a lower concentration (10%) is required to produce this.
Serum supplementation leads to decreased T cell differentiation, a finding which
becomes manifest with increasing concentration of fulminant serum. It is not clear if
this is a representation of increased cell death or a specific reduction in T cell
differentiation. One possible explanation would be that T cells produced from stem
cells are in turn susceptible to the injurious effects of acute liver injury serum. There
may also be lower levels of factors necessary to facilitate differentiation of stem cells
into T cells present in acute liver injury serum. These include factors such as flt-3
ligand, interleukin-3 (IL-3), stem cell factor (SCF), and IL-2 (Pawelec et al 1998),
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which are know to be important in T cell differentiation. Given that there is increased
sepsis in patients with acute liver failure, it is possible to speculate that diminished T
cell differentiation ofhost stem cells plays a role in the diminished response to
infection. Further studies are required to explore this hypothesis.
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CHAPTER 5
STUDY OF HUMAN HAEMATOPOIETIC STEM CELL TRANS-
DIFFERENTIATION IN THE NOD-SCID MOUSE




5.5 STATISTICAL ANALYSIS OF DATA
5.6 RESULTS
5.7 CONCLUSIONS
5.1 BACKGROUND AND AIMS
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As detailed in the Background and Aims in Chapter 4 stem cells have been
demonstrated to have greater plasticity than previously thought That adult human
stem cells also share some of these pluripotent properties has been demonstrated in
studies utilising archival biopsy samples (Alison et al 2000) in which donor-derived
hepatocytes and cholangiocytes have been observed in the recipient. In both of these
studies, the presumed origin of stem cells was the bone marrow, and both studies
used cross-sex transplants to differentiate host from recipient hepatocytes. A study
by Korbling et al (Korbling et al 2002) demonstrated that human stem cells
mobilised by gCSF (as used in the management of haematological conditions) also
retained the ability to differentiate down hepatocytic and other non-haematopoietic
lineages. As yet, the biological relevance of human stem cell transdifferentiation
remains to be clarified; with concerns existing that human stem cells may not share
the same pluripotentiality as rodent stem cells. However, no in vivo model systems
exist to test human stem cell pluripotency prospectively thereby limiting our ability
to fully appraise the role human stem cells have to play. The present study was
undertaken to answer the following questions:
1) Can human cord blood cells engraft anddifferentiate into human hepatic type
cells in the liver ofimmunocompromised mice?




Studies were undertaken using NOD-SCID mice (obtained from Jackson
Laboratories) and human cord blood obtained with patient consent and full approval
from the Lothian Regional Ethics Committee (LREC). In addition samples of healthy
human liver were obtained from donated liver organs, again with full LREC/MREC
consent.
5.3 METHODS
Freshly collected heparinised whole cord blood samples were received from the
Scottish National Blood Transfusion Service (Edinburgh, UK) following informed
donor consent. Mononuclear cells were isolated using Histopaque 1077 (Sigma, UK)
density centrifugation following the initial description by Boeyum (Boeyum A
1968). Briefly, heparin-treated (103IU/mL) whole blood was carefully layered over
an equal volume ofFicoll-Hypaque1M and spun at 540g for 20 minutes. The interface
('buffy coat') containing the mononuclear cells was collected and washed twice in
Hank's Balanced Salts Solution (HBSS; Gibco, UK). A trypan blue exclusion assay
was used to assess the viability of the harvested cells prior to their usage.
Animals
Four to 6 weeks old NOD-SCID mice were sub-lethally irradiated (250 rads) and
received a single tail-vein infusion of 50 x 106 human cord blood-derived
mononuclear cells resuspended in lOOgl of sterile Hank's Balanced Salt Solution
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(HBSS; Gibco, UK). Mice were, on occasions infused with samples from the same
cord donor, or from pooled cord donors. Mice were kept under specific pathogen free
(SPF) conditions in microinsulators and sacrificed at 1, 4, 6 and 16 weeks post cord
blood cell infusion. Experimental protocols involving animals were carried out in
accordance with permits and guidelines issued by the University ofEdinburgh
Ethical Review Committee and the UK Home Office.
In Vitro Culture Assays
In order to detect hematopoietic progenitor cells in human cord blood samples,
colony-forming units (CFUs) were evaluated by placing cord blood-derived
mononuclear cells in pre-tested complete semi-solid methylcellulose mixtures
(Methocult GF H4534; StemCell Technologies, Inc., Canada) comprising 1%
methylcellulose in Iscove's MDM, 30% fetal bovine serum, 1% bovine serum
albumin, 10"4M 2-mercaptoethanol, 2mM L-glutamine, 50ng/mL rh stem cell factor,
lOng/mL rh GM-CSF and lOng/mL rh 1L-3. 1,500 cells per mL ofmethylcellulose
were plated out in triplicate wells in a multidish plate (Nunc, UK) and cultured at
37°C in 5% CO2 for 12 days. At that time, the number of total CFUs was determined
under the microscope as an average count of all 3 wells. Control cultures were
included in each assay and these were grown in identical medium apart from the
absence of growth factors.
FACS Analysis
Cord blood mononuclear cell surface phenotype was characterised using standard
FACS analysis. Briefly, 100,000 cells per test were pelleted by centrifugation for 5
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minutes at lOOOrpm and cell pellets resuspended in individual monoclonal antibody
(mAb) solutions using the manufacturer's (Dako, UK; BD Pharmingen, UK; Sigma,
UK) recommended test concentrations (confirmed in our laboratory to give optimum
results in our hands). Test samples were immunostained for 20 minutes on ice with a
panel of directly FITC- and/or PE-conjugated mAb against human cell surface
markers. The panel included mAb against the following markers: MHC1 (pan-
nucleated cell) (200 pg/mL; Sigma, UK), gly-A (erythrocyte) (100 pg/mL; Dako,
UK), CD3 (T Cell) (12.5pg/mL; BD), CD1 lb (granulocyte) (lOOpg/mL; Dako),
CD14 (monocyte) (60pg/mL; Dako), CD19 (B cell) (25pg/mL; BD), CD33 (myeloid
progenitor) (6pg/mL; BD), CD34 (stem cell) (25pg/mL; BD), CD45 (pan-leukocyte)
(50pug/mL; BD) and CD56 (NK cell) (50pg/mL; Dako). Cell subsets were double-
immunostained using a subset-specific mAb as well as an antibody against CD45.
Following immunostaining, cells were pelleted, washed in FACS handling buffer
(lxPBS/1% BSA/0.1% Sodium Azide/0.5M EDTA) and resuspended in FACS fix
(1% formaldehyde) prior to analysis using CellQuest software on a Becton Dickinson
FACSCalibur machine.
Glucose Phosphate Isomerase Assay
Electrophoresis for variants ofglucose phosphate isomerase (GPI) was carried out as
described by Ansell & Micklem (Ansell et al 1986). This method can distinguish
between the human and murine isoforms of the enzyme on the basis of its
electrophoretic mobility. Thus, it permits a biochemical assessment for the presence
of human cells in murine tissue. Briefly, samples of single cell suspensions were
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pelleted by centrifugation, lysed using 'sample' buffer and stored at -80°C.
Electrophoresis was carried using the 'Helena' system (Helena Laboratories).
Samples were applied to Titan III cellulose acetate membranes at the anode and run
for 80 minutes at 350V using Supraheme buffer. Bands were developed using a
staining mixture containing substrate and co-factors for GPI and visualised using
tetrazolium dyes 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide
(MTT) and phenazine methosulfate (PMS).
Histology, Immunohistochemistry and Immunofluorescence
Histology Livers from NOD-SC1D mice were removed, fixed in 4% formaldehyde
overnight and embedded in paraffin blocks. 4pm sections were cut and placed onto
Vector-bonded slides. Slides were dewaxed through xylene and rehydrated through
graded alcohols and water. Positive controls included normal human liver obtained
with ethical approval from the Scottish Liver Transplant Unit (Royal Infirmary of
Edinburgh). Negative controls included mouse liver obtained from sublethally
irradiated NOD-SCID mice infused iv with medium only.
Immunohistochemistry Sections were microwaved for 15 min in 0.1M citrate buffer
and blocked in 1%H2C>2 for 15 min. Slides were then incubated with a 1:4 dilution of
a mouse mAb against cytokeratin 19 (as a marker of biliary epithelium) (Dako,
Cambridge, UK), a 1:25 dilution mouse mAb HepParl that was raised against human
hepatocytes (Dako, Cambridge, UK), a 1:25 dilution CD31 mouse mAb against human
endothelial cells (Dako, Cambridge, UK) and a 1.25 dilution CD;,4 mouse mAb
against human stem cells (Dako, Cambridge, UK). Slides were then washed and
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incubated with a horseradish peroxidase (HRP) polymer-conjugated detection
antibody followed by diaminobenzidine (DAB) chromagen (Envision™; Dako, UK).
Immunofluorescence Sections were microwaved for 20 min in 0.1 M citrate buffer,
cooled and washed in 2 x sodium saline citrate (SSC)(Dundas et al 2001).
Immunofluorescence was carried out using a 1:4 dilution of a mouse mAb against
cytokeratin 19 (Dako, Cambridge, UK), or a 1:25 dilution mouse mAb HepParl (Dako,
Cambridge, UK). Secondary antibody was a 1:100 dilution of donkey anti-mouse
FITC (Vector Laboratories, US).
Fluorescent in situ hybridisation (FISH) Analysis
1 pg total human genomic DNA was labelled with digoxigenin 11-dUTP (Roche,
Lewes, UK) and mouse genomic DNA was labelled with Alexa Fluor 594-5 dUTP
(Molecular Probes, Leiden, Netherlands), by nick translation. Unincorporated
nucleotides were removed by centrifiigation through Quick Spin G50 Sephadex
columns (Roche, UK). Specific activity of the probes was performed by dotting onto
nitrocellulose filters using anti-digoxigenin-Alkaline phosphatase Fab fragments
(Roche, UK). We then used a BCIP/NBT kit (Vector) which produces the purple
colour change on the filter, which we then compared to known standards (DNA of
known concentrations).
Slides were heated to 60°C for 20min to melt wax, and then washed in xylene 4 x for
10 min each before dehydration through an ethanol series (100%, 95%, 70%). Slides
were then microwaved for 20 min in 0.1M citrate buffer pH 6-0. Slides were then
denatured for 3 min at 75°C. After microwaving, liver sections were denatured for 3
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min at 75°C in 70%formamide/2 x SSC, plunged into ice-cold 70% ethanol for 3 min,
dehydrated through an alcohol series, and air-dried.
150 ng labelled human genomic DNA, 150 ng labelled mouse genomic DNA and 5
gg salmon sperm DNAwere denatured together for 5 min at 75°C in 50%
formamide, 10% dextran sulphate, 2 x SSC, 1% Tween20. Hybridisation was
overnight at 37°C. Slides were washed 4x for 3min in 2 x SSC at 45°C, then
incubated for 30 minutes with a 1:30 dilution of a sheep FITC anti-digoxigenin
antibody (Roche, UK), followed by a further 30 minutes with a 1:100 dilution of
FITC anti-sheep antibody (Vector Laboratories, US) (Fantes et al 1995). Slides were
mounted in Vectashield (Vector Laboratories, US) containing 1 pg/ml 4,6-
diaminidino-2-phenylindole (DAPI) counterstain.
Image analysis
Slides were visualised using a Zeiss Axioplan 2 fluorescence microscope
(Thornwood, US) equipped with a triple bandpass filter (Chroma #83000). Grayscale
images were collected with a cooled charge-coupled device (CCD) camera (Quantix
Corp. US) and analysed using custom IPLab scripts. Images were pseudocoloured
using image processing software (Adobe Photoshop, US).
Quantitation OfCord Blood-Derived Hepatocytes
Human hepatocytes were identified in two ways: (1) With positive staining of the
human specific HepParl antibody (figure 2). We have demonstrated that HepParl is
human specific and does not cross-react with NOD-SCID mouse liver (or human
cord blood). This observation is particular to NOD-SCID mice and is in keeping with
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that of other laboratories. We also performed Immunofluorescent HepParl staining
which permitted DAPI nuclear analysis. The nuclear DNA staining pattern of human
and mouse cells is quite distinct (figures 5.3/5.4) thus permitting further
differentiation between human and murine hepatocytes. The abundance of pericentric
heterochromatin on mouse chromosomes is manifest as bright foci ofDAPI staining
(Tate et al 1998), a feature not seen in human cells, which have less pericentric
heterochromatin. The combination ofbinding of a human specific liver antibody and
human nuclear morphology were taken as indicative that the cell was a human
hepatocyte. (2) With positive FISH signal for human DNA (figure 5.3) and
morphology typical of human hepatocytes. Hepatocytes were characterised as large
polyclonal cells, arranged in plates, which had large round nuclei. In addition their
cytoplasm was characteristically bright reflecting the FITC-type cytoplasmic
autofluorescence caused by bilirubin metabolic products (Theise et al 2000a). The
number of positive cells obtained by these two methods was used to provide a mean
value of cord blood-derived hepatocytes in each liver. Total human cells were
quantified by counting the number of cells with human FISH signal in the murine
liver section. Co-localisation studies ofHepParl staining and positive FISH signal
were attempted but FISH processing degraded the HepParl signal, and thus we were
unable to detect co-localisation of these markers even in human liver tissue.
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5.4 EXPERIMENTS
Human cord blood samples were characterised by FACS analysis and CFU analysis
to demonstrate that they were rich sources ofhuman stem cells (n=10).
In a subsequent set of experiments pooled sets of human cord blood were infused
into sub-lethally irradiated NOD-SCID mice as described in the methods section
(n=12) and these mice were kept in SPF conditions for 1, 4, 6 and 16 weeks before
termination. Bone marrow was analysed at these points for evidence of human-
mouse chimerism. Livers were also analysed for evidence ofhuman hepatic cell
differentiation by immunohistochemical and Immunofluorescent analysis. Evidence
of fusion between human and murine cells was also tested for using simultaneous
FISH.
5.5 STATISTICAL ANALYSIS OF DATA
Data are expressed as Mean +/- standard error of the mean (SEM).
5.6 RESULTS
Infused Human Cord Blood Samples Are Rich in Hematoprogenitor Cells
Initially, 10 individual human cord blood samples were characterised by FACS
analysis and in vitro culture assays prior to injection into NOD-SCID mice (see
Table 5 .1). The percentage of cells expressing a variety of haematopoietic markers is
detailed as well as mean values (along with their standard error and medians). The
results were that an average of 1% of cord blood mononuclear cells were CD34+ve
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stem cells. In line with this were the results from our in vitro culture assays which
demonstrated an average of48 colony forming units (CFU) per cord blood sample
(see Figure 5.1). Taken together, the results thus suggested that our infused cord
blood samples were rich in haematoprogenitor cells.
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Table 5.1 Characterisation of infused human cord blood prior to intravenous








MHCl 78-96 88 (2) 88
CD45 59-93 81(3) 83
GlyA 2-18 11(2) 11
CD3 0-70 54 (6) 58
CDllb 5-24 14(2) 14
CD14 1-21 6(2) 4
CD19 0-24 8(3) 1
CD33 0-21 4(2) 2
CD34 0-2 1(0) 1




Legend for Table 5.1
Characterisation of infused human cord blood prior to intravenous inoculation
into sub-lethally irradiated NOD/SC1D mice.
This table describes the analysis of 10 human cord blood preparations prior to their
infusion into sub-lethally irradiated NOD/SC1D mice. The percentage of cells
expressing a variety of haematopoietic markers is detailed as well as mean values
(along with their standard error, SE) and medians. In particular the percentage of
cells expressing CD34 is seen to be 1%. Colony-forming unit (CFU) measurement
confirms the presence of stem cells in the infused cord blood.
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Figure 5.1
Colony forming units demonstrated with cord blood derived
cells
Human Cord Blood Samples Engraft in NOD/SCID Mice
In order to assess in vivo engraftment of our human samples up to 16 weeks post-
inoculation, I used FACS and GPI analysis as well as in vitro culture assays to study
bone marrow samples from our infused NOD-SCID mice. Table 5.2 represents the
contribution of human cells to the bone marrow of irradiated NOD-SCID mice (n-6)
8 weeks after infusion of human cord blood cells. The column on the left denotes the
panel of markers (human and murine) screened for in the murine marrow The
middle column reflects the relative contribution of human cells to different
haematopoietic lineages in the NOD-SCID murine marrow (these were identified
using flow cytometric analysis with human specific antibodies). The column on the
right reflects murine haematopoietic cells identified by flow cytometric analysis with
mouse-specific antibodies. Using FACS, the results were that mice tested had
detectable levels (10-45% of counted cells; average 17%) of human CD45+ve
leukocytes in their bone marrow. In addition, there was evidence ofmultiple
haematopoietic lineages represented by human cells. The data correlated with results
of our GPI assay, which confirmed the presence of the human GPI isoenzyme in the
assayed samples (see Figure 5.2). Panel a, demonstrates the different electrophoretic
mobility of human and NOD-SCID mouse iso-enzymes. Panel b, shows the results
obtained in a representative NOD-SCID mouse bone marrow after (labelled
'recipient 1') inoculation with a human cord blood sample.
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Mean (%) Range (%) Mean (%) Range (%)
MHC 1 +ve 26 14-47 32 23-46




















Legend for Table 5.2
Human reconstitution of NOD-SCID murine bone marrow
This table represents the contribution of human cells to the bone marrow of irradiated
NOD-SCID mice (n=6) 8 weeks after infusion of human cord blood cells. The
column on the left denotes the panel of markers (human and murine) screened for in
the murine marrow. The middle column reflects the relative contribution of human
cells to different haematopoietic lineages in the NOD-SCID murine marrow (these
were identified using flow cytometric analysis with human specific antibodies). The
column on the right reflects murine haematopoietic cells identified by flow
cytometric analysis with mouse-specific antibodies. These data confirm that there is
marrow engraftment with human cord blood cells.
I?8
Figure 5.2
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Legend for figure 5.2. Glucose phosphate isomerase assay for in vivo detection
of human cells
GPI analysis of bone marrow-derived samples from NOD-SCID mice infused with
human cord blood cells for demonstration of the human isoenzyme. Panel a,
demonstrates the different electrophoretic mobility of human and NOD-SCID mouse
iso-enzymes. Panel b, shows the results obtained in a representative NOD-SCID
mouse bone marrow after (labelled 'recipient 1') inoculation with a human cord
blood sample. The results were in line with data obtained by FACS analysis and in
vitro cultures.
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HepParl Antibody Is Specific For Human Hepatocytes
In the next set of experiments, I ascertained the specificity of the HepParl mAb
using serial tissue sections. The results, which are shown in Figure 3, demonstrated
that when incubated for 1 hour at a concentration of 1:25, the HepParl antibody is
specific for human hepatocytes and does not cross-react with human cord blood or
NOD-SCID mouse liver elements. Panels a and b in Figure 5.3 illustrate negative
controls on human liver in the absence of antibody, but in the presence ofDAB
chromagen. Panels c and d in Figure 5.3 illustrate the characteristic cytoplasmic
staining of human hepatocytes with the HepParl antibody. Finally, panels e and f
illustrate that NOD-SCID murine liver sections did not demonstrate any binding to
the HepParl antibody, confirming that this is a human specific hepatocyte antibody.
Furthermore, I showed that there was no staining of the HepParl antibody in human
cord blood using a pelleted cord blood sample that had been mounted onto a slide.
Figure 5.3




Legend for figure 5.3
Immunohistochemistry on liver sections with antibody HepParl (brown) that detects
human, but not mouse, hepatocytes. Cells were counterstained with Haematoxylin
(pink), a-d, Human liver. e,f, mouse liver, a and b represent human liver with no
primary antibody, c to d, positive cells in the human liver, e and f represent NOD-
SCDD mouse liver which has no binding of the antibody.. Scale bar, 20p.m.
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Human Cord Blood Cells Can Engraft And Differentiate Into Hepatocytes In
The NOD-SCID Mouse Liver
Despite no evidence of hepatocyte damage after irradiation, human-derived cells
were detected in the liver of cord blood-injected NOD-SCID mice 1 week post-
infusion and at all subsequent timepoints. Human hepatocytes were demonstrated in
mouse liver 4 weeks post-infusion and at all subsequent timepoints.
Human hepatocyte differentiation in vivo was detected firstly by
immunohistochemical analysis using the human specific hepatocyte marker
(HepParl) demonstrating the presence of isolated positive cells within the NOD-
SCID mouse liver (see Figure 5.4). Positive cells were occasionally seen as clumps
of cells (Panels a-d) or as individual cells (Panels e-f) within the liver. Scale bar on
these panels is 20pm. Furthermore immunofluorescence analysis of these sections
using the same HepParl antibody confirmed the presence of isolated positive cells
integrated in the liver plate (see Figure 5.5), with characteristic human nuclear
morphology. These cells tended to be located within the hepatic plate in the vicinity
of portal tracts, suggesting that circulating cells derived from human cord blood had
invaded the liver and differentiated into mature hepatocytes. In Figure 5.5 Panels a
and b represent HepPar and DAPI nuclear staining on human and murine liver
sections respectively. Panel a demonstrates the characteristic cytoplasmic staining of
HepPar 1 on human hepatocytes. The panel on the right only looks at the blue DAPI
signal and converts it into greyscale to demonstrate the characteristic human nuclear
morphology. In contrast, panel b demonstrates the previously noted absence of
staining on murine liver of the HepPar 1 antibody. To the right the characteristic
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DAPI murine nuclear morphology is depicted in greyscale. Panels c and d are
indicative of isolated positive human hepatocytes within the NOD-SCID mouse liver,
which stain positive with the HepPar 1 antibody, but which also have characteristic
human DAPI nuclear morphology. Scale bars represent 20 pm.
Further evidence for the presence of human hepatocytes derived from the presence of
positive FISH signals in cells with typical hepatocyte morphology. Figure 5.6
illustrates the differences in human and murine staining with FISH probe. Panel a is
human liver after FISH staining for human DNA, demonstrating that human nucleii
have positive signal (FITC-labelled). In contrast, Panel b demonstrates that murine
liver does not have any positive staining. On processing of the murine livers after
cord-blood infusion many positive cells (ie human) were identified which had the
morphology (large nuclei and abundant cytoplasm) typical ofmature hepatocytes
(Panels c-d, g-h). In addition, many positive cells did not display hepatocyte
morphology and were presumed to be haematopoietic cells (panels e-f). Panel h
represents the light microscopic appearance ofPanel g, depicting the typical complex
hepatocytic cytoplasm of a cell which has stained positive with the human DNA
probe. Staining with the human biliary marker CK19 did not identify any human
biliary cells in the murine liver. Example positive staining on human liver is
demonstrated in Figure 5.7. Panels a-d depict fluorescent staining of human liver
with Cytokeratin 19, a biliary marker. Panels e is a negative control in human liver
(No primary antibody), whereas f represents negative staining in murine liver.
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Figure 5.4




Legend for figure 5.4
Immunohistochemistry on NOD-SCID mouse liver sections with antibody HepParl
(brown) after infusion of human cord blood cells. The panels represent positive
human hepatocytes in either clumps (a-d), or as isolated cells (e,f). Scale bar, 20p.m.
IB?
Figure 5.5 Immunofluorescent staining of HepParl
2 colour DAPI Greyscale
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Legend for figure 5.5
Immunofluorescence on liver sections with antibody HepParl (green) that detects
human, but not mouse, hepatocytes. Cells were counterstained with DAPI (blue).
Greyscale images ofDAPI staining are shown on the right. a, Human liver, b,
mouse liver, c to d, positive cells integrated into the hepatic plate of livers ofNOD-
SCED mice. Note the DAPI nuclear staining typical of human derived-cells in the
positively staining cells. Scale bar, 20jam.
m
Figure 5.6
FISH staining in NOD-SCID mouse liver sections
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Legend for figure 5.6
Detection of digoxigenin-labelled human DNA by FITC (green) in liver sections
counterstained with DAPI (blue). Greyscale images ofDAPI staining are shown on
the right, a, Human liver, b, mouse liver, c to d, human hepatocytic cells integrated
into the hepatic plate of livers ofNOD-SCID mice, e to f, human haematopoietic
cells entering the murine liver, g to h, represent greyscale H&E pictures of cells with
positive FISH signal and characteristic hepatocytic morphology. These cells had
morphology typical of hepatocytes with large polyclonal size with large round nuclei
and complex intracellular cytoplasm. Scale bar, 20p.m.
HI
Figure 5.7
Biliary staining in human and NOD-SCID liver sections
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Legend for figure 5.7
Immunofluorescence on liver sections with antibody CK19 (green) that detects
human, but not mouse, biliary duct cells. Cells were counterstained with DAPI
(blue), a-d, Human liver, e, mouse liver, f, Mouse liver after infusion of human cord
blood cells, demonstrating no human cells. Scale bar, 20jxm.
Figure 5.8
Staining of liver sections with CD34
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Legend for figure 5.8
Immunohistochemistry on NOD-SCID mouse liver sections (after infusion with
human cord blood cells) with antibodies against CD34 (brown). The panels represent
positive human hepatocytes in either clumps (a-d), or as isolated cells (e,f). Scale
bar, 20pm
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Table 5 .3 quantifies both the total number of human cells and the number of human
hepatocytes engrafted within the NOD-SCID mouse liver. Transdifferentiation
efficiency is expressed by dividing the total number of donor-derived hepatocytes by
the number of infused CD34+ cells. The mean number of human hepatocytes per
section was 47.8 (range 19-73). The observed frequency of human hepatocytic
transformation seen was modest, with such cells constituting on average 0.011% of
all cells on each section (maximum seen was 0.017%). When the number of trans-
differentiated hepatocytes is expressed as a percentage of the number of infused
CD34+ cells the mean value is 2.11%. No evidence of any human hepatocytes was
seen 1 week after cord blood infusion, although infiltrating CD34+ cells could be
seen entering through the portal tracts (see Figure 5.6, panels e-f, and Figure 5.8).
There did not appear to be an increase in the number of human hepatocytes seen in
the mouse liver after 4 weeks post cord blood infusion, with similar percentages
being found after 6 and 16 weeks. Furthermore, similar numbers of human cells were
also observed in vascular channels and/or had morphology that was more consistent
with haematopoietic lineages (see Figure 5.6, panels e-f). There was no evidence of
human biliary (cytokeratin 19+ve) or endothelial (CD31+) differentiation in any of
the sections (see Figure 5.7).
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Table 5.3 Number of human cells/hepatocytes in NOD-SCID mice transplanted
with human cord blood-derived mononuclear cells
Mouse Time Mean number of Mean number of Trans-
Post human cells (all types) human hepatocytes differentiation
CBI per mouse liver section per mouse liver efficiency of
(and value as a section (and value CD34+ cells
percentage of host as a percentage of becoming
cells) host cells) hepatocytes (%)
1 7d 45 (0.0072) 0(0) 0
2 7d 67 (0.018) 0(0) 0
3 7d 75 (0.012) 0(0) 0
4 4wk 91 (0.013) 62 (0.0089) 1.77
5 4wk 132(0.04) 46 (0.014) 2.79
6 4wk 83 (0.027) 52 (0.017) 3.40
7 6wk 108 (0.015) 71 (0.0099) 1.97
8 6wk 88 (0.021) 46 (0.011) 2.19
9 6wk 80 (0.013) 40 (0.0066) 1.31
10 6wk 54 (0.0082) 19(0.0028) 0.58
11 16wk 63 (0.017) 52 (0.014) 2.81
12 16wk 51 (0.013) 43 (0.011) 2.21
13 16wk 70 (0.014) 22 (0.0043) 0.88
14 16wk 117(0.027) 73 (0.017) 3.38
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Legend for table 5.3
This table quantifies both the total number ofhuman cells and the number ofhuman
hepatocytes engrafted within the NOD-SCID mouse liver. Transdifferentiation
efficiency is expressed by dividing the total number of donor-derived hepatocytes by
the number of infused CD34+ cells. Peak trans-differentiation is seen to occur at 4-6
weeks with no significant increment after this time. Total human cells were
quantified by counting the number of cells with human FISH signal in the murine
liver section.
198
Fusion Of Human And Murine Cells Does Not Occur In Vivo
The nuclear DNA staining pattern of human and mouse cells is quite distinct as
described previously (Tate et al 1998). Bright foci ofDAPI staining were evident in
sections ofmouse liver, whereas nuclei in human liver sections had a more uniform
staining pattern (see Figure 5.5). Cells hybridising to human DNA and engrafting
into mouse livers had characteristic human nuclear staining morphology, and there
was no evidence in these cells of bright DAPI foci characteristic ofmouse
chromosomes (see Figure 5.6). Similarly, cells staining with a human specific
hepatocyte antibody (see Figure 5.4) also had nuclear morphology typical of human
rather than mouse cells.
To confirm this I performed a simultaneous FISH analysis for murine and human
DNAs. To optimise the method I performed it on pure human liver sections and on
pure NOD-SCID mouse sections to confirm their specificity (see Figure 5.9). Figure
5.9 displays simultaneous FISH analysis of liver sections with total human (green)
and mouse (red) DNAs. Cells were counterstained with DAPI (blue). Greyscale
images of the DAPI staining, and mouse and human hybridisations signals are
shown, a, Human liver, b, mouse liver, c and d, Human positive (green) cells
integrated into the hepatic plate of livers ofNOD-SCID mice. In Panels c and d it is
important to note the absence of any detectable mouse DNA (red) in these nuclei and
their DAPI staining typical of human derived-cells. I then examined at least 5 liver
sections of each one of 14 different mouse livers (after infusion of human cord
blood). Each section had a mean of 80.3 positive cells/section giving a total number
of events screened of 5620. Not one of these cells was the result of fusion of human
and mouse cells (see Figure 5.9). Whilst I cannot totally exclude cellular fusion it is
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clearly exceedingly rare compared to human stem cell transdifferentiation. Taken
together, the data suggest that it was unlikely that the donor human cord blood cells
had fused with host mouse hepatocytes. The scale bar in this figure is 20p.m.
Figure 5.9
Simultaneous FISH on NOD-SCID liver sections
DAPI Mouse DNA Human DNA
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Legend for figure 5.9
Simultaneous FISH analysis of liver sections with total human (green) and mouse
(red) DNAs. Cells were counterstained with DAPI (blue). Greyscale images of the
DAPI staining, and mouse and human hybridisations signals are shown, a, Human
liver, b, mouse liver, c and d, Human positive (green) cells integrated into the
hepatic plate of livers ofNOD-SCID mice. Note the absence ofany detectable mouse




This data demonstrate that infused human cord blood cells are capable of engrafting
into NOD-SCID mouse liver and differentiating down the hepatocytic lineage
without fusion to host hepatocytes. This work confirms the recently published
observation by Danet et al (Danet et al 2002) who have identified a sub-population of
human cord blood cells which have the ability to differentiate down the hepatocytic
lineage upon infusion into the NOD-SCID mouse liver. In these experimental
animals, engrafted hepatocytes were most often scattered throughout the murine liver
parenchyma, usually appearing as isolated cells, although occasionally we observed
some small clumps of cells. The rate of hepatocytic differentiation of cord blood
cells occurred at low levels in our model (up to 0.017% of total cells), and it will be
important to determine in future if liver injury increases this frequency (Vessey et al
2001). There appears to be some variation in the amount of stem cell-derived
hepatocytic differentiation reported in the literature with groups reporting as few as
10 hepatocytes per murine section (Wagers et al 2002) whilst others observe levels as
high as 1.1% of recipient liver tissue (Theise et al 2000a). This variation may reflect
differences in species and strains of animal used, presence of liver injury (whether
intentional or non-intentional such as radiation) and methods used to identify stem
cell-derived hepatocytes. I have used several different methods to identify stem cell-
derived hepatocytes and notably our observed frequency falls in the lower end of this
range. The results further suggest that in the absence of liver injury, there is no
stimulus for trans-differentiated cord blood-derived hepatocytes to proliferate since
the proportion of human hepatocytes did not appear to increase with time following
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the 4 weeks timepoint. This is in keeping with the literature as reported by Theise et
al (Theise et al 2000a) who demonstrated that the proportions of donor murine bone
marrow-derived hepatocytes in myeloablated mouse recipient livers were similar up
to 12 months after bone marrow transplant. Whilst the observed level of engraftment
in this xenogeneic model is lower than that observed in vivo by Theise et al (up to
1.1% of total cells studied), part of this may be due to human stem cells being at a
relative survival/proliferative disadvantage when infused into xenogeneic
environments in absence of liver injury. In contrast, infusion of human hepatocytes
into mice suffering mild chronic liver injury leads to their populating up to 15% of
the mouse liver, but this is seen in the context ofurokinase-type plasminogen
activator (uPA) transgenic mice which have a liver-toxic phenotype (Dandri et al
2001). The majority of the transdifferentiated hepatocytes in our model were seen to
be located in the hepatic plate in the vicinity of portal tract areas and most of these
cells were found as isolated single cells (although occasional clumps of cells were
seen). In conjunction with the finding ofCD34+ human cells in the vicinity the portal
tracts these observations suggest that the portal tract may be a major route of entry of
hepatocyte progenitors into the liver. This is supported by the finding that human
cells with morphology that was more consistent with haematopoietic cells were
frequently seen to be entering through the portal tracts (see Figure 5.3f-i), although
tracking experiments would be required to confirm their subsequent hepatocytic
commitment. In the absence of any significant liver injury, human stem cells would
have no obvious reason to migrate further into the liver plate. Hence, their peri-portal
trans-differentiation may reflect their earliest exposure to murine hepatocytes and
other factors triggering differentiation. No evidence of human biliary (cytokeratin
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19+ve) or endothelial (CD31) differentiation was seen in any of the liver sections but
this may reflect the relatively low turnover of these cellular compartments (LeSage et
al 2001) and the fact that they represent only -2% of the cellular mass of the liver. In
view of the modest levels of hepatocytic trans-differentiation, the chances of
identifying other stem cell derived lineages would therefore be much lower.
I used unsorted human cord blood as a source of donor cells as it is known to contain
higher levels of stem cells than normal peripheral blood (Glimm et al 2002). Whilst
other groups have attempted to select out an enriched population of stem cells using
markers such as CD34, it is possible that the CD34-ve population may in fact contain
an even more pluripotent population of stem cells (Dao et al 2000; Goodell et al
1997; Nakauchi 1998). Therefore, there is ample evidence to suggest that hepatocyte
progenitors belong to a stem-cell compartment.
Somatic stem cell plasticity has recently been questioned, and it has been suggested
that this presumed differentiation might be the product of cell fusion between stem
cells and pre-existing differentiated cells (Terada et al 2002; Vogel 2002; Ying et al
2002). In contrast to recent ex vivo reports (Terada et al 2002; Ying et al 2002), I
found no evidence of cell fusion in our in vivo model. Whilst a type 2 error cannot be
totally excluded, the fact that not one of 5620 human cells in the murine liver are the
result of cellular fusion indicates that fusion is at best an exceedingly rare
phenomenon. A type 2 error is made when an incorrect null hypothesis is not
rejected, when a treatment effect is in fact present (eg fusion), but not observed,
perhaps because of too few events (cell transdifferentiation).
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This study would suggest therefore that it plays a negligible role in the phenomenon
of trans-differentiation The presence of cellular fusion in other studies may thus
reflect the ex vivo environment that the work was carried out in and not in vivo
conditions. If fusion is a rare event, it may become apparent in an in vivo model of
liver injury in which more hepatocyte transdifferentiation may take place. A further
demonstration that fusion was not contributing would be to show that there was loss
of donor haematopoietic cell markers (in this case CD45).
This work makes the fundamental observation that human cord blood-derived cells
have the ability to migrate, engraft and differentiate into hepatocytes in mouse liver
when infused into NOD-SCID mice. Furthermore, I show categorically that none of
our transdifferentiated hepatocytes are the result of cellular fusion of human cord
blood cells with murine hepatocytes. The results thus suggest new opportunities in
the study of human adult stem cell biology using pre-conditioned NOD-SCID mice
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6.1 ACUTE LIVER FAILURE AND HEPATOCYTE ENGRAFTMENT
The studies in chapters 2 and 3 explore the mechanisms which regulate the adhesion
and survival ofHepG2 cells in the environment of acute liver failure.
These studies demonstrate an up-regulation of Collagen IV expression on
paracetamol-damaged liver which is a potent ligand for Pi-integrin and a possible
entry point for hepatocytes post cellular transplantation. Furthermore, they
demonstrate that exposure ofHepG2 cells to serum from patients with acute liver
failure leads to reduced ability to adhere to collagen matrix, via a Pi-integrin
dependent pathway. The differential control and order of adhesion and anti-apoptotic
signals by integrin activation is not fully understood, and in the model used it is not
clear if apoptosis is resultant on decreased cellular adhesion or occurs independently.
The data suggests that cytoskeletal disruption (as determined by adhesion and actin
cytoskeleton) precedes the onset of apoptosis and suggest it may play a role in
inducing apoptosis. Pi-integrin is important not only in mediating adhesion and
hence survival but also plays an important role in cellular migration (Masumoto et al
1999). Thus the observed down-regulation of Pi-integrin suggests that this not only
decreases hepatocyte homing but also prevents some of the collagen mediated
binding on the damaged liver. It is notable therefore that prior incubation ofHepG2
cells with TS2/16, a Pi-integrin activating antibody, prevented much of the loss of
cellular adhesion and apoptosis.
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This work has important implications for hepatocyte, and potentially for any form of
cell, transplantation and identifies an avenue which may be usefully explored in the
optimisation of this treatment modality.
In this study the HepG2 cell line was used, which is a differentiated human hepatoma
cell line, but extrapolation of this data to primary hepatocytes does however require
recognition ofnotable differences. Primary human hepatocytes may for example be
more susceptible to apoptosis if they are unable to bind to extracellular matrix, as
immortalised/tumour cell lines have down-regulated some of their apoptotic
pathways (Wiesenauer et al 2004).
6.2 STEM CELL PLURIPOTENTIALITY
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The studies in chapters 4 and 5 examine the pluripotency of haematopoietic stem
cells in vitro and in vivo, as a first step to utilising such cells in the treatment of
patients with liver injury. The two chapters look at complementary strategies; chapter
4 aims to differentiate stem cells into hepatocytes in vitro to produce adequate
numbers of cells, which can then be infused as per hepatocyte transplantation.
Chapter 5 however aims to infuse undifferentiated stem cells into
immunocompromised mice, whereupon hepatocytic differentiation occurs as
required in vivo.
Despite extensive experimentation, no hepatocytic differentiation of haematopoietic
stem cells was observed in vitro in this thesis. This has been achieved subsequently
by other groups and with corroboration by others provides a blueprint for the larger
scale differentiation of such cells in vitro prior to therapeutic usage. The most
notable difference in culture conditions was matrix; other groups utilised Matrigel as
a more complex complete matrix. The usage of sarcoma-derived matrix does
however pose safety issues for subsequent human usage of such cells.
The demonstration that human cells could differentiate in vivo in the murine liver
without any observed cellular fusion was successful. This refuted the claim of other
groups that cellular fusion (Terada et al 2002; Vassilopoulos et al 2003; Wang et al
2003; Ying et al 2002) rather than transdifferentiation was the major explanation
behind observed stem cell plasticity.
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Notably other groups, also do not find evidence of fusion as a mechanism for
marrow-cell engraftment into insulin producing islet cells of the brain or pancreas
after minimal injury (Ianus et al 2003). These differences are likely to be due, at
least in part, to the different model systems in which the experiments have been
performed. In vitro work suggests that multiple mechanisms participate (Prockop et
al 2003), including fusion events and differentiation of single cells participate. In
vivo, it is likely that the type and extent of target organ injury will determine not only
the degree to which extra-organ stem cells engraft, but also the mechanisms by
which this occurs.
Given the absence of cell fusion in other models of stem cell plasticity (Ianus et al
2003; Tran et al 2003) and the compelling evidence supporting in vitro plasticity of
HSCs(Jiang et al 2002), it is possible that the observed fusion in this model reflects
the extreme architectural disruption and hepatocyte membrane instability that occurs
in the FAH"'" mouse. Since neither study reported that all of the marrow-derived
hepatocytes were formed by fusion, and given that hepatocytes themselves are
known to fuse in pathological conditions, it is important to recognise that whilst
fusion may occur it does not explain the majority of new hepatocytes. The role of
fusion derived hepatocytes is unclear, but in the FAH" " model such cells do result in
survival of the animal with no evidence of subsequent carcinogenesis (Lagasse et al
2000). Even if fusion does occur in vivo in human tissue it could be used as a basis
for gene therapy.
Also, there has been no reported activation of the intraorgan stem cell compartment
(so called "oval cells" derived from the biliary tree) as seen in other injury models
(Petersen et al 1999), suggesting that normal repair mechanisms are not activated. It
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should be also be noted that the current results presented byWang et al cannot be
accounted for by a single fusion event followed by subsequent proliferation. If this
were the case, then the expected ratio of%FAH wildtype DNA to %Ragl wildtype
DNA would be greater than 33%, a number that assumes all fusion events occur
between a diploid blood cell and a tetraploid hepatocyte. Four of the six mice have
significantly lower amounts ofFAH wild type DNA. These numbers can only be
explained by the fusion of a transplanted hepatocyte with a recipient cell or
consistent loss of one FAH allele. The latter case seems rather unlikely and while
fusion could occur with a second blood cell, this offers no selective advantage,
whereas hepatocyte-hepatocyte fusion might (Gupta 2000).
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6.3 FINAL DISCUSSION
This thesis has studied two complementary strategies ofcellular transplantation for
augmenting liver function. Each of these strategies has its advantages and
disadvantages. Hepatocyte transplantation has been studied much more extensively
than stem cell transplantation, and has in animal studies at least been demonstrated to
be efficacious. However only by developing a better understanding of the factors
which control the successful migration and engraftment of these cells in clinical
practice will this treatment deliver the hoped for benefit to patients.
There are many unanswered issues which require clarification. Do mice require
irradiation for the stem cells to engraft and trans-differentiate? Does the source of
stem cells influence the amount of trans-differentiation? Do human stem cells have
to be freshly isolated or could they be cryopreserved prior to use? Furthermore which
cells within the cord blood preparation are able to trans-differentiation? Is this
property confined to previously identified haematopoietic stem cell groups which
express markers such as CD34 or AC133? Even more important is this a stochastic
phenomenon or does it occur in response to injury signals? By using models of liver
injury which affect different parts of the lobule both acutely and chronically it may
be possible to gain insights into the mechanisms which control this phenomenon. It
can be hypothesized that the liver has 3 levels of cells in the hepatic lineage that
respond to injury or carcinogenesis: 1) the mature hepatocyte, which responds to
centrilobular injury, such as that induced by carbon tetrachloride (CCU); 2) the
ductular "bipolar" progenitor cell, which responds to centrilobular injury when the
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proliferation of hepatocytes is inhibited, and 3) the putative periductular stem cell,
which responds to periportal injury, such as induced by allyl alcohol. Hepatocytes
are numerous, respond rapidly by 1 or 2 cell cycles, but can only produce other
hepatocytes. The ductular progenitor cells are less numerous, may proliferate for
longer times than hepatocytes, and are generally considered "bipolar," (can give rise
to biliary cells or hepatocytes). Periductular stem cells are rare in the liver, have a
very long proliferation potential, and may be pluripotent. It is these cells which have
been suggested to be of bone marrow origin. Studies are needed to compare the
relative contributions of stem cells in such models of injury. This will facilitate the
identification of mechanisms controlling stem cell recruitment and
transdifferentiation, which in turn will permit greater clinical applications.
Finally does direct injection into spleen or intra-portally improve the efficiency of
this phenomenon? The more local injection of stem cells may lead to more directed
administration of this therapy, and is in keeping with methods used in hepatocyte
transplantation (Ohashi et al 2001).
Stem cell-derived hepatocytes are most likely to benefit liver diseases characterised
by abnormal gene/protein production such as Wilson's disease and the certain forms
of dyslipidaemias. Conventional hepatocyte transplantation (Fox et al 1998; Muraca
et al 2002) has already shown benefit in patients with certain hepatic defects. The use
of stem cell-derived hepatocytes in bio-artificial liver support systems is limited by
the need for very large numbers of cells for these devices, which can only be
achieved by the stable expansion of such cells in vitro first. The potential for utilising
bone marrow derived stem cells is even greater, as they could potentially offer an
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autologous source of new hepatocytes. Patients with metabolic defects or viral
hepatitis could have their own bone marrow samples taken followed by ex vivo
manipulation of bone marrow derived stem cells to either produce missing enzymes
or confer viral resistance. These engineered cells would have a survival advantage
over host hepatocytes, leading to more extensive repopulation within the liver
parenchyma (Lagasse et al 2000).
Further developments in the field will also depend on the development and usage of
appropriate techniques to track both hepatocytes and stem cells. Whilst the tracking
of stem cells may be difficult in rodent systems it is impossible to prospectively
analyse the migration and engraftment of such cells in the humans. For this reason
non-invasive strategies are required to track such cells on their respective journey
from marrow to liver, or indeed vice versa. Fluorescent cell membrane labels such as
PKH26 (Beerheide et al 2002; Krause et al 2001) have been important tools for cell
tracking in rodents. However, safety concerns of such labels has prevented their use
in clinical trials. Whilst radio-labelling techniques have been successfully and safely
used in humans single-cell visualisation or subsequent cell sorting has not been
achieved with radio-labelling techniques. Human haematopoietic progenitor cells can
be labelled with various magnetic resonance (MR) imaging contrast agents and
subsequently localised with MRI. (Daldrup-Link et al 2003; Frank et al 2003). Cells
have been labelled with ferumoxides, ferumoxtran, magnetic polysaccharide
nanoparticles-transferrin, P7228 liposomes, and gadopentetate dimeglumine
liposomes before MR imaging with Tl- and T2-weighted spin-echo and fast field-
echo sequences. Detection thresholds were 5 x 105 cells for gadopentetate
215
dimeglumine liposomes and ferumoxtran, 2.5 x 105 cells for ferumoxides and P7228
liposomes, and 1 x 105 cells for magnetic polysaccharide nanoparticles-transferrin
(Daldrup-Link et al 2003). While haematopoietic progenitor cells can be labelled
with MR contrast agents and can be depicted with a standard 1.5-T MR imager,
further in vivo work is required to enable rigorous testing of its potential for tracking
studies.
Stem cells are at the time ofwriting topical, exciting and offer a myriad ofpotential




750 ml Picric acid, saturated aqueous solution
250 ml 37-40% formalin (formaldehyde)






Activated charcoal (powder) 300mg
Annexin V Binding Buffer
10X Binding Buffer: 0.1 M HEPES, pH 7.4; 1.4 M Sodium Chloride; 25 mM
Calcium Chloride. Dilute to IX prior to use.
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Background & Aims: Studies have indicated that stem
cells have unexpected plasticity and can differentiate
down a multitude of nonhematopoietic cell lineages in
rodents. Our aim was to identify whether human cord
blood cells, which are a rich source of stem cells, would
be able to differentiate into hepatocytes when infused
into nonobese diabetic-severe combined immunodefi-
cient (NOD-SCID) mice. We also wanted to test whether
such differentiated cells were the result of cellular fusion
or true stem cell transdifferentiation. Methods: Unsorted
mononuclear cell preparations of human cord blood
were infused into sublethally irradiated NOD-SCID mice.
After death, immunohistologic analysis of murine livers
was performed using human specific hepatocyte, biliary,
and endothelial markers. Fluorescent in situ hybridiza¬
tion (FISH) for mouse and human DNA was also per¬
formed. Results: We show that human cord blood cells
have the ability to engraft into NOD-SCID liver and be¬
come mature hepatocytes. We were unable to identify
any biliary or endothelial differentiation. Furthermore,
we do not detect any evidence of cell fusion in any of the
human cells found in the mouse liver, suggesting that
human cord blood cells are capable of true transdiffer¬
entiation into hepatocytes in vivo. Conclusions: We con¬
clude that hepatocytes can derive from human cord
blood cells when infused into NOD-SCID mice in the
absence of fusion. The demonstration that human stem
cell differentiation can occur in this murine model per¬
mits comprehensive study of human stem cell plasticity
in vivo.
Recent studies have demonstrated that stem cellshave greater plasticity than previously thought and
can differentiate down multiple nonhematopoietic cell
lineages in rodents.1-4 Although much of this work has
used bone marrow—derived stem cells, there are several
reports suggesting that stem cells obtained from mus¬
cle5'6 and brain also share these pluripotent properties.7
Lagasse et al. were able to demonstrate that this phe¬
nomenon had functional significance when they showed
that infusion of murine adult bone marrow cells in the
FAH( —/—) mouse, an animal model of tyrosinemia type
I, rescued the mouse and restored the biochemical func¬
tion of its liver.8 Notably, this is the only model in which
infused stem cells have a survival advantage over host
cells, in this case hepatocytes. That adult human stem
cells also share some of these pluripotent properties has
been demonstrated in studies utilizing archival biopsy
samples9-11 in which donor-derived hepatocytes and
cholangiocytes have been observed in the recipient. As
yet, the biologic relevance of human stem cell transdif¬
ferentiation remains to be clarified, with concerns exist¬
ing that human stem cells may not share the same
pluripotentiality as rodent stem cells. However, the lack
of suitable in vivo model systems has hindered detailed
study of human stem cell plasticity. Furthermore, so¬
matic stem cell plasticity has recently been questioned,
and it has been suggested that this presumed differenti¬
ation may be the product of cell fusion between stem
Abbreviations used in this paper: BCIP/NBT, 5-bromo-4-chloro-3-
indolyl phosphate/nitroblue tetrazolium; DAB, diaminobenzidine;
DAPI, 4,6-diaminidino-2-phenylindole; FAH, fumarylacetoacetate hy¬
drolase; FISH, fluorescent in situ hybridization; FITC, fluorescein iso-
thiocyanate; HBSS, Hanks' balanced salt solution; HRP, horseradish
peroxidase; mAb, monoclonal antibody; NOD-SCID, nonobese diabetic-
severe combined immunodeficient; SSC, sodium saline citrate; uPA,
urokinase-type plasminogen activator.
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cells and preexisting differentiated cells.12-14 These obser¬
vations have important implications for stem cell usage and,
if confirmed in in vivo studies, would significantly limit the
benefits of stem cell transplantation. In this study, we
sought to examine whether human cord blood cells could
transdifferentiate into hepatocytes when infused into pre¬
conditioned, nonobese diabetic—severe combined immuno-
deficient (NOD-SCID) mice and whether cellular fusion of
human and murine cells occurs.
Materials and Methods
Human Cord Blood Sample Material
Freshly collected, heparinized, whole cord blood sam¬
ples were received from the Scottish National Blood Transfu¬
sion Service (Edinburgh, United Kingdom) following in¬
formed donor consent. Mononuclear cells were isolated using
Histopaque (Sigma, Dorset, United Kingdom) density centrif-
ugation following the initial description by Boeyum.15 Briefly,
heparin-treated (1CP IU/mL) whole blood was carefully layered
over an equal volume of Ficoll-Hypaque (Sigma) and spun at
540g for 20 minutes. The interface ("buffy coat") containing
the mononuclear cells was collected and washed twice in
Hanks' Balanced Salt Solution (HBSS; Gibco, United King¬
dom). A trypan blue exclusion assay was used to assess the
viability of the harvested cells prior to their usage.
Animals
Four- to 6-week-old NOD-SCID mice were sublethally
irradiated (250 rads) and received a single tail-vein infusion of
50 X 106 human cord blood-derived mononuclear cells resus-
pended in 100 |xL of sterile HBSS. Mice were kept under specific
pathogen free (SPF) conditions in microinsulators and killed at 1,
4, 6, and 16 weeks after cord blood cell infusion. Experimental
protocols involving animals were carried out in accordance with
permits and guidelines issued by the University of Edinburgh
Ethical Review Committee and the United Kingdom Home
Office.
In Vitro Culture Assays
To detect hematopoietic progenitor cells in human
cord blood samples, colony-forming units (CFUs) were evalu¬
ated by placing cord blood-derived mononuclear cells in pre¬
tested complete semisolid methylcellulose mixtures (Methocult
GF H4534; StemCell Technologies, Inc., Canada) comprising
1% methylcellulose in Iscove's MDM, 30% fetal bovine se¬
rum, 1% bovine serum albumin, 10-1 mol/L 2-mercaptoetha-
nol, 2 mmol/L L-glutamine, 50 ng/mL rh stem cell factor, 10
ng/mL rh GM-CSF, and 10 ng/mL rh IL-3. Fifteen hundred
cells per milliliter of methylcellulose were plated out in trip¬
licate wells in a multidish plate (Nunc, United Kingdom) and
cultured at 37°C in 5% CO, for 12 days. At that time, the
number of total CFUs was determined under the microscope as
an average count of all 3 wells. Control cultures were included
in each assay, and these were grown in identical medium apart
from the absence of growth factors.
FACS Analysis
Cord blood mononuclear cell surface phenotype was
characterized using standard FACS analysis. Briefly, 100,000
cells per test were pelleted by centrifugation for 5 minutes at
1000 rpm and cell pellets resuspended in individual monoclo¬
nal antibody (mAb) solutions using the manufacturer's (Dako;
BD Pharmingen, United Kingdom; Sigma, United Kingdom)
recommended test concentrations (confirmed in our laboratory
to give optimum results in our hands). Test samples were
immunostained for 20 minutes on ice with a panel of directly
FITC- and/or PE-conjugated mAb against human cell surface
markers. The panel included mAb against the following mark¬
ers: MHC1 (pannucleated cell; 200 fxg/mL; Sigma), gly-A
(erythrocyte; 100 p,g/mL; Dako), CD3 (T cell; 12.5 p.g/mL;
BD Pharmingen), CDllb (granulocyte; 100 (jtg/mL; Dako),
CD14 (monocyte; 60 pg/mL; Dako), CD19 (B cell; 25 pg/mL;
BD Pharmingen), CD33 (myeloid progenitor; 6 pg/mL; BD
Pharmingen), CD34 (stem cell; 25 pg/mL; BD Pharmingen),
CD45 (panleukocyte; 50 pg/mL; BD Pharmingen), and CD56
(NK cell; 50 pg/mL; Dako). Cell subsets were double immu¬
nostained using a subset-specific mAb as well as an antibody
against CD45. Following immunostaining, cells were pelleted,
washed in FACS-handling buffer (IX PBS/1% BSA/0.1%
sodium azide/0.5 mol/L EDTA) and resuspended in FACS fix
(1% formaldehyde) prior to analysis using CellQuest software
on a Becton Dickinson FACSCalibur machine.
Glucose Phosphate Isomerase Assay
Electrophoresis for variants of glucose phosphate
isomerase (GPI) was carried out as described by Ansell and
Micklem.16 Briefly, samples of single cell suspensions were
pelleted by centrifugation, lysed using "sample" buffer,
and stored at — 80°C. Electrophoresis was carried using the
"Helena" system (Helena Laboratories). Samples were applied
to Titan III cellulose acetate membranes at the anode and run
for 80 minutes at 350 V using Supraheme buffer. Bands were
developed using a staining mixture containing substrate and




Histology. Livers from NOD-SCID mice were re¬
moved, fixed in 4% formaldehyde overnight, and embedded in
paraffin blocks. Four-micrometer sections were cut and placed
onto Vector-bonded slides. Slides were dewaxed through xy¬
lene and rehydrated through graded alcohols and water. Pos¬
itive controls included normal human liver obtained with
ethical approval from the Scottish Liver Transplant Unit
(Royal Infirmary of Edinburgh). Negative controls included
mouse liver obtained from sublethally irradiated NOD-SCID
mice infused IV with medium only.
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Immunohistochemistry. Sections were microwaved
for 15 minutes in 0.1 mol/L citrate buffer and blocked in 1%
HiO, for 15 minutes. Slides were then incubated with a 1:4
dilution of a mouse mAb against cytokeratin 19 (as a marker
of biliary epithelium; Dako), a 1:25 dilution mouse mAb
HepParl that was raised against human hepatocytes (Dako), a
1:25 dilution CD31 mouse mAb against human endothelial
cells (Dako), and a 1:25 dilution CD34 mouse mAb against
human stem cells (Dako). Slides were then washed and incu¬
bated with a horseradish peroxidase (HRP) polymer-conju¬
gated detection antibody followed by diaminobenzidine
(DAB) chromagen (Envision; Dako).
Immunofluorescence. Sections were microwaved
for 20 minutes in 0.1 mol/L citrate buffer, cooled, and washed
in 2X sodium saline citrate (SSC).17 Immunofluorescence was
carried out using a 1:4 dilution of a mouse mAb against
cytokeratin 19 (Dako) or a 1:25 dilution mouse mAb HepParl
(Dako). Secondary antibody was a 1:100 dilution of donkey
anti-mouse FITC (Vector Laboratories).
FISH Analysis
One microgram total human genomic DNA was
labelled with digoxigenin 11-dUTP (Roche, Lewes, United
Kingdom), and mouse genomic DNA was labelled with
Alexa Fluor 594-5 dUTP (Molecular Probes, Leiden, The
Netherlands) by nick translation. Unincorporated nucleo¬
tides were removed by centrifugation through Quick Spin
G50 Sephadex columns (Roche). Specific activity of the
probes was performed by dotting onto nitrocellulose filters
using anti-digoxigenin-alkaline phosphatase Fab fragments
(Roche). We then used a BCIP/NBT kit (Vector), which
produces the purple change on the filter, which we then
compared with known standards (DNA of known concen¬
trations).
Slides were heated to 60°C for 20 minutes to melt wax then
washed in xylene 4 times for 10 minutes each before dehydra¬
tion through an ethanol series (100%, 95%, 70%). Slides were
then microwaved for 20 minutes in 0.1 mol/L citrate buffer,
pH 6.0. After microwaving, liver sections were denatured for
3 minutes at 75°C in 70% formamide/2X SSC, plunged into
ice-cold 70% ethanol for 3 minutes, dehydrated through an
alcohol series, and air-dried.
One hundred fifty nanograms labeled human genomic
DNA, 150 ng labelled mouse genomic DNA, and 5 |xg
salmon sperm DNA were denatured together for 5 minutes at
75°C in 50% formamide, 10% dextran sulphate, 2X SSC, and
1% Tween 20. Hybridization was overnight at 37°C. Slides
were washed 4 times for 3 minutes in 2X SSC at 45°C then
incubated for 30 minutes with a 1:30 dilution of a sheep FITC
anti-digoxigenin antibody (Roche), followed by a further 30
minutes with a 1:100 dilution of FITC anti-sheep antibody
(Vector Laboratories).18 Slides were mounted in Vectashield
(Vector Laboratories) containing 1 pg/mL 4,6-diaminidino-2-
phenylindole (DAPI) counterstain.
Table 1. Characterization of Infused Human Cord Blood
Prior to Intravenous Inoculation Into Sublethally
Irradiated NOD/SCID Mice
Cell surface marker Range {%) Mean (SE) Median
MHC1 78-96 88 (2) 88
CD45 59-93 81 (3) 83
GlyA 2-18 11 (2) 11
CD3 0-70 54 (6) 58
CDllb 5-24 14 (2) 14
CD14 1-21 6(2) 4
CD19 0-24 8(3) 1
CD33 0-21 4(2) 2
CD34 0-2 1(0) 1
CD56 0-2 1(0) 0
Number of CFU 0-100 48 (12) 51
NOTE. Table describes the analysis of 10 human cord blood prepa¬
rations prior to their infusion into sublethally irradiated NOD/SCID
mice. The percentage of cells expressing a variety of hematopoietic
markers is detailed as well as mean values (along with their standard
error, SE = SD/Vn) and medians. In particular, the percentage of
cells expressing CD34 is seen to be 1%. Colony-forming unit (CFU)
measurement confirms the presence of stem cells in the infused cord
blood.
Image Analysis
Slides were visualized using a Zeiss Axioplan 2 fluo¬
rescence microscope (Thornwood) equipped with a triple band¬
pass filter (Chroma No. 83000). Grayscale images were col¬
lected with a cooled charge-coupled device (CCD) camera
(Quantix Corp.) and analyzed using custom IPLab scripts.
Images were pseudocolored using image processing software
(Adobe Photoshop).
Results
Infused Human Cord Blood Samples Are
Rich in Hematoprogenitor Cells
Initially, we characterized 10 individual human
cord blood samples by FACS analysis and in vitro culture
assays prior to injection into NOD-SCID mice (Table 1).
The results were that an average of 1% of cord blood
mononuclear cells were CD34+ve stem cells. In line with
this were the results from our in vitro culture assays,
which demonstrated an average of 48 colony-forming
units (CFU) per cord blood sample. Taken together, the
results thus suggested that our infused cord blood sam¬
ples were rich in hematoprogenitor cells.
Human Cord Blood Samples Engraft in
NOD/SCID Mice
To assess in vivo engraftment of our human sam¬
ples up to 16 weeks postinoculation, we used FACS and
GPI analysis as well as in vitro culture assays to study
bone marrow samples from our infused NOD-SCID
mice. Using FACS, the results were that mice tested had
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Table 2. Human Reconstitution of NOD-SCID Murine Bone
Marrow
Human Murine
Hematopoietic Mean Range Mean Range
markers (%) (%) (%) (%)
MHCl+ve 26 14-47 32 23-46







NOTE. Table represents the contribution of human cells to the bone
marrow of irradiated NOD-SCID mice (n = 6) 8 weeks after infusion of
human cord blood cells. The column on the left denotes the panel of
markers (human and murine) screened for in the murine marrow. The
middle column reflects the relative contribution of human cells to
different hematopoietic lineages in the NOD-SCID murine marrow
(these were identified using flow cytometric analysis with human
specific antibodies). The column on the right reflects murine hemato¬
poietic cells identified by flow cytometric analysis with mouse-specific
antibodies. These data confirm that there is marrow engraftment with
human cord blood cells.
MHC1, Major histocompatibility 1 antigen.
detectable levels (10%—45% of counted cells; average,
17%) of human CD45+ve leukocytes in their bone mar¬
row (Table 2). In addition, there was evidence of multi¬
ple hematopoietic lineages represented by human cells.
The data correlated with results of our GPI assay, which
confirmed the presence of the human GPI isoenzyme in
the assayed samples (Figure 1). In in vitro culture assays,
samples gave rise to colonies in methyl cellulose, albeit at
low numbers (data not shown).
HepParl Antibody Is Specific for Human
Hepatocytes
In the next set of experiments, we ascertained the
specificity of the HepParl mAb using serial tissue sec¬
tions. The results, which are shown in Figure 2, demon¬
strated that, when incubated for 1 hour at a concentra¬
tion of 1:25, the HepParl antibody is specific for human
hepatocytes and does not cross-react with human cord
blood or NOD-SCID mouse liver elements.
Quantitation of Cord Blood-Derived
Hepatocytes
Human hepatocytes were identified in 2 ways:
The first way was with positive staining of the human
specific HepParl antibody (Figure 2). We have demon¬
strated that HepParl is human specific and does not
cross-react with NOD-SCID mouse liver (or human cord
blood). This observation is particular to NOD-SCID
mice and is in keeping with that of other laboratories.
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We also performed immunofluorescent HepParl stain¬
ing, which permitted DAPI nuclear analysis (data not
shown). The nuclear DNA staining pattern of human
and mouse cells is quite distinct (Figures 3 and 4), thus
permitting further differentiation between human and
murine hepatocytes. The abundance of pericentric het-
erochromatin on mouse chromosomes is manifest as
bright foci of DAPI staining,19 a feature not seen in
human cells, which have less pericentric heterochroma-
tin. The combination of binding of a human specific liver
antibody and human nuclear morphology were taken as
indicative that the cell was a human hepatocyte. The
second way human hepatocytes were identified was with
positive FISH signal for human DNA (Figure 3) and cell
morphology typical of human hepatocytes. Hepatocytes
were large polyclonal cells, arranged in plates, and had
large round nuclei. In addition, their cytoplasm was
characteristically bright, reflecting the FITC-type cyto¬
plasmic autofluorescence caused by bilirubin metabolic
products.2 The number ofpositive cells obtained by these
2 methods was used to provide a mean value of cord
blood-derived hepatocytes in each liver. Total human
cells were quantified by counting the number of cells
with human FISH signal in the murine liver section.
Colocalization studies of HepParl staining and positive
FISH signal were attempted, but FISH processing de¬
graded the HepParl signal, and, thus, we were unable to
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Figure 1. Glucose phosphate isomerase assay for in vivo detection of
human cells. GPI analysis of bone marrow-derived samples from
NOD-SCID mice infused with human cord blood cells for demonstra¬
tion of the human isoenzyme. (4) Demonstrates the different electro-
phoretic mobility of human and NOD-SCID mouse iso-enzymes. (6)
Shows the results obtained in a representative NOD-SCID mouse
bone marrow after (labeled "recipient 1") inoculation with a human
cord blood sample. The results were in line with data obtained by
FACS analysis and in vitro cultures.
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Figure 2. Detection of human hepatocytes with immunohistochemistry. Immunohistochemistry on liver sections with antibody HepParl (brown)
that detects human, but not mouse, hepatocytes. Cells were counterstained with Hematoxylin (blue). (A) Human liver. (B) Mouse liver. (C-F)
Positive cells integrated into the hepatic plate of livers of NOD-SCID mice. (C and D) Represent the more typical finding of isolated single positive
cells (higher magnification of C). (E and F) Represents the occasional clump of cells seen in the parenchyma. (Bar = 20 p.m.)
Human Cord Blood Cells Can Engraft and
Differentiate Into Hepatocytes in the NOD-
SCID Mouse Liver
Despite no evidence of hepatocyte damage after
irradiation, human-derived cells were detected in the
liver of cord blood—injected NOD-SCID mice 1 week
postinfusion and at all subsequent time points. Human
hepatocytes were demonstrated in mouse liver 4 weeks
postinfusion and at all subsequent time points. Human
hepatocyte differentiation in vivo was detected first by
immunohistochemical analysis using the human-specific
hepatocyte marker (HepParl), demonstrating the pres-
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Figure 3. Detection of human cells in liver sections by FISH. Detection of digoxigenin-labeled human DNA by FITC (green) in liver sections
counterstained with DAPI (blue). Greyscale images of DAPI staining are shown on the right. (A) Human liver. (B) Mouse liver. (Cand D) Human
hepatocytic cells integrated into the hepatic plate of livers of NOD-SCID mice. (Eand F) Human hematopoietic cells entering the murine liver. (G—/)
Human CD34+ cells detected with immunohistochemistry entering the murine liver. (J and K) Represent greyscale H&E pictures of cells with
positive FISH signal and characteristic hepatocytic morphology. These cells had morphology typical of hepatocytes with large polyclonal size, large
round nuclei, and complex intracellular cytoplasm. (Bar = 20 p.m.)
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Figure 4. Assessment of donor-host cell fusion. Simultaneous FISH analysis of liver sections with total human {green) and mouse (red) DNAs.
Cells were counterstained with DAPI (blue). Greyscale images of the DAPI staining and mouse and human hybridization signals are shown. (-4)
Human liver. (B) Mouse liver. (C and D) Human positive (green) cells integrated into the hepatic plate of livers of NOD-SCID mice. Note the
absence of any detectable mouse DNA (red) in these nuclei and their DAPI staining typical of human derived cells. (Bar = 20 jurt.)
ence of isolated positive cells within the NOD-SCID
mouse liver (Figure 2). Occasionally, clumps of cells were
seen within the liver. Furthermore, immunofluorescence
analysis of these sections using the same HepParl anti¬
body confirmed the presence of isolated positive cells
integrated in the liver plate (data not shown), with
characteristic human nuclear morphology. These cells
tended to be located within the hepatic plate in the
vicinity of portal tracts, suggesting that circulating cells
derived from human cord blood had invaded the liver
and differentiated into mature hepatocytes. Further evi¬
dence for the presence of human hepatocytes derived
from the presence of positive FISH signals in cells with
typical hepatocyte morphology. Many of these cells had
the morphology (large nuclei and abundant cytoplasm)
typical ofmature hepatocytes (Figure 3). The mean num¬
ber of human hepatocytes per section was 47.8 (range,
19—73). The observed frequency of human hepatocytic
transformation seen was modest (Table 3), with such
cells constituting on average 0.011% of all cells on each
section (maximum seen was 0.017%). When the number
of transdifferentiated hepatocytes is expressed as a per-
1898 NEWSOME ET AL. GASTROENTEROLOGY Vol. 124, No. 7





Mean number of human
cells (all types) per mouse
liver section (and value as a
percentage of host cells)
Mean number of human
hepatocytes per mouse liver
section (and value as a





1 7 d 45 (0.0072) 0(0) 0
2 7 d 67 (0.018) 0(0) 0
3 7 d 75 (0.012) 0(0) 0
4 4 wk 91 (0.013) 62 (0.0089) 1.77
5 4 wk 132 (0.04) 46 (0.014) 2.79
6 4 wk 83 (0.027) 52 (0.017) 3.40
7 6 wk 108 (0.015) 71 (0.0099) 1.97
8 6 wk 88 (0.021) 46 (0.011) 2.19
9 6 wk 80 (0.013) 40 (0.0066) 1.31
10 6 wk 54 (0.0082) 19 (0.0028) 0.58
11 16 wk 63 (0.017) 52 (0.014) 2.81
12 16 wk 51 (0.013) 43 (0.011) 2.21
13 16 wk 70 (0.014) 22 (0.0043) 0.88
14 16 wk 117 (0.027) 73 (0.017) 3.38
NOTE. Table quantifies both the total number of human cells and the number of human hepatocytes engrafted within the NOD-SCID mouse liver.
Transdifferentiation efficiency is expressed by dividing the total number of donor-derived hepatocytes by the number of infused CD34+ cells. Peak
trans differentiation is seen to occur at 4 to 6 weeks with no significant increment after this time. Total human cells were quantified by counting
the number of cells with human FISH signal in the murine liver section.
CBI, Cord blood infusion.
centage of the number of infused CD34+ cells, the mean
value is 2.11%. No evidence of any human hepatocytes
was seen 1 week after cord blood infusion, although
infiltrating CD34+ cells could be seen entering through
the portal tracts (Figure 3)- There did not appear to be an
increase in the number of human hepatocytes seen in the
mouse liver 4 weeks after cord blood infusion, with
similar percentages being found after 6 and 16 weeks.
Furthermore, similar numbers of human cells were also
observed in vascular channels and/or had morphology
that was more consistent with hematopoietic lineages
(Figure 3). There was no evidence of human biliary
(cytokeratin 19+ ve) or endothelial (CD31 +) differentia¬
tion in any of the sections.
Fusion of Human and Murine Cells Does
Not Occur In Vivo
The nuclear DNA staining pattern of human and
mouse cells is quite distinct, as described previously.19
Bright foci of DAPI staining were evident in sections of
mouse liver, whereas nuclei in human liver sections had
a more uniform staining pattern (Figure 4A and B). Cells
hybridizing to human DNA and engrafting into mouse
livers had characteristic human nuclear staining mor¬
phology, and there was no evidence in these cells of
bright DAPI foci characteristic of mouse chromosomes
(Figure 3C—F). Similarly, cells staining with a human-
specific hepatocyte antibody (Figure 2C—F) also had
nuclear morphology typical of human rather than mouse
cells.
To confirm this, we performed a simultaneous FISH
analysis for murine and human DNAs. The results were
that we did not detect any cells, either hepatocytic or
nonhepatocytic, that were positive for both human and
mouse DNA (Figure 4). We examined at least 5 liver
sections of each of 14 different mouse livers. Each section
had a mean of 80.3 positive cells/section, giving a total
number of events screened of 5620. Not one of these cells
was the result of fusion of human and mouse cells.
Although we cannot totally exclude cellular fusion, it is
clearly exceedingly rare compared with human stem cell
transdifferentiation. Taken together, the data suggest
that it was unlikely that the donor human cord blood
cells had fused with host mouse hepatocytes.
Discussion
Our data demonstrate that infused human cord
blood cells are capable of engrafting into NOD-SCID
mouse liver and differentiating down the hepatocytic
lineage without fusion to host hepatocytes. This work
confirms the recently published observation by Danet et
al.,20 who have identified a subpopulation of human cord
blood cells that have the ability to differentiate down the
hepatocytic lineage upon infusion into the NOD-SCID
mouse liver. In our experimental animals, engrafted
hepatocytes were most often scattered throughout the
murine liver parenchyma, usually appearing as isolated
cells, although occasionally, we observed some small
clumps of cells. The rate of hepatocytic differentiation of
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cord blood cells occurred at low levels in our model (up
ro 0.017% of total cells), and it will be important to
determine in the future whether liver injury increases
this frequency.21 There appears to be some variation in
the amount of stem cell—derived hepatocytic differenti¬
ation reported in the literature, with groups reporting as
few as 10 hepatocytes per murine section,22 whereas
others observe levels as high as 1.1% of recipient liver
tissue.2 This variation may reflect differences in species
and strains of animal used, presence of liver injury
(whether intentional or nonintentional such as radiation),
and methods used to identify stem cell—derived hepato¬
cytes. We have used several different methods to identify
stem cell—derived hepatocytes, and, notably, our ob¬
served frequency falls in the lower end of this range. The
results further suggest that, in the absence of liver injury,
there is no stimulus for transdifferentiated cord blood-
derived hepatocytes to proliferate because the proportion
of human hepatocytes did not appear to increase with
time following the 4 weeks time point. This is in keep¬
ing with the literature as reported by Theise et al.,2 who
demonstrated that the proportions of donor murine bone
marrow—derived hepatocytes in myeloablated mouse re¬
cipient livers were similar up to 12 months after bone
marrow transplant. Although our observed level of en-
graftment in our xenogeneic model is lower than that
observed in vivo by Theise et al. (up to 1.1% of total cells
studied), part of this may be due to human stem cells
being at a relative survival/proliferative disadvantage
when infused into xenogeneic environments in absence of
liver injury. In contrast, infusion of human hepatocytes
into mice suffering mild chronic liver injury leads to
their populating up to 15% of the mouse liver, but this
is seen in the context of urokinase-type plasminogen
activator (uPA) transgenic mice, which have a liver-toxic
phenotype.23 The majority of the transdifferentiated
hepatocytes in our model were seen to be located in the
hepatic plate in the vicinity of portal tract areas, and
most of these cells were found as isolated single cells
(although occasional clumps of cells were seen). In con¬
junction with the finding of CD34+ human cells in the
vicinity the portal tracts these observations suggest that
the portal tract may be a major route of entry of hepa-
tocyte progenitors into the liver. This is supported by
our finding that human cells with morphology that was
more consistent with hematopoietic cells were frequently
seen to be entering through the portal tracts (Figure
3D—I), although tracking experiments would be re¬
quired to confirm their subsequent hepatocytic commit¬
ment. In the absence of any significant liver injury,
human stem cells would have no obvious reason to
migrate further into the liver plate. Hence their peripor¬
tal, transdifferentiation may reflect their earliest exposure
to murine hepatocytes and other factors triggering dif¬
ferentiation. No evidence of human biliary (cytokeratin
19+ve) or endothelial (CD31) differentiation was seen in
any of the liver sections, but this may reflect the rela¬
tively low turnover of these cellular compartments24 and
the fact that they represent only ~2% of the cellular
mass of the liver. In view of the modest levels of hepa¬
tocytic transdifferentiation, the chances of identifying
other stem cell—derived lineages would therefore be
much lower.
We used unsorted human cord blood as a source of
donor cells because it is known to contain higher levels
of stem cells than normal peripheral blood.25 Although
other groups have attempted to select out an enriched
population of stem cells using markers such as CD34, it
is possible that the CD34-ve population may in fact
contain an even more pluripotent population of stem
cells.26-28 Therefore, there is ample evidence to suggest
that hepatocyte progenitors belong to a stem-cell com¬
partment.
Somatic stem cell plasticity has recently been ques¬
tioned, and it has been suggested that this presumed
differentiation might be the product of cell fusion be¬
tween stem cells and preexisting differentiated cells.12-14
In contrast to recent ex vivo reports,12-13 we found no
evidence of cell fusion in our in vivo model. Although a
type 2 error cannot be totally excluded, the fact that not
one of 5620 human cells in the murine liver are the result
of cellular fusion indicates that fusion is at best an
exceedingly rare phenomenon. Our study would suggest,
therefore, that it plays a negligible role in the phenom¬
enon of transdifferentiation. The presence of cellular
fusion in other studies may thus reflect the ex vivo
environment that the work was carried out in and not in
vivo conditions. If fusion is a rare event, it may become
apparent in an in vivo model of liver injury in which
more hepatocyte transdifferentiation may take place.
This work makes the fundamental observation that
human cord blood—derived cells have the ability to mi¬
grate, engraft, and differentiate into hepatocytes in
mouse liver when infused into NOD-SCID mice. Fur¬
thermore we show categorically that none of our trans¬
differentiated hepatocytes are the result of cellular fusion
of human cord blood cells with murine hepatocytes. The
results thus suggest new opportunities in the study of
human adult stem cell biology using preconditioned
NOD-SCID mice, and future work should aim to opti¬
mize this model system for further studies of hepatocyte
progenitors.
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